Azolylpyridine pyridazinone amide as SOS1 inhibitor
Patent Information
- Application Number
- MYPI2025004696
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-02-16
- Filing Date
- 2024-02-16
- Publication Date
- 2024-08-16
AI Technical Summary
Current methods face challenges in directly or indirectly inhibiting RAS proteins due to their picomolar affinity and broad protein-protein interaction surfaces, making it difficult to develop effective small molecule drugs, and targeting farnesyl transferase has not resulted in approved drugs, with SOS1 being a critical but hard-to-target GEF for RAS family protein signaling.
Development of novel azolylpyridine pyridazinone amide compounds that inhibit the catalytic site of SOS1, preventing its interaction with RAS family proteins and thereby reducing oncogenic signaling, particularly in cancers with KRAS mutations.
The compounds effectively inhibit SOS1-mediated activation of RAS family proteins, potentially offering a new approach for treating cancers with KRAS mutations by disrupting the SOS1-RAS interaction, thereby reducing tumor cell survival and oncogenic signaling.
Smart Images

Figure PI2025004696_DRAWING_001 
Figure PI2025004696_DRAWING_002 
Figure PI2025004696_DRAWING_003
Abstract
Description
Azolylpyridine pyridazinone amide as an SOS1 inhibitor
[0001] The present invention relates to a novel compound having SOS1 inhibitory activity, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing or treating a disease comprising the same as an active ingredient, and a pharmaceutical use thereof.
[0002] Mutations in the RAS gene are a major oncogene with a high incidence in human cancer, occurring in 20–30% of human cancers, and are particularly prevalent in lung, colon, rectal, and pancreatic cancers. RAS-family proteins include KRAS, NRAS, and HRAS.
[0003] RAS proteins are small GTPases that exist in cells in either GTP- or GDP-bound states, functioning as molecular switches that cycle between an active GTP-bound state and an inactive GDP-bound state. Mutations in the RAS gene reduce the ability of the GTPase RAS to hydrolyze GTP, thereby maintaining this molecular switch in a constitutively active GTP-bound form, thereby inducing oncogenic downstream signaling pathways (e.g., the Raf-MEK-ERK pathway or the PI3K-PDK1-Akt pathway).
[0004] Meanwhile, binding of GTPase-activating proteins (GAPs), such as NF1, accelerates the weak intrinsic GTPase activity of RAS proteins, downregulating active RAS and reverting it to an inactive form. Conversely, binding of guanine nucleotide exchange factors (GEFs), such as SOS1, promotes GDP release from RAS proteins and increases the GTP-bound active state.
[0005] Previous studies have explored direct and indirect inhibition of RAS. However, direct inhibition of RAS has proven extremely challenging due to the picomolar affinity of GTP for its binding site, the lack of other well-defined pockets, and the fact that RAS interacts with GEFs, GAPs, and effectors via a broad, flat protein-protein interaction surface that makes small-molecule drugs difficult to target. Furthermore, indirect inhibition of RAS by targeting farnesyl transferase has also been attempted, but no approved drugs have yet been developed. Based on these failures in direct and indirect RAS inhibition, RAS has generally been considered a challenging target for drug development.
[0006] Under these circumstances, a new method of inhibiting RAS by inhibiting the interaction between RAS and GEF and thereby preventing GTP reloading has emerged.
[0007] Son of Sevenless 1 (SOS1) is a guanine nucleotide exchange factor (GEF) that promotes GDP release from RAS family proteins, allowing GTP binding, thereby regulating RAS family protein signaling. Son of Sevenless (SOS) exists in two isoforms, SOS1 and SOS2, and only SOS1 is phosphorylated by ERK. Growth factor-induced phosphorylation of SOS1 is largely mediated by ERK, which phosphorylates at least four serine residues in the C-terminal domain of SOS1. This suggests that SOS1 plays a crucial role in the negative feedback regulation of the KRAS pathway. The SOS1 protein consists of 1333 amino acids (150 kDa). SOS1 is a multidomain protein with a Dbl homology domain (DH) followed by two tandem N-terminal histone domains (HD), a pleckstrin homology domain (PH), a helical linker (HL), a RAS exchange motif (REM), a CDC25 homology domain, and a C-terminal proline-rich domain (PR). SOS1 has two binding sites for RAS family proteins: a catalytic site that binds GDP-bound RAS family proteins to catalyze the exchange of guanine nucleotides, and an allosteric site that upregulates the catalytic site activity of SOS1 by binding GTP-bound RAS family proteins (J. Med. Chem. 2021, 64, 10, 6569-6580). Selective pharmacological inhibition of SOS1 binding to the catalytic site of RAS family proteins is expected to prevent SOS1-mediated activation of RAS family proteins in the GTP-bound form.
[0008] Therefore, novel SOS1 inhibitor compounds are being developed that bind to the SOS1 catalytic site and prevent binding to and activation of RAS family proteins, as SOS1 inhibitor compounds are expected to inhibit signaling (e.g., ERK phosphorylation) downstream of RAS-family proteins.
[0009] SOS1 has been reported to be crucially involved in mutant KRAS activation and oncogenic signaling in cancer (Current Opinion in Chemical Biology, 2021, 62: 109-118). Depletion of SOS1 levels decreased the survival of tumor cells harboring KRAS mutations, but no such effect was observed in KRAS wild-type cell lines. The SOS1 depletion effect was observed in SOS1 cells with a damaged catalytic site. F929A It cannot be rescued by SOS1 mutants (SOS1L687E / R688A) that are defective in GTP-KRAS binding at the catalytic or allosteric site, suggesting that targeting the catalytic or allosteric site of SOS1 may be a viable option for the treatment of KRAS mutant cancers.
[0010] Furthermore, SOS1 is crucial for the activation of RAS family protein signaling in cancer through mechanisms other than mutations in RAS family proteins. SOS1 interacts with the adaptor protein Grb2 to form the SOS1 / Grb2 complex. This complex binds to activated / phosphorylated receptor tyrosine kinases (e.g., EGFR, ErbB2, ErbB3, ErbB4, PDGFR-A / B, FGFR1 / 2 / 3, IGF1R, INSR, ALK, ROS, TrkA, TrkB, TrkC, RET, c-MET, VEGFR1 / 2 / 3, AXL). SOS1 has also been reported to localize to other phosphorylated cell surface receptors, such as the T-cell receptor (TCR), B-cell receptor (BCR), and monocyte colony-stimulating factor receptor, resulting in the activation of RAS family proteins.
[0011] Furthermore, SOS1 is a GEF for the activation of the GTPase RAC1 (Ras-related C3 botulinum toxin substrate 1). RAC1, like other RAS-family proteins, is known to be involved in the pathogenesis of various cancers and other diseases.
[0012] Currently, BI-3406, BI-1701963, MRTX0902, etc. are being developed as SOS1 activity inhibitors, but they are still in the early stages of development, and there is still a need in the art for the development of novel compounds and pharmaceutical compositions containing the same for treating cancer by inhibiting SOS1.
[0013] An object of the present invention is to provide a compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.
[0014] Another object of the present invention is to provide a pharmaceutical composition comprising a compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.
[0015] Another object of the present invention is to provide a method for preventing or treating an SOS1-mediated disease by administering a compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.
[0016] Another object of the present invention is to provide a use of a compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of SOS1-mediated diseases.
[0017] Each description and embodiment disclosed in this application may also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application is not limited by the specific descriptions described below.
[0018]
[0019] One aspect of the present invention provides a compound, solvate, stereoisomer or pharmaceutically acceptable salt of the following formula (I).
[0020] [Chemical Formula I]
[0021]
[0022] In the above chemical formula I,
[0023] Z 1 and Z 3 are each independently N or CH;
[0024] Z 2 is N or CR a And Z 4 is CH; or
[0025] Z 2 is CR a And Z 4 is N;
[0026] R a is H, halogen, OH, CN, substituted or unsubstituted C1-C6alkoxy, amino, substituted or unsubstituted C1-C6alkylamino, substituted or unsubstituted di(C1-C6alkyl)amino, substituted or unsubstituted C1-C6thioalkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C7 partially unsaturated or saturated cycloalkyl, or a 4- to 7-membered heterocyclyl containing 1 or 2 heteroatoms selected from N, O and S;
[0027] R 1 is H; D; halogen; OH; CN; C1-C6 alkyl optionally substituted with one or more deuterium, OH, oxo (=O) or halogen; -NR A R B ; -OR A ; partially unsaturated or saturated C3-C7 cycloalkyl; optionally substituted C6-C 10 Aryl; optionally substituted 5- to 10-membered heteroaryl; or and;
[0028] RA and R B are each independently H or R a is a C1-C6 alkyl optionally substituted with;
[0029] R 2 is H; C1-C6 alkyl optionally substituted with one or more deuterium, OH, C1-C6 alkoxy or halogen; one or more R 21a A 4- to 7-membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, optionally substituted with; or one or more R 21b is a C3-C7 partially unsaturated or saturated cycloalkyl optionally substituted with;
[0030] R 21a and R 21b are each independently C1-C6 alkyl optionally substituted with one or more halogen, CN, OH, C1-C6 alkoxy, carboxy or oxo; C1-C6 acyl; carboxy; C1-C6 alkoxycarbonyl; or C1-C6 alkylsulfonyl;
[0031] R 3 is H, halogen, OH, C1-C6alkoxy, NH2, C1-C6alkylamino, di(C1-C6alkyl)amino, NO2 or CN;
[0032] R 4 is H, halogen, OH, C1-C6alkoxy, NH2, C1-C6alkylamino, di(C1-C6alkyl)amino, NO2 or CN;
[0033] A 1 Silver deuterium, halogen, OH, C1-C3 alkoxy, And C1-C6 alkyl substituted with one or more substituents independently selected from the group consisting of C1-C3 alkyl; or partially unsaturated or saturated C3-C7 cycloalkyl; wherein the one or more substituents may be bonded to the same or different carbons, and two C1-C3 alkyl bonded to the same carbon atom may optionally form a C3-C4 cyclic ring together with the carbon atoms to which they are bonded;
[0034] A 2 is H, halogen, OH, CN or C1-C6 alkyl;
[0035] A 3 is H, amino, C1-C6 alkylamino or di(C1-C6 alkyl)amino;
[0036] Carbon atoms marked with * and ** are optionally replaced with one or more deuterium atoms;
[0037] The compound of formula I is This is not it.
[0038] In the above chemical formula I, Z 1 is N or CH. Z 3 is N or CH. In one specific example, Z 1 is N, and Z 3 can be N or CH. In one specific example, Z 1 is CH, and Z 3 can be N or CH.
[0039] In chemical formula I, Z 2 is N or CR a It is Z 2 is CR a And Z 4 can be CH. Z 2 is CR a And Z 4 can be N. Alternatively, Z 2 is N, and Z 4 can be CH.
[0040] The above R ais H, halogen, OH, CN, substituted or unsubstituted C1-C6alkoxy, amino, substituted or unsubstituted C1-C6alkylamino, substituted or unsubstituted di(C1-C6alkyl)amino, substituted or unsubstituted C1-C6thioalkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C7partially unsaturated or saturated cycloalkyl, or a 4- to 7-membered heterocyclyl containing 1 or 2 heteroatoms selected from N, O or S. In one specific embodiment, R a may be H, halogen, OH, CN, C1-C6 alkoxy, amino, C1-C6 alkylamino, di(C1-C6 alkyl)amino, or C1-C6 alkyl. In one specific embodiment, R a is a C3-C7 partially unsaturated or saturated cycloalkyl, or a 4- to 7-membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O, or S. For example, the 4- to 7-membered heterocyclyl may be a 4- to 6-membered heterocyclyl comprising 1 or 2 heteroatoms selected from N and O. For example, the 4- to 7-membered heterocyclyl or the 4- to 6-membered heterocyclyl may be, but is not limited to, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, azetidinyl, or oxetanyl. For example, the 4- to 7-membered heterocyclyl or the 4- to 6-membered heterocyclyl may be morpholinyl. In one specific embodiment, R a is H, F, -NHCH3, -N(CH3)2, -OCH3, -CH3 or It could be.
[0041] In the above chemical formula I, R 4 is H, halogen, OH, C1-C6 alkoxy, NH2, C1-C6 alkylamino, di(C1-C6 alkyl)amino, NO2 or CN. In one specific example, R 4 can be H or halogen. For example, R 4 can be H or F.
[0042] In one embodiment, the N-containing ring bonded to the pyridazinone / pyridinone core of formula I may not be substituted with any substituent. In one embodiment, Z 4 is N, and Z 2 can be CH. Also, Z 4 is CH, and Z 2 can be N. In one specific example, Z 4 is CH, and Z 2 is CR a and R a and R 4 All of them can be H.
[0043] Alternatively, one or more substituents R on the N-containing ring bonded to the pyridazinone / pyridinone core of formula I a and / or R 4 can be introduced. For example, R a R is a 4- to 6-membered heterocyclyl containing 1 or 2 heteroatoms selected from halogen, OH, CN, C1-C6 alkoxy, amino, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C1-C6 alkyl, C3-C7 partially unsaturated or saturated cycloalkyl, or N and O; 4 can be H or halogen. For example, R a is H, and R 4 may be a halogen. In one specific example, Z 2 and Z 4 are CH and R respectively 4 can be H or halogen.
[0044] In the above chemical formula I, R 1 is H; D; halogen; OH; CN; C1-C6 alkyl optionally substituted with one or more deuterium, OH, oxo (=O) or halogen; -NR A R B ; -OR A ; partially unsaturated or saturated C3-C7 cycloalkyl; optionally substituted C6-C 10Aryl; optionally substituted 5- to 10-membered heteroaryl; or is. The above R A and R B are each independently H or R a is a C1-C6 alkyl optionally substituted with R. For example, R A and R B are each independently H or C1-C6 alkyl. Here, A 1 , A 2 and A 3 are as described below, respectively. In one specific example, R 1 is H; D; halogen; CN; C1-C6 alkyl optionally substituted with one or more deuterium, OH, oxo (=O) or halogen; partially unsaturated or saturated C3-C7 cycloalkyl; C6-C 10 Aryl; or It can be. For example, R 1 is H, D, F, Br, Cl, CN, methyl, ethyl, CD3, CF3, -CH2OH, -CH(OH)CH3, -C(OH)(CH3)2, -C(=O)CH3, cyclopropyl, cyclohexyl, cyclohexenyl, phenyl, or It can be. In one specific example, R 1 may be CN. In one specific example, R 1 may be C1-C6 alkyl substituted with OH. For example, R 1 can be, but is not limited to, -CH2OH, -CH(OH)CH3, or -C(OH)(CH3)2. In one specific example, R 1 may be C1-C6 alkyl substituted with halogen. For example, R 1 can be CF3. In one specific example, R 1 may be C1-C6 alkyl substituted with oxo (=O). For example, R 1 can be -C(=O)CH3. In one specific example, R 1 Carbon atoms or R contained in 1One or more of these bonded carbon atoms may be replaced by one or more deuterium atoms. For example, R 1 can be, but is not limited to, D or CD3.
[0045] In the above chemical formula I, R 2 is H; C1-C6 alkyl optionally substituted with one or more deuterium, OH, C1-C6 alkoxy or halogen; one or more R 21a A 4- to 7-membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, optionally substituted with; or one or more R 21b is a C3-C7 partially unsaturated or saturated cycloalkyl optionally substituted with R. In one specific example, R 2 may be C1-C6 alkyl optionally substituted with one or more deuterium, OH, C1-C6 alkoxy or halogen. For example, R 2 may be C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C1-C6 alkoxy-C1-C6 alkyl. In this case, one or more carbon atoms included in the alkyl moiety may be replaced with one or more deuterium. Alternatively, R 2 is one or more R 21a It may be a 4- to 6-membered heterocyclyl containing 1 or 2 heteroatoms selected from N and O, optionally substituted with R. In addition, R 2 is one or more R 21b It may be a C3-C7 partially unsaturated or saturated cycloalkyl optionally substituted with R. For example, R 2 may be a C3-C7 partially unsaturated or saturated cycloalkyl optionally substituted with one or more halogens (e.g., F). In one specific embodiment, R 2 One or more of the carbon atoms contained in may be replaced by one or more deuterium atoms.
[0046] The above R 2 In the definition of R 21a and R 21bare each independently C1-C6 alkyl optionally substituted with one or more halogen, CN, OH, C1-C6 alkoxy, carboxy or oxo; C1-C6 acyl; carboxy; C1-C6 alkoxycarbonyl; or C1-C6 alkylsulfonyl. In one specific embodiment, R 21a may be C1-C4 alkyl optionally substituted with one or more OH, C1-C4 alkoxy or oxo; C1-C4 acyl; C1-C4 alkoxycarbonyl; or C1-C4 alkylsulfonyl. In one specific embodiment, R 21b may be halogen.
[0047] In one specific example, R 2 may be C1-C6 alkyl optionally substituted with one or more deuterium or OH. In one specific embodiment, R 2 is R 21a It may be oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazine optionally substituted with R. In one specific example, R 2 may be a C3-C6 cycloalkyl optionally substituted with 1 to 3 halogens.
[0048] For example, R 2 is -CH3, -CD 3, -CH2CH3, -CH(CH3)2, -CH2CH2OH, cyclopropyl, , cyclobutyl,
[0049] or It may be, but is not limited to.
[0050] In the above chemical formula I, R 3 is H, halogen, OH, C1-C6 alkoxy, NH2, C1-C6 alkylamino, di(C1-C6 alkyl)amino, NO2 or CN. In one specific example, R 3 can be H or halogen. For example, R 3 can be H or Cl.
[0051] In one embodiment, the pyrazole / triazole ring of formula I has one or more substituents R 2 and / or R 3 can be introduced. For example, R 2 is C1-C6 alkyl optionally substituted with one or more deuterium, OH, C1-C6 alkoxy or halogen, and R 3 can be H. For example, R 2 is C1-C6 alkyl optionally substituted with one or more deuterium, OH, C1-C6 alkoxy or halogen, and R 3 can be a halogen. For example, R 2 is one or more R 21a A 4- to 6-membered heterocyclyl comprising 1 or 2 heteroatoms selected from N and O, optionally substituted with; or one or more R 21b is a C3-C7 partially unsaturated or saturated cycloalkyl optionally substituted with R; 3 can be H. For example, R 2 is one or more R 21a A 4- to 6-membered heterocyclyl comprising 1 or 2 heteroatoms selected from N and O, optionally substituted with; or one or more R 21b is a C3-C7 partially unsaturated or saturated cycloalkyl optionally substituted with R; 3 can be a halogen. In this case, R 21a and R 21b is as described above, and R described above 2 and R 3 The same specific examples can be applied.
[0052] In the above chemical formula I, A 1 Silver deuterium, halogen, OH, C1-C3 alkoxy, And C1-C6 alkyl substituted with one or more substituents independently selected from the group consisting of C1-C3 alkyl; or partially unsaturated or saturated C3-C7 cycloalkyl. The one or more substituents may be bonded to the same or different carbons. As the one or more substituents, when two C1-C3 alkyls are bonded to the same carbon atom, they may optionally form a C3-C4 cyclic ring together with the carbon atom to which they are bonded. In one specific embodiment, A 1 is C1-C6 alkyl substituted with two or more substituents selected from deuterium, F, OH and C1-C3 alkoxy and C1-C3 alkyl, wherein said C1-C3 alkyl may be C1-C6 alkyl in which two are bonded to the same carbon atom to form a C3-C4 cyclic ring. For example, A 1 -CHF2, -CF3, -CF2CH3, -CF2CH2F, -CF2CH2OH, -CF2CD2OH, -CF2CH2OCH3, or It can be, but is not limited to, for example, A 1 may be cyclobutyl or cyclobutenyl. For example, A 1 silver It could be.
[0053] In the above chemical formula I, A 2 is H, halogen, OH, CN or C1-C6 alkyl. In one specific embodiment, A 2 can be H, halogen or C1-C4 alkyl. For example, A 2 can be H, F, Cl or -CH3.
[0054] In the above chemical formula I, A 3 is H, amino, C1-C6 alkylamino or di(C1-C6 alkyl)amino. In one specific example, A 3 can be H or amino.
[0055] In one specific example, in Chemical Formula I can be selected from the following structures.
[0056]
[0057]
[0058]
[0059] In the compound of formula I according to the present invention, one or more carbon atoms may be substituted with one or more deuterium atoms. R of formula I 1 , R 2 and / or A 1 may include one or more deuterium atoms. In addition, one or more of the carbon atoms indicated by * and ** in formula I may be optionally substituted with one or more deuterium atoms. The deuterium substitution may provide therapeutic benefits resulting from higher metabolic stability, such as increased half-life in the body and / or reduced administration dose. Even if the term "deuterium" is not separately described in the hydrogens included in each substituent other than the above, it should be understood that this does not exclude them and is within the scope of the present invention.
[0060]
[0061] According to one specific example, the compound represented by the above chemical formula I may be a compound represented by the following chemical formula I-1.
[0062] [Chemical Formula I-1]
[0063]
[0064] Z 1 and Z 3 are each independently N or CH;
[0065] Z 2 is N or CR a and;
[0066] R ais H, halogen, OH, CN, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6alkylamino, substituted or unsubstituted C1-C6thioalkoxy, or substituted or unsubstituted C1-C6alkyl;
[0067] R 1 is H, halogen, OH, CN, C1-C6 alkyl optionally substituted with one or more deuterium or halogen, -NR A R B , -OR A , C3-C6 cycloalkyl, optionally substituted C6-C 10 Aryl, or an optionally substituted 5- to 10-membered heteroaryl;
[0068] R A and R B are each independently R a is a C1-C6 alkyl optionally substituted with;
[0069] R 2 is H, or C1-C6 alkyl optionally substituted with one or more deuterium or halogen;
[0070] A 1 is C1-C6 alkyl substituted with one or more substituents independently selected from the group consisting of halogen, OH, C1-C3 alkoxy and C1-C3 alkyl, wherein said one or more substituents may be bonded to the same or different carbons, and two C1-C3 alkyl bonded to the same carbon atom may optionally form a C3-C4 cyclic ring together with the carbon atoms to which they are bonded;
[0071] A 2 is H, halogen, OH, CN or C1-C6 alkyl;
[0072] A 3 is H or amino,
[0073] The compound of chemical formula I-1 is This is not it.
[0074] In chemical formula I-1, Z 1 and Z 3are each independently N or CH.
[0075] In chemical formula I-1, Z 2 is N or CR a In this case, R a is H, halogen, OH, CN, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6alkylamino, substituted or unsubstituted C1-C6thioalkoxy, or substituted or unsubstituted C1-C6alkyl. For example, R a can be H, halogen, OH, CN, or C1-C6 alkyl. For example, R a can be H, halogen or C1-C3 alkyl. For example, R a can be H, F, -CH3.
[0076] According to one specific example, in the chemical formula I-1 of the present invention, Z 1 is N, and Z 2 is CR a And Z 3 can be N or CH. In this case, R a is H, halogen, OH, CN, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6alkylamino, substituted or unsubstituted C1-C6thioalkoxy, or substituted or unsubstituted C1-C6alkyl. For example, R a may be H, halogen, OH, CN, or C1-C6 alkyl, for example, H. For example, Z 1 is N, and Z 2 is CH, and Z 3 can be N. Also, Z 1 is N, and Z 2 is CH, and Z 3 can be CH.
[0077] According to one specific example, in the chemical formula I-1 of the present invention, Z 1 is CH, and Z 2 is CR a And Z 3can be N or CH. In this case, R a is H, halogen, OH, CN, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6alkylamino, substituted or unsubstituted C1-C6thioalkoxy, or substituted or unsubstituted C1-C6alkyl. For example, R a may be H, halogen, OH, CN, or C1-C6 alkyl, for example, H. For example, Z 1 is CH, and Z 2 is CH, and Z 3 can be N. Also, Z 1 , Z 2 and Z 3 All of them can be CH.
[0078] According to one specific example, in the chemical formula I-1 of the present invention, Z 1 and Z 2 are all N, and Z 3 can be CH. Also, Z 1 , Z 2 and Z 3 go All can be N.
[0079] In the chemical formula I-1 of the present invention, R 1 is H, halogen, OH, CN, C1-C6 alkyl optionally substituted with one or more deuterium or halogen, -NR A R B , -OR A , C3-C6 cycloalkyl, optionally substituted C6-C 10 Aryl, or an optionally substituted 5- to 10-membered heteroaryl. In this case, R A and R B are each independently R a It can be a C1-C6 alkyl optionally substituted with R a is as described above. For example, R a can be H, halogen, OH, CN, or C1-C6 alkyl.
[0080] In one specific example, R 1is C1-C6 alkyl or C3-C6 cycloalkyl optionally substituted with H, halogen, OH, CN, one or more deuterium or halogen. In one specific embodiment, R 1 may be C1-C3 alkyl or C3-C5 cycloalkyl optionally substituted with H, halogen, CN, one or more deuterium or halogen. For example, R 1 This can be H, F, Cl, Br, CN, methyl or cyclopropyl.
[0081] In the chemical formula I-1 of the present invention, R 2 is H, or C1-C6 alkyl optionally substituted with one or more deuterium. In one specific embodiment, R 2 may be C1-C3 alkyl optionally substituted with one or more deuteriums. For example, R 2 It can be -CH3, -CD3 or -CH2CH3.
[0082] The above R 1 and R 2 When R is an alkyl substituted with one or more deuteriums, it may be preferable in terms of providing therapeutic advantages resulting from higher metabolic stability, such as increased half-life in the body and / or reduced administration dose. In the chemical formula I-1 of the present invention, R 1 and R 2 Even if the term “deuterium” is not separately described in hydrogen contained in other substituents, it is not excluded and should be understood to fall within the scope of the present invention.
[0083] In the chemical formula I-1 of the present invention, A 1 is C1-C6 alkyl substituted with one or more substituents selected from the group consisting of halogen, OH and C1-C3 alkoxy. The above A 1There is no limitation on the number of substituents as long as they are chemically stable and exhibit the desired activity, for example, C1-C6 alkyl can be substituted with 1, 2, 3, 4 or 5 substituents. The one or more substituents can be different or the same. In addition, the one or more substituents can be bonded to the same or different carbons. For example, A 1 In the case of ethyl substituted with two F and one OH, the two F can be bonded to the same carbon and one OH can be bonded to a different carbon to form -CF2CH2OH. Two C1-C3 alkyl bonded to the same carbon atom can optionally form a C3-C4 cyclic ring with the carbon atom to which they are bonded.
[0084] According to one specific example, in the chemical formula I-1 of the present invention, A 1 may be C1-C3 alkyl substituted with two or more substituents independently selected from the group consisting of F, OH and methoxy. For example, the C1-C3 alkyl may be methyl or ethyl, and may have two F substituted on the same carbon atom, and optionally one F, OH and methoxy substituted on the same or different carbon atoms. For example, A 1 It can be -CHF2, -CF3, -CF2CH3, -CF2CH2F, -CF2CH2OH and -CF2CH2OCH3.
[0085] In the chemical formula I-1 of the present invention, A 2 is H, halogen, OH, CN or C1-C6 alkyl. According to one specific example, A 2 can be H, halogen or C1-C3 alkyl. For example, A 2 can be H, F, Cl or -CH3.
[0086] In the chemical formula I-1 of the present invention, A 3 may be H or amino. In one specific embodiment, A 3 can be H. Alternatively, A 3may be amino.
[0087] In one specific example, in the chemical formula I-1 of the present invention, A 1 is C1-C6 alkyl substituted with one or more substituents independently selected from the group consisting of halogen, OH and C1-C3 alkoxy, and A 2 is H, halogen, OH, CN or C1-C6 alkyl, and A 3 can be H. In this case, A 1 may be C1-C3 alkyl substituted with two or more substituents independently selected from the group consisting of F, OH and methoxy. For example, A 1 This can be -CHF2, -CF3, -CF2CH3, -CF2CH2F, -CF2CH2OH and -CF2CH2OCH3. In this case, A 2 can be H, halogen or C1-C3 alkyl. For example, A 2 can be H, F, Cl or -CH3.
[0088] According to one specific example, in the chemical formula I-1 of the present invention, A 1 C1-C3 alkyl substituted with two or more F, and A 2 A is H, halogen or C1-C3 alkyl, and A 3 A may be amino. In this case, A 1 can be -CHF2 or -CF3. Also, the above A 2 can be H, F, CH3.
[0089]
[0090] In one specific embodiment, the compound of formula I of the present invention may be a compound selected from the following group:
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
[0100]
[0101]
[0102]
[0103]
[0104]
[0105]
[0106]
[0107]
[0108]
[0109]
[0110]
[0111]
[0112]
[0113]
[0114]
[0115]
[0116]
[0117]
[0118]
[0119]
[0120]
[0121]
[0122]
[0123]
[0124]
[0125] definition
[0126] All technical and scientific terms used herein have the meaning commonly understood by one of ordinary skill in the art, and unless otherwise stated, conventional measuring methods, manufacturing methods, conventional ingredients or materials based on conventional techniques of pharmacology, pharmaceutical manufacturing, mass spectrometry, NMR, HPLC, biochemistry, etc. are used.
[0127] The individual features and components of each embodiment described and illustrated in this specification may be combined with the features and components of any other embodiment without departing from the scope or spirit of the present disclosure.
[0128] Unless otherwise specified, in this specification and the appended claims, "or" and "and" mean "and / or." The terms "comprises" and "comprising" are open-ended, meaning that the compound, composition, or method may include additional features or components in addition to the specific features or components listed. Throughout the description and claims of this specification, the singular includes the plural unless the context requires otherwise. In particular, where the indefinite article "a" is used, it is to be understood that this specification contemplates the plural as well as the singular, unless the context requires otherwise.
[0129] In this specification, a numerical range indicated using the term "within" refers to a range that includes the numerical values described before and after the term "within" as the lower and upper limits, respectively. In this specification, a numerical value indicated using the term "about" may refer to a range of ±20% of the corresponding numerical value, preferably ±10% of the corresponding numerical value.
[0130] As used herein, the terms "optional" or "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. For example, the term "optionally substituted" means that the occurrences include instances where the occurrences are either substituted or unsubstituted with the specified substituent.
[0131]
[0132] compound
[0133] The term "alkyl" as used herein refers to a fully saturated branched or unbranched (or straight-chain or linear) hydrocarbon. The alkyl may be a substituted or unsubstituted alkyl group. The term "alkyl" as used herein may refer to, for example, C1-C6 alkyl, C1-C3 alkyl, etc. The C1-C6 alkyl may be an alkyl group that is C1 to C6, C1 to C5, C1 to C4, C1 to C3, or C1 to C2. Non-limiting examples of the alkyl may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, n-pentyl, isopentyl, neopentyl, iso-amyl, or n-hexyl.
[0134] As used herein, the term "alkoxy" refers to a substituent in which a substituted or unsubstituted straight or branched chain alkyl moiety is linked to another chemical structure via oxygen, unless otherwise stated. The term "alkoxy" as used herein may refer to, for example, C1-C6 alkoxy, C1-C3 alkoxy, etc. The alkoxy may include, without limitation, all possible isomers thereof, such as, for example, methoxy, ethoxy, propoxy, and butoxy, or isopropoxy, isobutoxy, and t-butoxy.
[0135] As used herein, the term "thioalkoxy" refers to a substituent in which a substituted or unsubstituted straight or branched chain alkyl moiety is linked to another chemical structure by a sulfur atom.
[0136] As used herein, the term "cycloalkyl" refers to a saturated hydrocarbon ring having the specified number of carbon atoms as ring elements (i.e., C3-C6 cycloalkyl refers to a cycloalkyl group having 3, 4, 5, or 6 carbon atoms as ring elements). The term "cycloalkyl" as used herein may refer to, for example, C3-C6 cycloalkyl, C3-C5 cycloalkyl, or C3-C4 cycloalkyl. The cycloalkyl may be, for example, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. If the cycloalkyl contains one or more double bonds, it is referred to as a "partially unsaturated" cycloalkyl, but does not include an aryl ring.
[0137] The term "halogen" as used herein refers to an atom belonging to Group 17 of the periodic table. Halogen atoms include fluorine, chlorine, bromine, and iodine, and may be used interchangeably with the term "halo," which refers to a monovalent functional group composed of halogen.
[0138] The term "cyano" as used herein refers to a functional group consisting of a triple bond between a carbon atom and a nitrogen atom, as in -CN.
[0139] The term “hydroxy” as used herein refers to an -OH functional group (hydroxyl group).
[0140] The term “oxo” as used herein refers to a double bonded oxygen substituent (=O).
[0141] The term "acyl" as used herein refers to a substituent in which the substituted carbon in an alkyl substituent is replaced with oxo. For example, C1 acyl refers to formyl (-C(=O)H), and C2 acyl refers to acetyl (-C(=O)CH3).
[0142] The term “carboxy” as used herein refers to -COOH.
[0143] The term "carbonyl" as used herein refers to a divalent substituent of -C(=O)-.
[0144] The term "alkoxycarbonyl" as used herein refers to a substituent (-C(=O)-alkoxy) in which one bond of carbonyl is replaced with alkoxy.
[0145] The term “amino” as used herein means -NH2.
[0146] The term “alkylamino” as used herein means that one of the H groups in -NH2 is replaced with alkyl.
[0147] The term "di(alkyl)amino" as used herein means that both H of -NH2 are replaced by alkyl. The two substituted alkyls may be the same or different.
[0148] The term "sulfonyl" as used herein refers to a divalent substituent of -SO2-.
[0149] The term "alkylsulfonyl" as used herein refers to a monovalent substituent (-SO2-alkyl) in which one bond of sulfonyl is replaced with alkyl.
[0150] As used herein, the term "aryl" refers to an aromatic hydrocarbon ring group, which also includes groups in which the ring is fused to one or more carbon rings. For example, aryl is a group having a ring number of C6 to C 10It can be an aryl group. The aryl can be phenyl, naphthyl, or tetrahydronaphthyl.
[0151] As used herein, the term "heteroaryl" refers to a heterocyclic aromatic group containing at least one heteroatom selected from B, N, O, S, P(=O), Si and P as a ring-forming atom. When the heteroaryl contains N, B or P in the ring, the N, B or P of the heteroaryl may be linked to another moiety. The heteroaryl may also include a form in which two or more rings are simply attached to each other (pendant) or condensed. The heteroaryl may contain 1 to 4 heteroatoms selected from N, O and S, 1 to 3 heteroatoms, 1 or 2 heteroatoms, or 1 heteroatom. The heteroaryl may contain 5 to 10, or 5 to 6 ring atoms. Examples of monocyclic heteroaryls include thiophenyl, furanyl, pyrrolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, imidazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like.
[0152] As used herein, the term "heterocyclyl" refers to a monocyclic or polycyclic saturated or partially unsaturated ring system having a specified number of ring elements, and containing one or more heteroatoms selected from B, N, O, S, Si and P, unless otherwise stated (i.e., a 3- to 7-membered heterocyclyl means a heterocyclyl having 3, 4, 5, 6 or 7 ring elements, including the heteroatoms). When the heterocyclyl contains N, B or P in the ring, the N, B or P of the heterocyclyl may be linked to another moiety. A polycyclic heterocyclyl may have two or more heterocyclyl rings that are simply pendant to each other, bridged or condensed, or may also include a spiro configuration. The heterocyclyl may contain 1 to 4 heteroatoms, 1 to 3 heteroatoms, 1 or 2 heteroatoms, or 1 heteroatom selected from N, O, and S. For example, the heteroatom may be N or O. In addition, the heterocyclyl may contain 5 to 10, 4 to 7, 5, or 6 ring atoms. For example, the heterocyclyl may include, but is not limited to, morpholinyl, oxetanyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxanyl, and the like.
[0153] The term "deuterium" as used herein refers to the isotope of hydrogen with a mass number of 2, referred to as heavy hydrogen or deuterium, or by its abbreviation "D". The terms "deuterated" and "substituted with deuterium" are used interchangeably to refer to a moiety or compound in which all or part of the hydrogens contained in the substituent are replaced with deuterium.
[0154] The term "substitution" in the above "substituted or unsubstituted" refers to introducing instead of a hydrogen atom when forming a derivative by replacing one or more hydrogen atoms in an organic compound with another atomic group, and "substituent" refers to the introduced atomic group. Unless otherwise limited, the substituent may be, for example, a halogen atom, a C1-C6 alkyl group substituted with a halogen atom (e.g., CCF3, CHCF2, CH2F, CCl3, etc.), a C1-C6 alkoxy, a C2-C6 alkoxyalkyl, a hydroxy group, an amine group, an imine group, a nitro group, a cyano group, an amino group, an amidino group, a hydrazine, a hydrazone, a carboxyl group or a salt thereof, a sulfonyl group, a sulfamoyl group, a sulfonic acid group or a salt thereof, a phosphoric acid or a salt thereof, a C1-C6 alkyl, a C2-C6 alkenyl, a C2-C6 alkynyl, a C1-C 20 Heteroalkyl group, C6-C 20 Aryl group, C6-C 20 Arylalkyl group, C6-C 20 Heteroaryl group, C7-C 20 Heteroarylalkyl group, C6-C 20 Heteroaryloxy group, C6-C 20 Heteroaryloxyalkyl group, and C6-C 20 It may be a heteroarylalkyl group, etc.
[0155] In this specification, when a combination of substituents is referred to as one group, for example, arylalkyl, cycloalkylalkyl, etc., it generally contains the atom attached to the end of the molecule as the last mentioned group.
[0156] In this specification, "-" is used to indicate the position at which a substituent is bonded to the remaining residue of the compound. For example, when - is displayed at the end of a substituent, it means that the end is bonded to the remaining residue of the compound. Also, when two or more substituents are connected by "-", it means that the substituent immediately before "-" is bonded to the substitutable atom of the substituent immediately after "-".
[0157] The term "solvate" as used herein may refer to a compound of the present invention or a salt thereof that contains a stoichiometric or non-stoichiometric solvent bound by non-covalent intermolecular forces. Preferred solvents for this purpose may be volatile, non-toxic, and / or suitable for human administration. The solvent may be water, in which case the "solvate" is referred to as a "hydrate."
[0158] The term "stereoisomer" as used herein may mean a compound of the present invention or a salt thereof having the same chemical formula or molecular formula but being optically or sterically different, and specifically may be a diastereomer, an enantiomer, or a geometric isomer.
[0159] In some embodiments, the compounds of the present invention may contain one or more asymmetric centers, and may be in the form of racemates, single enantiomers, mixtures of enantiomers, single diastereomers, mixtures of diastereomers, etc. In one embodiment, due to the nature or restricted rotation of the asymmetric center, the compounds of the present invention may exist in the form of enantiomers or diastereomers.
[0160] When two or more asymmetric centers are present in the compounds of the present invention, multiple diastereoisomers and enantiomers of the chemical structures disclosed herein may exist, and all such pure isomers, isolated isomers, partially pure isomers, or racemic mixtures are intended to fall within the scope of the present invention.
[0161] Purification of the above isomers and separation of the isomer mixture can be achieved by standard techniques known in the art. For example, a diastereomeric mixture can be separated into individual diastereoisomers by chromatographic processes or crystallization, and racemates can be separated into individual enantiomers by chiral phase chromatographic processes or resolution.
[0162] The compound of the present invention can be used in the form of a pharmaceutically acceptable salt derived from an inorganic acid or an organic acid, for example, the salt can be a salt derived from hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, or the like.
[0163] A pharmaceutically acceptable salt of the above compound can be prepared by dissolving the compound of formula I in a water-miscible organic solvent, such as acetone, methanol, ethanol, or acetonitrile, adding an excess of an organic acid or an aqueous solution of an inorganic acid, and then precipitating or crystallizing the mixture. Subsequently, the solvent or the excess of acid is evaporated from the mixture, followed by drying to obtain an addition salt, or the precipitated salt can be prepared by suction filtration.
[0164]
[0165] General method for preparing compounds
[0166] The compound according to the present invention can be prepared through chemical modifications well known to those skilled in the art of organic / medicinal chemistry, according to the representative methods illustrated below.
[0167] The following general reaction scheme is a general example of a representative method for preparing a compound of chemical formula I. A person skilled in the art will be able to easily prepare a compound of chemical formula I by appropriately selecting a starting material, reaction temperature, reaction conditions, catalyst, solvent, treatment method, etc. suitable for the desired compound based on the preparation method specifically disclosed in the examples of the present application.
[0168] In the following reaction formulas, the designation of each substituent of the compound of formula I and intermediates is the same as the substituent at the corresponding position in formula I, unless otherwise specified. In addition, in the following reaction formulas, R' represents an alkyl group, and Hal represents a halo group (preferably Br or Cl). For the convenience of explanation, each ring structure of the compound of formula I is referred to as the A-part, B-part, C-part, and D-part, as follows.
[0169]
[0170] In one aspect, the compound of formula I can be prepared according to the preparation method of the following reaction scheme I.
[0171] [Reaction Formula I]
[0172]
[0173] Z of the above reaction formula I 1 , Z 2 , Z 3 , Z 4 , R 1 , R 2 , R 3 , R 4 , A 1 , A 2 and A 3 is the same as in Chemical Formula I. R' in Scheme I may be C1-C6 alkyl (e.g., methyl or ethyl), and Hal may be halogen (e.g., Br).
[0174] In step 1 of the above reaction scheme I, intermediate a can be prepared by coupling a dihalogenated C-part intermediate and an organotin D-part intermediate in the presence of a suitable solvent (e.g., toluene) and a Pd catalyst. The reaction of step 1 can be carried out at a temperature of about 80° C. to about 120° C., about 90° C. to about 100° C., for about 10 hours to about 30 hours, about 15 hours to about 25 hours, for example, 16 hours or 24 hours.
[0175] In step 2, intermediate a can be boronated using a suitable boronating reagent (e.g., bis(pinacolato)diboron) and a catalyst (e.g., a Pd catalyst) to produce intermediate b. The reaction of step 2 can be carried out at a temperature of about 80° C. to about 120° C., about 90° C. to about 100° C., for about 10 hours to about 30 hours, about 15 hours to about 25 hours, such as 16 hours or 24 hours.
[0176] In step 3, intermediate b can be coupled with an A-part ester intermediate in the presence of a suitable base (e.g., pyridine) and a catalyst (e.g., Cu(OAc)2) to produce intermediate c. The reaction of step 3 can be carried out at a temperature of about 80°C to about 120°C, about 90°C to about 100°C, or about 90°C, for about 10 hours to about 30 hours, about 15 hours to about 25 hours, such as about 16 hours.
[0177] In step 4, the ester group of intermediate c can be hydrolyzed using a suitable base (e.g., LiOH or NaOH) to prepare intermediate d. The reaction of step 4 can be carried out at a temperature of about 10° C. to about 20° C., such as about 25° C., for about 10 hours to about 30 hours, about 15 hours to about 25 hours, such as about 16 hours.
[0178] In step 5, the compound of formula I can be prepared by amide coupling of intermediate d with an A-part intermediate. In addition to those described in Scheme I, the amide coupling reagents can be suitably changed as needed, and accordingly, reaction conditions such as an appropriate reaction time and reaction temperature can be selected. If needed, the amide coupling reagents can be suitably changed to, for example, HATU, TEA, DMF, DIEA, DMAP, DCM, etc. The amide coupling reaction of step 5 can be carried out at about 20°C to about 30°C for about 2 hours to about 25 hours. For example, the amide coupling reaction of Scheme 1 can be carried out at about 25°C for about 2 hours to about 20 hours, about 5 hours to about 16 hours, or about 16 hours.
[0179] Alternatively, intermediate c of the above reaction scheme I can be prepared according to the following reaction scheme I-1. The preparation method of the following reaction scheme I-1 differs from the coupling sequence of the reaction scheme I in that the D-part intermediate is coupled after the coupling of the B-part intermediate and the C-part intermediate. However, the reagents and reaction conditions in each step of the reaction scheme I-1 are the same or similar to the corresponding step of the reaction scheme I.
[0180] [Reaction Scheme I-1]
[0181]
[0182] Alternatively, A 3 Compounds of formula I, wherein the amino group is an intermediate, can be prepared by amide coupling of intermediate d and intermediate having a NO2 group in the same manner as in Scheme I, followed by reduction of the NO2 group to an NH2 group under appropriate nitro reducing conditions (e.g., Fe and NH4Cl) (see Scheme I-2 below).
[0183] [Reaction Scheme I-2]
[0184]
[0185] The above nitro reduction reaction can be performed at about 60°C to about 100°C, about 70°C to about 90°C, or about 80°C for about 5 hours to about 20 hours, about 10 hours to about 15 hours, or about 12 hours.
[0186] Alternatively, R 1 Compounds of formula I having substituents other than this halogen (e.g., CN or cyclopropyl, etc.) are R 1 The desired R is obtained by using a suitable cyanating reagent (e.g., CuCN and NMP) or a suitable coupling reagent (e.g., Pd(OAc)2, PCy3, cycloalkylboronic acid compound) on the compound of formula I, which is a halogen. 1 It can be manufactured by introducing Qi.
[0187] Alternatively, R 1 A compound of formula I having a substituent can be prepared by using a B-part intermediate having the corresponding substituent in the above reaction scheme I, I-1 or I-2.
[0188] Alternatively, intermediate c of Scheme I can be prepared according to the following Scheme I-3.
[0189] [Reaction Scheme I-3]
[0190]
[0191] Step 1 of Scheme I-3 can be carried out in the same manner as Step 1 of Scheme I, except that a nitrated and halogenated C-part intermediate is used. Furthermore, Step 2 is a nitroreduction reaction in the same manner as Step 2 of Scheme I-2.
[0192] In step 3, the product of step 2 can be reacted with 3-oxopentanedioate in the presence of a suitable solvent and catalyst (e.g., NaNO2, NaOAc, aq HCl, EtOH) to form a hydrazone compound. The reaction of step 3 can be carried out at a temperature of about -10°C to about 30°C, about -5°C to about 25°C, or about 0°C to about 20°C for about 30 minutes to about 5 hours, about 1 hour to about 2 hours, or about 1 hour.
[0193] In step 4, the product of step 3 can be heated in a suitable solvent (e.g., 1,2-dichlorobenzene) to form a dihydropyridazinone ring. The reaction of step 4 can be carried out at a temperature of about 120°C to about 220°C, about 150°C to about 200°C, or about 180°C for about 5 hours to about 10 hours, or about 8 hours.
[0194] In step 5, a trifluoromethylsulfonyloxy group can be introduced to the dihydropyridazinone ring by adding Tf2O to the product of step 4 in a suitable solvent (e.g., TEA, DCM). The reaction of step 5 can be carried out at a temperature of about -100°C to about 50°C, about -80°C to about 30°C, or about -70°C to about 20°C, for about 30 minutes to about 5 hours, about 1 hour to about 3 hours, or about 2 hours.
[0195] In step 6, the product of step 5 can be reacted with DPPF and Et3SiH in the presence of a suitable catalyst (e.g., Pd(OAc)2) in a suitable solvent (e.g., DMF) to remove the trifluoromethylsulfonyloxy group, thereby producing intermediate c. The reaction of step 6 can be performed at a temperature of about 50°C to about 150°C, about 80°C to about 120°C, or about 100°C, for about 30 minutes to about 3 hours, about 1 hour to about 2 hours, or about 1 hour.
[0196] In one aspect, the compound of formula I can be prepared as shown in the following reaction scheme IA. The preparation method of the following reaction scheme IA differs from the coupling order in reaction scheme I and reaction scheme I-1 in that the coupling of the B-part intermediate and the C-part intermediate is followed by the sequential coupling of the A-part intermediate and the D-part intermediate. However, the reagents and reaction conditions in each step of reaction scheme IA are the same as or similar to the corresponding step in reaction scheme I or reaction scheme I-1.
[0197] [Reaction Scheme IA]
[0198]
[0199]
[0200] Medicinal uses, pharmaceutical compositions and methods of administration
[0201] The compound, stereoisomer, solvate, or pharmaceutically acceptable salt of the above formula I can be used to prevent or treat SOS1-mediated diseases. The compound, stereoisomer, solvate, or pharmaceutically acceptable salt of the above formula I are as described above.
[0202] As used herein, the term "preventing" or "prevention" refers to preventing a disease, condition or disorder, for example, in a subject who may be predisposed to the disease, condition or disorder but does not yet experience or exhibit the pathology or signs of the disease.
[0203] As used herein, the term "treating" or "treatment" includes inhibiting a disease, condition or disorder, e.g., inhibiting the disease, condition or disorder in a subject experiencing or exhibiting the pathology or signs of the disease, condition or disorder, i.e., preventing recurrence or further development of the pathology and / or signs after treatment of the pathology and / or signs, or ameliorating a disease, condition or disorder, e.g., ameliorating the disease, condition or disorder in a subject experiencing or exhibiting the pathology or signs of the disease, condition or disorder, i.e., reversing the pathology and / or signs, e.g., reducing disease severity.
[0204] The above SOS1-mediated disease may include a disease that can be prevented or treated by inhibiting the interaction between SOS1 and a RAS family protein, and / or SOS1 and RAC1. The SOS1-mediated disease may include a disease associated with abnormal activity of SOS1 and / or a RAS family protein. The SOS1-mediated disease may be, for example, cancer. The cancer may be, for example, pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma, uterine cancer, cervical cancer, endometrial cancer, thyroid cancer, chronic lymphocytic leukemia, acute myeloid leukemia, bladder cancer, urothelial cancer, gastric cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, hepatocellular carcinoma, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer, or sarcoma. In one specific example, the cancer may be pancreatic cancer, lung cancer (e.g., non-small cell lung cancer), biliary tract cancer, or colorectal cancer.
[0205] The cancer may be, for example, a cancer dependent on the RAS family and MAPK signaling pathway. Such cancers may include, for example, cancers exhibiting mutations, gene amplification and / or overexpression of proteins or genes in the RAS family and MAPK signaling pathway (e.g., mutations, amplification or overexpression of RAF, MEK), such as KRAS, NRAS, HRAS, receptor tyrosine kinases (e.g., EGFR, ErbB2, ErbB3, ErbB4, PDGFR-A / B, FGFR1 / 2 / 3, IGF1R, INSR, ALK, ROS, TrkA, TrkB, TrkC, RET, c-MET, VEGFR1 / 2 / 3, AXL), GAP (e.g., NF1) and SOS1. In addition, the cancer may be a RAC1-dependent cancer.
[0206] SOS1-mediated diseases may be, for example, diseases associated with dysregulation of the RAS family protein pathway, i.e., RASopathies. Such RASopathies may include Neurofibromatosis type 1 (NF1), Noonan Syndrome, Noonan Syndrome with Multiple Lentigines (NSML), also called Leopard Syndrome, Capillary Malformation-Arteriovenous Malformation Syndrome (CM-AVM), Costello Syndrome, Cardio-Facio-Cutaneous Syndrome (CFC Syndrome), Legius Syndrome (also called NF1-like syndrome), or Hereditary gingival fibromatosis.
[0207] In one embodiment, the compound of formula I can be used to treat diseases associated with abnormal activity of SOS1 or RAS family proteins, or with abnormal regulation of pathways of RAS family proteins, by inhibiting the interaction between SOS1 and RAS family proteins, or SOS1 and RAC1.
[0208] In one embodiment, the pharmaceutical composition may include a conventional pharmaceutically acceptable carrier, excipient, or additive. The pharmaceutical composition may be formulated according to a conventional method and may be prepared in various oral dosage forms such as tablets, pills, powders, capsules, syrups, emulsions, microemulsions, etc., or in parenteral dosage forms such as intramuscular, intravenous, or subcutaneous administration. The pharmaceutical composition may be a single composition or separate compositions. The pharmaceutical composition includes a compound, stereoisomer, solvate, or pharmaceutically acceptable salt according to one aspect as an active ingredient of the pharmaceutical composition.
[0209] When the pharmaceutical composition of the present invention is manufactured in the form of an oral dosage form, examples of additives or carriers used include cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspending agents, emulsifiers, diluents, etc. When the pharmaceutical composition of the present invention is manufactured in the form of an injection, examples of additives or carriers include water, saline solution, glucose aqueous solution, pseudo-sugar aqueous solution, alcohol, glycol, ether (e.g., polyethylene glycol 400), oil, fatty acid, fatty acid ester, glyceride, surfactant, suspending agent, emulsifier, etc.
[0210] The dosage of the pharmaceutical composition is an amount effective for the treatment or prevention of an individual or patient, and may be administered orally or parenterally, depending on the purpose. For oral administration, the dosage is 0.01 to 1000 mg, more specifically 0.1 to 300 mg per kg of body weight per day, based on the active ingredient, and for parenteral administration, the dosage is 0.01 to 100 mg, more specifically 0.1 to 50 mg per kg of body weight per day, based on the active ingredient, and may be administered once or in several divided doses. The dosage for a specific individual or patient should be determined in light of various related factors such as the patient's weight, age, sex, health condition, diet, administration time, administration method, and severity of the disease, and it should be understood that it can be appropriately increased or decreased by a specialist, and the above dosage is not intended to limit the scope of the present invention in any way. A physician or veterinarian having ordinary skill in the relevant art can easily determine and prescribe an effective amount of the required pharmaceutical composition. For example, a physician or veterinarian may start the dosage of a compound of the present invention used in a pharmaceutical composition at a level lower than that required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
[0211] In one embodiment, the pharmaceutical composition includes within its scope a pharmaceutical composition comprising, as an active ingredient, a therapeutically effective amount of at least one compound according to one embodiment, alone or in combination with a pharmaceutical carrier. The term "therapeutically effective amount" or "effective amount" means an amount sufficient to produce a beneficial or desired clinical result, e.g., an amount sufficient to alleviate, improve, stabilize, reverse, slow, or delay the progression of a disease.
[0212] Meanwhile, as described below, when the compound of formula I or formula I-1 according to the present invention is co-administered with one or more other therapeutic agents, a pharmaceutical composition comprising the compound of the present invention and the other therapeutic agents is provided herein. Accordingly, in one specific embodiment, a pharmaceutical composition for preventing or treating cancer is provided, comprising a compound of formula I or formula I-1, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof; and an anticancer agent as active ingredients. The compound of formula I or formula I-1 and the anticancer agent may be included in one pharmaceutical composition, or may be formulated as individual pharmaceutical compositions. The anticancer agent to be co-administered is as described below.
[0213] Combination administration
[0214] Optionally, the compound according to one embodiment may be administered alone, in combination with a compound according to another embodiment, or concurrently, separately, or sequentially with one or more other therapeutic agents, e.g., anticancer agents or other pharmaceutically active substances.
[0215] When used for cancer treatment, the compound of formula I or formula I-1 of the present invention may be administered in combination with another anticancer agent. Here, the compounds of formula I and formula I-1 are as described above.
[0216] In one specific example, in the compound of formula I according to the present invention co-administered with the anticancer agent, R 2 is one or more R 21a A 4- to 7-membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, optionally substituted with; or one or more R 21b It may be a C3-C7 partially unsaturated or saturated cycloalkyl optionally substituted with R. Here, R 21a and R 21bare each independently C1-C6 alkyl optionally substituted with one or more halogen, CN, OH, C1-C6 alkoxy, carboxy or oxo; C1-C6 acyl; carboxy; C1-C6 alkoxycarbonyl; or C1-C6 alkylsulfonyl.
[0217] For example, in the compound of formula I according to the present invention administered in combination with the anticancer agent, R 2 is one or more R 21a A 4- to 6-membered heterocyclyl comprising 1 or 2 heteroatoms selected from N and O, optionally substituted with; or one or more R 21b It may be a C3-C7 partially unsaturated or saturated cycloalkyl optionally substituted with R. Here, R 21a is C1-C4 alkyl optionally substituted with one or more OH, C1-C4 alkoxy or oxo; C1-C4 acyl; C1-C4 alkoxycarbonyl; or C1-C4 alkylsulfonyl, and R 21b may be a halogen. For example, the above R 2 is cyclopropyl, , cyclobutyl,
[0218] or It could be.
[0219] In one specific example, in the compound of formula I according to the present invention co-administered with the anticancer agent, R 1 may be C1-C6 alkyl optionally substituted with one or more deuterium, OH, oxo (=O), or halogen. For example, the R 1 may be C1-C6 alkyl substituted with OH. For example, the above R 1 can be, but is not limited to, -CH2OH, -CH(OH)CH3, or -C(OH)(CH3)2. Alternatively, the R 1 may be C1-C6 alkyl substituted with halogen. For example, R 1 can be CF3. Alternatively, the R 1may be C1-C6 alkyl substituted with oxo (=O). For example, R 1 It can be -C(=O)CH3.
[0220] The anticancer agent that can be administered in combination with the compound of formula I or formula I-1 of the present invention may be selected from the group consisting of chemotherapeutic agents, targeted anticancer agents, anticancer viruses, antibody therapeutic agents, cell therapeutic agents, immune checkpoint inhibitors, and combinations thereof.
[0221] In one embodiment, the compound of formula I or formula I-1 of the present invention is used alone or in combination with other anticancer therapies, such as radiotherapy, taxane derivatives (e.g., paclitaxel, docetaxel), platinum compounds (e.g., cisplatin, carboplatin), antimetabolites (e.g., 5-FU, gemcitabine, cytarabine, 6-thioguanine), CDK4 / 6 inhibitors (e.g., abemaciclib, palbociclib), immunotherapeutic agents (e.g., anti-CTLA4 antibodies, anti-PD1 antibodies), angiogenesis inhibitors (e.g., bevacizumab, nintedanib, regorafenib), topoisomerase inhibitors (e.g., irinotecan, SN-38, doxorubicin), ERK inhibitors (e.g., ulixertinib, lineterkip), MDM2 inhibitors (e.g., alizomedlin), PARP inhibitors (niraparib), MCL-1 inhibitors, mTOR inhibitors (e.g., rapamycin, temsirolimus, INK-128 (sapanisertib), everolimus), BET inhibitors (JQ1), CDK9 inhibitors (e.g., AT-7519), IGF1 / 2 or IGF1-R inhibitors (NVP-ADW742), PIK inhibitors (duvelisib), EGFR inhibitors (e.g., afatinib, osimertinib, cetuximab, lazertinib, gefitinib, neratinib), ErbB2 (HER2) inhibitors (e.g., trastuzumab, irbinitinib, neratinib), ALK inhibitors (e.g., crizotinib, alectinib), MEK inhibitors (e.g., trametinib, cobimetinib), BCR-ABL inhibitors (e.g., imatinib, nilotinib, dasatinib), FGFR1, FGFR2 or FGFR3 inhibitors (e.g., nintedanib), ROS1 inhibitors (e.g., crizotinib, entrectinib, repotrectinib), c-MET inhibitors (e.g., tepotinib), AXL inhibitors (e.g., bemcentinib), NTRK1 inhibitors (e.g., repotrectinib), RET inhibitors (e.g., pralsetinib), KRAS G12C inhibitors (e.g., sotorasib, adagrasib, trametinib, JDQ443), KRAS G12D inhibitors (e.g., MRTX1133), SHP2 inhibitors (e.g., TNO155), mutBRAF inhibitors (e.g., dabrafenib),PI3K inhibitors (e.g., alpelisib, apitolisib), Aurora A inhibitors (e.g., MK-5108), pan Aurora inhibitors (e.g., danucertib, AMG-900, reversine), BTK inhibitors (e.g., ibrutinib), Wee1 inhibitors (e.g., MK-1775), DHFR inhibitors (e.g., methotrexate), HSP90 inhibitors (e.g., BIIB021), A3AR antagonists (e.g., reversine), ubiquitin E1 enzyme inhibitors (e.g., MLN-7243), Bcl-2 inhibitors (e.g., ABT-737), EZH2 inhibitors (e.g., GSK-343), ARID1A inhibitors (e.g., GSK-343), SUMOylation inhibitors (e.g., 2-D08), Chk1 inhibitors (e.g., SCH-900776), HDAC inhibitors (e.g., entinostat), JAK1 / 2 inhibitors (e.g., ruxolitinib), proteasome inhibitors (e.g., carfilzomib), Akt inhibitors (e.g., ipatasertib), GR inhibitors (e.g., prednisolone), PLK1 inhibitors (e.g., volasertib), or pan-RAF inhibitors (e.g., sorafenib).
[0222] The compound of formula I or formula I-1 of the present invention can be used in combination with other anticancer therapies described above to enhance the action of the anticancer therapies, thereby significantly inhibiting the expression and activity of target proteins or genes. Specifically, the compound of formula I or formula I-1 not only has its own anticancer efficacy, but can also enhance the anticancer efficacy of the target inhibitor. Therefore, when formula I or formula I-1 is used in combination with the anticancer therapy, it can exhibit anticancer efficacy superior to the sum of the anticancer efficacy of each when used alone.
[0223] In this specification, the term "chemotherapeutic agent" is also referred to as an antitumor drug or cytotoxic agent. It is a general term for drugs that exhibit anticancer activity by acting directly on DNA to block DNA replication, transcription, and translation processes, interfering with the synthesis of nucleic acid precursors in metabolic pathways, and inhibiting cell division. The antitumor drugs exhibit cytotoxicity not only on tumor cells but also on normal cells. Chemotherapeutic agents can be used for maintenance therapy. In addition, the term "maintenance therapy" as used herein refers to a treatment method implemented to prevent or delay cancer recurrence by treating cancer with drugs after initial anticancer treatment.
[0224] Specifically, the chemotherapeutic agent may be any one selected from the group consisting of an alkylating agent, a microtubule inhibitor, an antimetabolite, and a topoisomerase inhibitor. The alkylating agent may be any one selected from the group consisting of mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, thiotepa, altretamine, procarbazine, busulfan, streptozotocin, carmustine, lomustine, dacarbazine, cisplatin, carboplatin, and oxaliplatin. The microtubule inhibitor may be any one selected from the group consisting of docetaxel, paclitaxel, velban, oncovin, and navelbine. The anti-metabolite may be any one selected from the group consisting of Fluorouracil, Capecitabine, Cytarabine, Gemcitabine, Fludarabine, Methotrexate, Pemetrexed, 6-thioguanine, and Mercaptopurine. The topoisomerase inhibitor may be any one selected from the group consisting of Hycamtin, Camptosar, Vepesid, Blenoxane, Adriamycin, SN-38, Doxorubicin, and Cerubidine.
[0225] As used herein, the term "targeted anticancer agent" refers to a therapeutic agent that specifically kills cancer cells by targeting specific proteins or genetic changes that are abundant only in cancer cells and blocking signals involved in cancer growth and development. These agents are categorized as monoclonal antibodies that react outside the cell and small molecules that act inside the cell. Monoclonal antibodies are anticancer agents that block cancer cell-inducing signals transmitted outside the cell, acting on initiating signals related to proliferation and apoptosis, while small molecules act on complex signaling that occurs inside the cell.
[0226] Specifically, the targeted proteins are mTOR, PI3K, EGFR, VEGFR, CD20, CD38, RNAK-L, BTK, Bcr-abl, PDGFR / FGFR family, MEK, KRAS, ERK1 / 2, HER2 / Neu, Ubiquitin, JAK, ALK, PARP, TGFβR, Proteasome, Bcl-2, C-Met, VR1, VR2, VR3, c-kit, AXL, RET, BRAF, pan-RAF, SHP2, SRC, LCK, DNMT, CDK4 / 6, CDK9, BET, MDM2, IGF1 / 2 or IGF1-R, ROS1, NTRK1, PIK, DHFR, pan Aurora, Aurora A, WEE1, HSP90, A3AR, EZH2, ARID1A, Chk1, ATR, HDAC1 / 3, These could be Akt, PLK1, SUMOylation-related proteins, STING, etc.
[0227] The targeted anticancer drugs are Rapamycin, Sirolimus, Temsilorimus, Everolimus, Ridaforolimus, INK-128, Alpelisib, Cetuximab, Trastuzumab, Pertuzumab, Gefitinib, Erlotinib, Osimertinib, Lazertinib, Panitumumab, Axitinib, Lenvatinib, Bevacizumab, Ramucirumab, Aflibercept, Rituximab, Obinutuzumab, Daratumumab, Denosumab, Ibrutinib, Dasatinib, Nilotinib, Imatinib, Bosutinib, Galunisertib, Vactosertib, Futibatinib, Nintedanib, Sunitinib, Sorafenib, Cabozantinib, Regorafenib, Masitinib, Semaxanib, Tivozanib, Vandetanib, Pazopanib, Dabrafenib, Sotorasib, Adagrasib, JDQ443, MRTX1133, Ulixertinib, Afatinib, Lapatinib, Neratinib, Lenalidomide, Ixazomib, Ruxolitinib, Lestaurtinib, Pacritinib, Trametinib, Cobimetinib, Selumetinib, Binimetinib, Alectinib, Lorlatinib, Crizotinib, Venetoclax, Bemcentinib, Gilteritinib, Selpercatinib, Pralcetinib, Encorafenib, Vemurafenib, Belvarafenib, RMC-4630, Batoprotafib, WH-4-023, Olaparib, Talazoparib, Niraparib, Rucaparib, Azacitidine, Decitabine, Guadecitabine, Abemaciclib,<h2 style=";text-align:left;direction:ltr">Ribociclib, Palbociclib, CDNs, SB11285, Rineterkib, Repotrectinib, Tepotinib, Alrizomadlin, JQ1, NVP-ADW742, Duvelisib, Irbinitinib, Danusertib, MK-1775, AMG-900, BIIB021, Reversine, MLN-7243, ABT-737, MK-5108, GSK-343, 2-D08, SCH-900776, Entinostat, Carfilzomib, Apitolisib, Ipatasertib, Volasertib, AT-7519, Methotrexate, Wortmannin, ERAS-007, PYR-41, MLN4924, RO-5503781, MK-8242, PF-07284892 TNO155, Hesperadin, LY3295668, Tozasertib, Azenosertib, ZNL-02-096, RP-6306, GSK-1520489A, BIIB028, MPC-3100, PU-H71, Debio093, SNX-5422, AUY922, KF-26777, MRS-545, CAY10498, DZNep, EPZ005687, EI1, GSK126, UNC1999, Tazemetostat, Sinefungin, GSK-343, Davidiin, CID9549553, SRA737, V158411, PF-477736, AZD7762, Prexasertib, Berzosertib, Gartisertib, Ceralasertib, Panobinostat, Mocetinostat,Trichostatin A, CBUD1001, Abexinostat, VQD-002, Perifosine, Miltefosine, MK-2206, AZD5363, Rigosertib, I-BET 151, I-BET 762, OTX-015, TEN-010, CPI-203, CPI-0610, Olinone, RVX-208, ABBV-744, LY294002, AZD5153, MT-1, MS645, Figitumumab, Mecasermin, rhIGF-1, BI 885578, Buparlisib, Copanlisib, Dactolisib, Idelalisib, Parsaclisib, Paxalisib, Taselisib, Zandelisib, Inavolisib, AZD4573, Atuveciclib, It may be any one selected from the group consisting of VIP152, A-1592668, JSH-150, SLS009, Roscovitine and DMXAA.
[0228] As used herein, the term “mTOR (mammalian target of rapamycin)”, also called mechanistic target of rapamycin or FRAP1 (FK506 binding protein 12-rapamycin associated protein 1), is a protein belonging to the PIKK (phosphatidylinositol 3-kinase-related kinase) family. mTOR is encoded by the FRAP1 gene in humans and is a serine / threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. mTOR inhibitors can suppress tumor survival by inhibiting autophagy, adipogenesis, proliferation, and protein synthesis. mTOR inhibitors may be, for example, Rapamycin, Sirolimus, Temsilorimus, Everolimus, Ridaforolimus or INK-128 (Sapanisertib, MLN0128, TAK-228).
[0229] In this specification, “PI3K (Phosphoinositide 3-kinase)” is also called phosphatidylinositol 3-kinase, and is an enzyme involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival, and intracellular signal regulation, and is related to cancer. PI3K contains subunits such as p110-α / β / γ / δ (PI3Kα / β / γ / δ). PI3K-targeting anticancer drugs may include Alpelisib, Wortmannin, LY294002, Idelalisib, Copanlisib, Duvelisib, Apitolisib (GDC-0980, RG7422, GNE 390), etc.
[0230] As used herein, the term "epidermal growth factor receptor (EGFR)" refers to a cell membrane receptor that regulates cell growth, division, survival, and apoptosis. EGFR expression is increased in tumor tissues of various cancers. Tumor tissues with increased EGFR are known to have high invasion, metastasis, and anticancer drug resistance. As an EGFR inhibitor, a substance that inhibits EGFR may be, for example, Cetuximab, Trastuzumab, Pertuzumab, Gefitinib, Erlotinib, Osimertinib, Lazertinib, or Panitumumab.
[0231] As used herein, the term "Vascular Endothelial Growth Factor Receptor (VEGFR)" refers to a cell membrane receptor of an angiogenic factor that induces angiogenesis, and a VEGFR inhibitor inhibits angiogenesis, thereby suppressing tumor growth and metastasis. A specific example of a VEGF inhibitor or VEGFR inhibitor may be Axitinib, Lenvatinib, Bevacizumab, Ramucirumab, or Aflibercept.
[0232] In this specification, the term "CD20 (B lymphocyte antigen CD20)" refers to a protein expressed on the surface of B cells and is used as a target protein for treating B cell lymphoma. The CD20 target inhibitor may be Rituximab or Obinutuzumab.
[0233] In this specification, the term "CD38 (Cluster of differentiation 38)" refers to a protein that acts as a signal transduction receptor in immune cells and regulates cell proliferation and death, and an inhibitor targeting this may be Daratumumab.
[0234] In this specification, the term "RNAK-L (Receptor activator of nuclear factor kappa-β ligand)" refers to the RANK receptor expressed on the surface of osteoclasts, which, when activated by binding to a ligand, causes bone destruction. RANK-L inhibitors are mainly used for cancer patients suffering from bone metastasis or osteoporosis, and may be specifically Denosumab.
[0235] In this specification, the term "BTK (Bruton's tyrosine kinase)" refers to an enzyme involved in the proliferation of B cells, which, when overexpressed, can develop into blood cancer. A specific example of a BTK target inhibitor may be Ibrutinib.
[0236] As used herein, the term "Bcr-abl" refers to a fusion protein highly expressed in patients with chronic myeloid leukemia, known to induce abnormal proliferation of blood cells. Specifically, the inhibitor of the protein may be Dasatinib, Nilotinib, Imatinib, or Bosutinib.
[0237] As used herein, the term "tumor growth factor β receptor (TGFβR)" refers to a cell membrane receptor of a tumor growth factor, which regulates the growth, migration, differentiation, and apoptosis of epithelial cells and hematopoietic cells. Examples of the TGFβR target inhibitor include, but are not limited to, Galunisertib or Vactosertib.
[0238] In this specification, the term "PDGFR (Platelet derived growth factor)" refers to a cell membrane receptor of PDGF, which is frequently expressed in cancer cells, and is known to regulate cancer growth, metastasis, and drug resistance by participating in angiogenesis. Fibroblast growth factor receptor (FGFR) is a receptor for fibroblast growth factor (FGF) and regulates various biological processes including cell growth, differentiation, and migration. The FGFR gene is prone to mutation, and such variants are commonly observed in breast cancer, uterine cancer, ovarian cancer, and cervical cancer. Inhibitors targeting PDGFR or FGFR may be Futibatinib, Nintedanib, Sunitinib, Imatinib, Sorafenib, Cabozantinib, Lenvatinib, Regorafenib, Masitinib, Semaxanib, Tivozanib, Vandetanib, Axitinib, or Pazopanib.
[0239] As used herein, the term “MEK (Mitogen-activated protein kinase kinase)” refers to a dual-specificity kinase enzyme that phosphorylates MAPK (mitogen-activated protein kinase), also called MAP2K, MEK, or MAPKK, and inhibition of MEK blocks cell proliferation and induces cell death. The MEK-targeting anticancer agent may be Cobimetinib, Selumetinib, Trametinib, or Binimetinib.
[0240] In this specification, the term “KRAS (Kirsten rat sarcoma virus)” refers to a gene that makes a protein called K-Ras, which is part of the RAS / MAPK pathway and is an oncogene that instructs cells to signal growth, division, proliferation, and differentiation. The KRAS-targeting anticancer agent may be Sotorasib, Adagrasib, JDQ443, or MRTX1133.
[0241] As used herein, the term “ERK1 / 2 (extracellular signal-regulated kinases 1 / 2)” refers to a widely expressed protein kinase intracellular signaling molecule involved in functions including regulation of meiosis, mitosis, and post-mitotic functions in cells, and disruption of the ERK pathway is commonly observed in cancer. The ERK1 / 2-targeting anticancer agent may be Rineterkib, Ulixertinib (BVD-523), or ERAS-007.
[0242] In this specification, the term "HER-2 / neu (Human epidermal growth factor receptor 2) regulates cell proliferation by activating PI3K / AkT. It is overexpressed in metastatic breast cancer and ovarian cancer, etc., and is known to induce anticancer drug resistance. The Her2 / neu targeted anticancer agent may be Trastuzumab, Afatinib, Lapatinib, Irbinitinib (Tucatinib), or Neratinib.
[0243] As used herein, the term "ubiquitin" refers to a protein that binds to other proteins and induces protein degradation by the proteasome, a protein-degrading enzyme (ubiquitin-proteasome system, UPS), thereby maintaining cellular homeostasis. Abnormal expression or activity of the UPS is observed in various tumors, and inhibitors thereof exhibit anticancer activity. For example, ubiquitin E1 enzyme target inhibitors may include MLN-7243 (TAK-243), PYR-41, MLN4924, etc., and MDM2 E3 ubiquitin ligase inhibitors may include RO-5503781 (Idasanutlin), MK-8242, SAR-405838, CGM097, DS3032b, etc.
[0244] As used herein, a “proteasome inhibitor” can treat cancer by blocking the action of the proteasome, a cellular complex that degrades proteins. Proteasome inhibition prevents the degradation of pro-apoptotic factors such as the p53 protein, thereby activating programmed cell death in tumor cells that depends on inhibition of the pro-apoptotic pathway. Proteasome inhibitors may include Lactacystin, Disulfiram, Epigallocatechin-3-gallate, Marizomib (salinosporamide A), Oprozomib (ONX-0912), Delanzomib (CEP-18770), Epoxomicin, MG132, Beta-hydroxy beta-methylbutyrate, Bortezomib, Carfilzomib, Ixazomib, and the like.
[0245] In this specification, the term "JAK (Janus kinase)" refers to a protein above STAT, a transcription factor that regulates cell proliferation, cell survival, cell migration, and immune response, and JAK inhibitors are known to reduce cell proliferation and induce apoptosis by inhibiting the activity of STAT. JAK includes JAK1, JAK2, JAK3, and TYK2 (tyrosine kinase 2). The JAK target inhibitor may be Ruxolitinib, Lestaurtinib, or Pacritinib.
[0246] As used herein, the term "ALK (Anaplastic lymphoma kinase)" refers to a signal transduction mediator that promotes cell proliferation, cell migration, angiogenesis, and inhibits apoptosis, and is overactivated in various cancer tissues. The ALK target inhibitor may be Alectinib, Lorlatinib, or Crizotinib.
[0247] As used herein, the term "Bcl-2" refers to a protein that inhibits cell death and is overexpressed or overactivated in various cancer tissues. Inhibitors targeting Bcl-2 may include Venetoclax, ABT-737, Navitoclax (ABT-263), and the like.
[0248] As used herein, the term "C-Met" refers to a receptor for hepatocyte growth factor (HGF), which activates signaling involved in cell growth, formation, motility, survival, and angiogenesis. The C-Met targeted anticancer agent may be Crizotinib, Tepotinib, or Cabozantinib.
[0249] In this specification, the term "VR (Vanilloid receptor)" is also known as TRPV (Transient receptor potential vanilloid) and exists in the form of VR1, VR2, VR3, VR4, VR5 and VR6. VR is known to regulate the proliferation, death, migration, invasion and angiogenesis of cancer cells at each stage in the cancer progression process.
[0250] As used herein, the term "c-kit," also known as CD117, induces signaling that activates cell survival, proliferation, and differentiation. c-kit is a proto-oncogene, and its overexpression or mutation is associated with cancer development. Specific examples of c-kit-targeting anticancer agents include Imatinib, Dasatinib, and Regorafenib.
[0251] As used herein, the term "AXL (Yyrosine-protein kinase receptor UFO)" refers to a cell surface tyrosine kinase receptor that mediates signal transduction involved in cell proliferation and survival. It is known to be involved in anticancer drug resistance in cancer treatment. A specific example of an AXL-targeting anticancer agent may be Bemcentinib or Gilteritinib.
[0252] In this specification, the term "RET (Rearragned during transfection)" refers to a receptor that mediates signals involved in cell proliferation, apoptosis, and survival, and mutations in RET are known to be involved in the development of cancer. The RET target inhibitor may be, but is not limited to, Selpercatinib or Pralsetinib.
[0253] As used herein, the term "BRAF" refers to a MAPK signaling mediator involved in cell proliferation, cell cycle regulation, cell survival, angiogenesis, cell migration, etc., and genetic mutations are observed in cancer cells. The inhibitor targeting BRAF may be Dabrafenib, Encorafenib (LGX818), or Vemurafenib.
[0254] In this specification, the term "pan-RAF" encompasses RAF family substances such as BRAF, ARAF, CRAF, etc., and the inhibitor targeting pan-RAF may be Naporafenib, Belvarafenib, or Sorafenib.
[0255] In this specification, the term “SHP2 (Src homology region 2 domain-containing phosphatase-2)”, also called Tyrosine-protein phosphatase non-receptor type 11 (PTPN11) or Protein-tyrosine phosphatase 1D / 2C (PTP-1D / 2C), is known as a signaling molecule that regulates various cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. Activating mutations of SHP2 are found in neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, lung cancer, and colon cancer. Inhibitors targeting SHP2 may include, for example, PF-07284892, RMC-4630 (SHP2-IN-7) or Batoprotafib (TNO155).
[0256] As used herein, the term "SRC (Proto-oncogene tyrosine-protein kinase)" refers to a non-receptor tyrosine kinase protein, also known as c-Src, which regulates embryonic development and cell growth, and its elevated activity level is known to be associated with cancer progression. An SRC inhibitor may be, for example, Dasatinib or Bosutinib.
[0257] As used herein, the term "LCK (lymphocyte-specific protein tyrosine kinase)" belongs to the SFK (Src kinase family) and activates T cell receptor signaling. Mutations and dysfunction of LCK impair T cell activation, and cancer, asthma, diabetes mellitus 1, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, and inflammatory bowel diseases (Crohn's disease and ulcerative colitis) are known to be associated with overexpression of LCK. An inhibitor targeting LCK may be, for example, WH-4-023.
[0258] As used herein, the term "PARP (Poly[ADP-ribose]polymerase)" refers to a protein that recognizes damaged DNA in the nucleus, becomes activated, and then activates DNA repair-related proteins. A PARP target inhibitor inhibits the proliferation of cancer cells by inhibiting DNA repair in cancer cells. A specific example of the PARP target inhibitor may be Olaparib, Talazoparib, Niraparib, or Rucaparib.
[0259] As used herein, the term "DNA methyltransferase (DNMT)" refers to an enzyme that attaches a methyl group to the histone protein that wraps DNA, thereby suppressing gene expression. The DMNT target inhibitor exhibits anticancer activity by inhibiting hypermethylation of tumor suppressor genes and inducing normal expression of the tumor suppressor genes. Specific examples of the DNMT target inhibitor may be Azacitidine, Decitabine, or Guadecitabine.
[0260] As used herein, the term "CDK (Cyclin-dependent kinase) 4 / 6" refers to a protein that promotes cell growth by regulating the cell cycle, and is overactive in the development and progression of various malignant tumors. CDK4 / 6 targeted inhibitors exhibit anticancer activity by inhibiting cell proliferation and inducing apoptosis by inhibiting the cell cycle of cancer cells. The CDK4 / 6 targeted inhibitor may be Abemaciclib (LY2835219), Ribociclib, or Palbociclib.
[0261] As used herein, “Aurora kinase” is a serine / threonine kinase essential for cell proliferation and a phosphotransferase enzyme that helps dividing cells distribute their genetic material to daughter cells. Aurora kinase plays a crucial role in cell division by controlling chromatid segregation, and defects in segregation can lead to tumorigenesis. Aurora A (Aurora 2) functions during mitotic prophase and is involved in the proper replication and segregation of centrosomes (the microtubule-organizing center of eukaryotic cells). Aurora B (Aurora 1) is responsible for attaching the mitotic spindle to the centromere. Aurora C (AURKC) acts in germ cells. Aurora A-targeting inhibitors may include MK-5108, Hesperadin, LY3295668, etc. Pan-Aurora target inhibitors may include Danusertib, AMG-900, Reversine, and Tozasertib (VX-680).
[0262] In this specification, “WEE1” is a 96 kDa nuclear kinase belonging to the Ser / Thr protein kinase family, also called mitosis inhibitor protein kinase Wee1. Mitosis-promoting factor (MPF) regulates apoptosis induced by DNA damage, and negative regulation of MPF by WEE1 induces abnormal mitosis, resulting in resistance to apoptosis induced by DNA damage. A WEE1-targeting inhibitor can reduce the sensitivity to apoptosis induced by DNA damage in cancer cells by regulating WEE1. WEE1-targeting inhibitors may include MK-1775 (Adavosertib), Azenosertib (ZN-C3), ZNL-02-096, etc.
[0263] In this specification, “PKMYT1 (protein kinase, membrane-associated tyrosine / threonine 1)” belongs to the Wee1 protein kinase family and, as a regulator of CDK1 phosphorylation, is a potent therapeutic target for the treatment of certain types of DNA damage-responsive cancers through the lethality of CCNE1 amplification. PKMYT1-targeted inhibitors may include RP-6306, GSK-1520489A, etc.
[0264] As used herein, "HSP90 (heat shock protein 90)" is a chaperone protein that helps other proteins fold properly, stabilizes proteins from heat stress, and aids protein degradation. It can exhibit anticancer effects by stabilizing numerous proteins necessary for tumor growth. HSP90 inhibitors may include BIIB021, BIIB028, MPC-3100, PU-H71, Debio093, SNX-5422, AUY922, and the like.
[0265] In this specification, “A3AR (adenosine A3 receptor; ADORA3)” is a G protein-coupled receptor that binds Gi / Gq and is involved in various intracellular signaling pathways and physiological functions. It is overexpressed in pathological human cells and can mediate cell proliferation and apoptosis. A3AR-targeting therapeutic agents may include Reversine, KF-26777, MRS-545, CAY10498, and the like.
[0266] As used herein, "EZH2 (enhancer of zeste homolog 2)" refers to a histone-lysine N-methyltransferase enzyme encoded by the EZH2 gene, which participates in histone methylation and ultimately transcriptional repression. EZH2 is an attractive target for anticancer therapy because it promotes cancer cell division and proliferation, and is found in higher amounts in a wide range of cancers, including breast, prostate, bladder, uterine, and renal cancers, as well as melanoma and lymphoma, compared to healthy cells. EZH2-targeting inhibitors may include DZNep, EPZ005687, EI1, GSK126, UNC1999, Tazemetostat, Sinefungin, etc.
[0267] In this specification, “ARID1A (AT-rich interactive domain-containing protein 1A)” is a member of the SWI / SNF family, which has helicase and ATPase activities and regulates the transcription of specific genes by altering the chromatin structure around the gene. The ARID domain is a DNA binding domain that can specifically bind to AT-rich DNA sequences known to be recognized by the SWI / SNF complex in the beta-globin locus, and the C-terminus of the protein can stimulate glucocorticoid receptor-dependent transcriptional activation. This gene is frequently mutated in gastric cancer, ovarian clear cell carcinoma, and pancreatic cancer. Inhibitors targeting EZH2 / ARID1A may include GSK-343, etc.
[0268] As used herein, "SUMOylation" is a post-translational modification that covalently attaches a small ubiquitin-like modifier (SUMO) polypeptide to a lysine residue of a target protein. The enzymatic pathway of SUMOylation is very similar to that of ubiquitination and involves an activating enzyme, a conjugating enzyme, a ligase, and a deconjugating enzyme. Dysregulation of the SUMOylation pathway has been observed in cancer and neurological diseases, with SUMO enzymes being upregulated in many cancers, and SUMO levels directly correlate with prognosis and disease progression. SUMOylation inhibitors may include Davidiin, CID9549553, and 2-D08.
[0269] In this specification, “Chk1 (checkpoint kinase 1; CHEK1)” is a serine / threonine-specific protein kinase that regulates the DNA damage response (DDR) and cell cycle checkpoint responses. Activation of Chk1 leads to the initiation of cell cycle checkpoints, cell cycle arrest, DNA repair, and apoptosis, thereby preventing damaged cells from progressing through the cell cycle. Chk1 is overexpressed in numerous tumors, including breast, colon, liver, gastric, and nasopharyngeal cancers, and the positive correlation between Chk1 expression and tumor grade and disease recurrence suggests that Chk1 may promote tumor growth. Chk1-targeting inhibitors may include SCH-900776, SRA737, V158411, PF-477736, AZD7762, and LY2880070 (Prexasertib).
[0270] As used herein, the term “ATR (Ataxia telangiectasia mutated (ATM) and RAD3-related kinase)” is a protein kinase involved in the cellular response to certain forms of DNA damage (e.g., double-strand breaks and replication stress). Normal cells repair damaged DNA using the ATM / ATR signaling pathway, which regulates the cellular response to double-strand DNA breaks and replication stress, referred to as the DNA Damage Response ("DDR"). In contrast, many cancer cells exhibit a high dependence on DNA repair proteins, including ATR, due to defects in ATM in the DNA repair process. The ATR-targeting inhibitor may be Berzosertib (VX-970), Gartisertib (VX-803), or Ceralasertib (AZD6738).
[0271] As used herein, “HDAC (histone deacetylases)” are enzymes that remove acetyl groups from the ε-N-acetyl lysine amino acid of histones and non-histone proteins, and regulate DNA expression by acetylation and deacetylation by making histones wrap DNA more tightly. HDACs include subgroups such as class I, such as HDAC1, HDAC2, and HDAC3, and class IIA, such as HDAC4, HDAC5, and HDAC7. HDAC inhibitors have shown anticancer efficacy in studies on pancreatic cancer, esophageal squamous cell carcinoma (ESCC), multiple myeloma, prostate carcinoma, gastric cancer, leukemia, breast cancer, liver cancer, ovarian cancer, lung cancer, Hodgkin lymphoma, and neuroblastoma. HDAC target inhibitors may include Panobinostat (LBH589), Entinostat, Mocetinostat, Trichostatin A, CBUD1001, Abexinostat (PCI-24781, CRA-024781), etc.
[0272] As used herein, "Akt (protein kinase B: PKB)" refers to a family of serine / threonine-specific protein kinases that play a key role in various cellular processes, such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell death, and are associated with tumor cell survival, proliferation, and invasiveness. Akt activation is commonly observed in human cancer and tumor cells, and tumor cells depend on Akt for survival. Akt-targeting inhibitors may include VQD-002, Perifosine, Miltefosine, MK-2206, AZD5363, Ipatasertib, and the like.
[0273] In this specification, “PLK1 (Polo-like kinase 1)”, also called serine / threonine-protein kinase 1 or serine / threonine-protein kinase 13 (STPK13), is a 66 kDa enzyme consisting of 603 amino acids. Many colon and lung cancers are caused by mutations in K-RAS and are known to be dependent on PLK1. Silencing PLK1 expression by RNA interference in cell culture can selectively kill K-RAS cells without harming normal cells. PLK1-targeting inhibitors may include Volasertib, Rigosertib, etc.
[0274] In this specification, “BET (Bromodomain and extraterminal domain protein)” refers to a bromodomain composed of approximately 110 amino acid proteins that recognize acetylated lysine residues, including BRD2, BRD3, BRD4, and BRDT, and transduce signals transmitted by acetylated lysine residues into various normal or abnormal phenotypes. The bromodomain translates dysregulated cellular acetylomes into disease phenotypes, and BET is a target for cancer and multiple sclerosis. BET target inhibitors may include JQ1, I-BET 151 (GSK1210151A), I-BET 762 (GSK525762), OTX-015, TEN-010, CPI-203, CPI-0610, Olinone, RVX-208, ABBV-744, LY294002, AZD5153, MT-1, MS645, etc.
[0275] As used herein, “IFG (insulin-like growth factor)” refers to a protein with high sequence similarity to insulin, which is involved in communication between cells and the physiological environment, and includes IGF1 / 2, IGF-1R, and IGF-2R. IGF-1 stimulates the growth of prostate and breast cancer cells, and IGFs are being found to be involved in diseases such as cancer and diabetes. IGF1 / 2 or IGF-1R targeting inhibitors may include NVP-ADW742, Figitumumab, Mecasermin, rhIGF-1, BI 885578, and the like.
[0276] As used herein, “PIK (phosphatidylinositol kinase)” consists of phosphatidylinositol 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K). PI3K phosphorylates phosphoinositides at the 3-hydroxyl group of the inositol ring and is involved in cell signaling, and PI4K acts on phosphatidylinositol (PI) to produce the second messenger inositol-1,4,5-trisphosphate, and abnormalities of these are associated with cancer. PIK target inhibitors may include Duvelisib, Buparlisib, Copanlisib, Dactolisib, Idelalisib, Parsaclisib, Paxalisib, Taselisib, Zandelisib, Inavolisib, and the like.
[0277] As used herein, "CDK9 (cyclin-dependent kinase 9)" is a cell cycle regulator that is associated with P-TEFb. CDK9 participates in several protein-protein interaction networks that are often implicated in transcriptional deregulation in cancer. CDK9-targeting inhibitors may include, for example, AZD4573, atuveciclib, VIP152, A-1592668, JSH-150, SLS009, AT-7519, and Roscovitine.
[0278] As used herein, “DHFR (dihydrofolate reductase)” is an enzyme that reduces dihydrofolate to tetrahydrofolate using NADPH as an electron donor, and is a component of the multiprotein complex TAK / P-TEFb, an elongation factor for transcription and function by RNA polymerase II, by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. DHFR is responsible for the level of intracellular tetrahydrofolate, and inhibition of DHFR can limit cell growth and proliferation, which is a characteristic of cancer and bacterial infection. DHFR target inhibitors may include Methotrexate, Pralatrexate, Pemetrexed, Raltitrexed, Trimetrexate, Nolatrexed, Piritrexim, Talotrexin, and the like.
[0279] As used herein, the term "STING (Stimulator of Interferon Genes)" refers to an in vivo sensor that recognizes DNA fragments released from cancer cells, stimulates interferon genes, and activates immune cells in the body, such as dendritic cells. The STING agonist exhibits immune-enhancing and tumor angiogenesis-inhibiting effects. Examples of STING agonists include CDNs, SB11285, and DMXAA.
[0280] The compound of formula I or formula I-1 of the present invention can be used in combination with other target inhibitors described above to enhance the action of the target inhibitor, thereby significantly inhibiting the expression and activity of the target protein or gene. Specifically, the compound of formula I or formula I-1 not only has its own anticancer efficacy, but can also enhance the anticancer efficacy of the target inhibitor. Therefore, when formula I or formula I-1 is used in combination with the target inhibitor, it can exhibit an anticancer efficacy superior to the sum of the anticancer efficacy of each when used alone.
[0281] As used herein, the term "oncolytic virus therapy" refers to a therapeutic agent that kills cancer by inserting a specific gene targeting cancer cells into a virus capable of replication and infection. The oncolytic virus therapy may be Talimogene Laherparepvec.
[0282] As used herein, the term "antibody therapeutic agent" refers to a therapeutic agent that exhibits an anticancer effect by utilizing an antibody that recognizes a specific protein of a cancer cell as an antigen. Antibody therapeutic agents may be Cetuximab, Trastuzumab, Emtansine, Emtansine, Rituximab, Ibritumomab, Tositumomab, Brentuximab, Ofatumumab, Obinutuzumab, Necitumumab, Bevacizumab, Ramucirumab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, Ipilimumab, etc.
[0283] As used herein, the term "immunotherapy" refers to a treatment that uses immune cells such as dendritic cells, natural killer cells, and T cells to activate the immune response in the body and exhibit an anticancer effect. Immunotherapy is used by extracting immune cells from the body, strengthening them, or genetically modifying them, and then reinjecting them into the body. Representative immunotherapy agents include T cell receptor-modified T cells (TCR-T) and chimeric antigen receptor-modified T cells (CAR-T). Specifically, it may be, but is not limited to, Tisagenlecleucel or Axicabtagene Ciloleucel.
[0284] As used herein, the term "immune checkpoint inhibitor" refers to a substance that inhibits the activity of immune checkpoint proteins that suppress the differentiation, proliferation, and activity of immune cells, and is known to eliminate cancer cells by preventing cancer cells from exercising their function of evading the immune system. The immune checkpoint inhibitor may be any one selected from the group consisting of anti-CTLA-4 antibodies, anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-PD-L2 antibodies, anti-B7-H4 antibodies, anti-HVEM antibodies, anti-TIM3 antibodies, anti-GAL9 antibodies, anti-LAG3 antibodies, anti-VISTA antibodies, anti-KIR antibodies, anti-BTLA antibodies, and anti-TIGIT antibodies. In a specific example, the immune checkpoint inhibitor may be, but is not limited to, Ipilimumab, Pembrolizumab, Nivolumab, Cemiplimab, Atezolizumab, Avelumab, and Durvalumab.
[0285] As used herein, the term "ADC (Antibody Drug Conjugate)" refers to a therapeutic agent that exhibits high anticancer efficacy through targeted delivery by chemically combining an antibody and a cytotoxic drug. Examples thereof include Gemtuzumab-Ozogamicin, Brentuximab-Vedotin, Trastuzumab-Emtansine, Inotuzumab-Ozogamicin, and Eribulin-Mesylate.
[0286] The anticancer agent may include one or more anticancer agents. Specifically, the compound, solvate, stereoisomer, or pharmaceutically acceptable salt thereof may be compatible with two anticancer agents. For example, the anticancer agent and a targeted anticancer agent; the anticancer agent and an anticancer virus; the targeted anticancer agent and an antibody therapeutic agent; the anticancer agent and a cell therapeutic agent; and the anticancer agent and an immune checkpoint inhibitor may be used. In addition, the anticancer agent and an anticancer virus; the targeted anticancer agent and an antibody therapeutic agent; the targeted anticancer agent and a cell therapeutic agent; and the targeted anticancer agent and an immune checkpoint inhibitor may be used. In addition, the anticancer agent and an antibody therapeutic agent; the anticancer agent and an immune checkpoint inhibitor may be used. In addition, the anticancer agent and an antibody therapeutic agent; the anticancer agent and an immune checkpoint inhibitor may be used.
[0287] The above compound, solvate, stereoisomer, or pharmaceutically acceptable salt thereof may be used in combination with three anticancer agents. A different anticancer agent may be additionally included in addition to the above two anticancer agents.
[0288] The above compounds, solvates, stereoisomers, or pharmaceutically acceptable salts thereof may be used in combination with four anticancer agents. A different anticancer agent may be additionally included in addition to the above three anticancer agents.
[0289] The above compounds, solvates, stereoisomers, or pharmaceutically acceptable salts thereof may be used in combination with five anticancer agents. Additional anticancer agents may be added to the above four anticancer agents.
[0290] The above compounds, solvates, stereoisomers or pharmaceutically acceptable salts thereof can be used in combination with six anticancer agents.
[0291] The above compounds, solvates, stereoisomers or pharmaceutically acceptable salts thereof can be used in combination with anticancer vaccines.
[0292] As used herein, the term "anticancer vaccine" refers to an active immunotherapy method that enhances the body's immune function and eliminates cancer cells by administering tumor-specific antigens (TSA) produced by cancer cells to cancer patients, thereby activating the immune system. Depending on the type of antigen and delivery method, anticancer vaccines include DNA vaccines, peptide vaccines, and cell vaccines. Currently, cell vaccines and DNA vaccines, which introduce antigens, are the most representative vaccines being developed.
[0293] The above compounds, solvates, stereoisomers, or pharmaceutically acceptable salts thereof may be used in combination with the above anticancer agents and anticancer vaccines. Here, the compounds and anticancer agents are the same as those described above.
[0294] Another aspect provides a method of preventing or treating an SOS1-mediated disorder comprising administering to a subject a compound of formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same.
[0295] Any terms or elements mentioned in the description of the above method that are identical to those mentioned above are as described above.
[0296] The above administration may be oral or parenteral. In case of oral administration, the active ingredient may be administered in an amount of 0.01 to 1000 mg, more specifically 0.1 to 300 mg per kg of body weight per day, and in case of parenteral administration, the active ingredient may be administered in an amount of 0.01 to 100 mg, more specifically 0.1 to 50 mg per kg of body weight per day, and may be administered in one or more divided doses. The dosage for a specific individual or patient should be determined in light of various related factors such as the patient's weight, age, sex, health condition, diet, administration time, administration method, and severity of the disease, and may be appropriately increased or decreased by a specialist.
[0297] As used herein, the term "subject" means a subject in need of treatment for a disease, and more specifically, a mammal such as a human or non-human primate, mouse, dog, cat, horse, and cow.
[0298]
[0299] Another aspect provides a method for inhibiting the interaction of SOS1 and a RAS family protein, and / or SOS1 and RAC1, in a sample or cell, comprising administering to the sample or cell a compound of formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof.
[0300] Another aspect provides a pharmaceutical use of a compound of formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, for the prevention or treatment of a SOS1-mediated disease; or a use of a compound of formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of a SOS1-mediated disease.
[0301] Any terms or elements mentioned in the description of the above method or use that are identical to those already mentioned are as described above.
[0302] The compound of formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof has an effective inhibitory activity against SOS1, and specifically, inhibits the interaction between SOS1 and a RAS family protein, or SOS1 and RAC1, and is useful for the prevention or treatment of SOS1-mediated diseases, specifically diseases associated with abnormal activity of SOS1 and / or a RAS family protein.
[0303] Figure 1 is a graph showing the results of evaluating cell viability according to single or combined administration of the compounds of the examples and Sotorasib to lung cancer cells NCI-H358.
[0304] Figure 2 is a graph showing the results of evaluating cell viability according to single or combined administration of the compounds of the examples and Sotorasib to pancreatic cancer cells MIA PaCa-2.
[0305] Figure 3 is a graph showing the results of evaluating cell viability according to single or combined administration of the compounds of the example and Adagrasib to lung cancer cells NCI-H358.
[0306] Figure 4 is a graph showing the results of cell viability evaluation according to single or combined administration of the compounds of the example and Adagrasib to pancreatic cancer cells MIA PaCa-2.
[0307] Figures 5a and 5b are graphs showing the results of evaluating cell viability according to single or combined administration of the compounds of the examples and Trametinib to lung cancer cells NCI-H358.
[0308] Figures 6a and 6b are graphs showing the results of evaluating cell viability according to single or combined administration of the compounds of the examples and Trametinib to gastric cancer cells SNU1.
[0309] Figures 7a and 7b are graphs showing the results of evaluating cell viability according to single or combined administration of the compounds of the examples and Trametinib to colon cancer cells SW480.
[0310] Figure 8 is a graph showing the results of evaluating cell viability according to single or combined administration of the compounds of the example and Osimertinib to lung cancer cells H1975.
[0311] Figure 9 is a graph showing the results of evaluating cell viability according to single or combined administration of the compounds of the example and Osimertinib to lung cancer cells HCC827.
[0312] Figure 10 is a graph showing the results of evaluating cell viability according to single or combined administration of the compounds of the example and Lazertinib to lung cancer cells H1975.
[0313] Figure 11 is a graph showing the results of evaluating cell viability according to single or combined administration of the compounds of the examples and Lazertinib to lung cancer cells HCC827.
[0314] Figure 12 is a graph showing the results of evaluating cell viability according to single or combined administration of the compound of the example and Alpelisib to PIK3CA mutant breast cancer cells MCF7.
[0315] Figure 13 is a graph showing the results of evaluating cell viability according to single or combined administration of the compound of the example and JDQ443 to lung cancer cells H358 having a KRAS G12C mutation.
[0316] Figure 14 is a graph showing the results of cell viability evaluation according to single or combined administration of the compound of the example and TNO155 to lung cancer cells H358 having KRAS G12C mutation.
[0317] Figure 15 is a graph showing the results of evaluating cell viability according to single or combined administration of the compound of the example and Cisplatin to lung cancer cells H358 having a KRAS G12C mutation.
[0318] Figure 16 is a graph showing the results of cell viability evaluation according to single or combined administration of the compound of the example and Rineterkib to lung cancer cells H358 having KRAS G12C mutation.
[0319] Figure 17 is a graph showing the results of cell viability evaluation according to single or combined administration of the compound of the example and Ulixertinib to lung cancer cells H358 having KRAS G12C mutation.
[0320] Figure 18 is a graph showing the results of cell viability evaluation according to single or combined administration of the compound of the example and Pralsetinib to lung cancer cells H358 having KRAS G12C mutation.
[0321] Figure 19 is a graph showing the results of cell viability evaluation according to single or combined administration of the compound of the example and Repotrectinib to lung cancer cells H358 having KRAS G12C mutation.
[0322] Figure 20 is a graph showing the results of evaluating cell viability according to single or combined administration of the compound of the example and Tepotinib to c-Met overexpressing gastric cancer cells SNU-5.
[0323] Figure 21 is a graph showing the results of evaluating cell viability according to single or combined administration of the compound of the example and Bemcentinib to PC-9 lung cancer cells with high AXL expression.
[0324] Figure 22 is a graph showing the results of evaluating cell viability according to single or combined administration of the compound of the example and Alrizomadlin to lung cancer cells A549 having KRAS G12S mutation.
[0325] Figure 23 is a graph showing the results of evaluating cell viability according to single or combined administration of the compound of the example and Everolimus to colon cancer cells LoVo having KRAS G13D mutation.
[0326] Figure 24 is a graph showing the results of cell viability evaluation according to single or combined administration of the compound of the example and MRTX1133 to lung cancer cells AsPC-1 having KRAS G12D mutation.
[0327] Figures 25a to 25c are graphs showing the results of evaluating the synergy of combined administration of example compounds against lung cancer cells H358 using SynergyScreen.
[0328] Figures 26a to 26c are graphs showing the results of evaluating the synergy of combined administration of example compounds against lung cancer cells H358 using SynergyScreen.
[0329] Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.
[0330] [Manufacturing example]
[0331] Manufacturing Example 1: 2-[3-[(1R)-1-aminoethyl]-2-fluoro-phenyl]-2,2-difluoro-ethanol (A-1)
[0332]
[0333] Step 1: Synthesis of 1-(2-fluoro-3-iodo-phenyl)ethanol
[0334] To a solution of 2-fluoro-3-iodo-benzaldehyde (4.0 g, 16.00 mmol) in THF (40 mL) was added MeMgBr (3 M, 8.00 mL) dropwise at -78 °C and stirred for 3 h. The reaction mixture was poured into a saturated aqueous NH4Cl solution (50 mL) and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product. The residue was purified by silica gel column chromatography (7% EtOAc in petroleum ether) to give 1-(2-fluoro-3-iodo-phenyl)ethanol (4.45 g, 83.63% yield) as a yellow oil. 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.72-7.64 (m, 1H), 7.55-7.45 (m, 1H), 6.93 (t,J= 7.6 Hz, 1H), 5.20 (q,J= 6.4 Hz, 1H), 1.52 (d,J= 6.4 Hz, 3H).
[0335] Step 2: Synthesis of 1-(2-fluoro-3-iodo-phenyl)ethanone
[0336] To a solution of 1-(2-fluoro-3-iodo-phenyl)ethanol (4.45 g, 16.73 mmol) in MeCN (50 mL) were added TPAP (Tetrapropylammonium perruthenate; 587.80 mg, 1.67 mmol) and NMO (N-methyl morpholine-N-oxide; 2.94 g, 25.09 mmol), and the mixture was stirred at 20 °C for 2 h. The mixture was filtered and concentrated under reduced pressure to obtain a crude product, which was then purified by silica gel column chromatography (0% EtOAc in petroleum ether) to give 1-(2-fluoro-3-iodo-phenyl)ethanone (3.8 g, 12.95 mmol, 77.44% yield, 90% purity) as a white solid. 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.97-7.88 (m, 1H), 7.85-7.78 (dm, 1H), 7.00 (t,J= 7.6 Hz, 1H), 2.65 (d,J= 5.2 Hz, 3H).
[0337] Step 3: Synthesis of ethyl 2-(3-acetyl-2-fluoro-phenyl)-2,2-difluoro-acetate
[0338] To a solution of 1-(2-fluoro-3-iodo-phenyl)ethanone (3.0 g, 11.36 mmol) and ethyl 2-bromo-2,2-difluoro-acetate (6.92 g, 34.09 mmol, 4.38 mL) in DMSO (30 mL) was added Cu (2.17 g, 34.09 mmol), and the mixture was stirred at 80 °C for 12 h. The reaction mixture was poured into water (50 mL) and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product. Purification by silica gel column chromatography (5% EtOAc in petroleum ether) gave ethyl 2-(3-acetyl-2-fluoro-phenyl)-2,2-difluoro-acetate (1.8 g, 56.05% yield, 92.07% purity) as a colorless oil. 1 H NMR (400 MHz, CHLOROFORM-d) δ 8.08-8.00 (m, 1H), 7.87-7.81 (m, 1H), 7.36 (t,J= 7.6 Hz, 1H), 4.42-4.37 (m, 2H), 2.66 (d,J= 5.2 Hz, 3H), 1.35 (t,J= 7.2 Hz, 3H); MS (ESI) m / z = 261.0 [M+H] + .
[0339] Step 4: Synthesis of ethyl 2-[3-[[(R)-tert-butylsulfinyl]-C-methyl-carboimidoyl]-2-fluoro-phenyl]-2,2-difluoro-acetate
[0340] To a solution of ethyl 2-(3-acetyl-2-fluoro-phenyl)-2,2-difluoro-acetate (1.8 g, 6.92 mmol) and (R)-2-methylpropane-2-sulfinamide (1.26 g, 10.38 mmol) in THF (20 mL) was added Ti(OEt)4 (4.73 g, 20.75 mmol), and the mixture was stirred at 80 °C for 16 h. The reaction mixture was poured into water (30 mL) and EtOAc (30 mL), filtered, and the filtrate was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (6% EtOAc in petroleum ether) to give ethyl 2-[3-[[(R)-tert-butylsulfinyl]-C-methyl-carboimidoyl]-2-fluoro-phenyl]-2,2-difluoro-acetate (1.9 g, 74.09% yield, 98.03% purity) as a yellow oil. 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.86-7.72 (m, 2H), 7.32 (t, J= 7.6 Hz, 1H), 4.44-4.30 (m, 2H), 2.77 (s, 3H), 1.32 (s, 9H); MS (ESI) m / z = 364.0 [M+H] + .
[0341] Step 5: Synthesis of (R)-N-[(1R)-1-[3-(1,1-difluoro-2-hydroxyethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0342] To a solution of ethyl 2-[3-[[(R)-tert-butylsulfinyl]-C-methyl-carboimidoyl]-2-fluoro-phenyl]-2,2-difluoro-acetate (900 mg, 2.48 mmol) in THF (10 mL) and H2O (0.2 mL) was added NaBH4 (210 mg, 5.55 mmol) at -78 °C, slowly warmed to 10 °C, and stirred at 10 °C for 2 h. The reaction mixture was poured into iced water (30 mL) and extracted with EtOAc. The combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give the crude product. After primary purification by silica gel column chromatography (50% EtOAc in petroleum ether), two diastereoisomers (approximately 3:1 ratio) were separated and purified using prep-HPLC (Xtimate C18 150*40 mm*10 um, mobile phase: [water (NH3H2O)-ACN]; B%: 25%-55%, 10 min). MeCN was removed under reduced pressure, and the remaining solvent was removed by lyophilization to obtain the major product (R)-N-[(1R)-1-[3-(1,1-difluoro-2-hydroxyethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (440 mg, 50.90% yield, 92.65% purity, >99% ee) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.70 (t,J= 6.8 Hz, 1H), 7.48-7.39 (m, 1H), 7.35-7.25 (m, 1H), 5.87 (d,J= 7.6 Hz, 1H), 5.70 (t,J= 6.4 Hz, 1H), 4.68 (quint,J= 7.2 Hz, 1H), 3.90 (dt,J= 6.4, 14.4 Hz, 2H), 1.40 (d,J= 6.8 Hz, 3H), 1.10 (s, 9H); MS (ESI) m / z = 324.3 [M+H] + .
[0343] Step 6: Synthesis of 2-[3-[(1R)-1-aminoethyl]-2-fluoro-phenyl]-2,2-difluoro-ethanol
[0344] To a solution of (R)-N-[(1R)-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (440 mg, 1.36 mmol) in dioxane (4 mL) at 0 °C was added 4N HCl / dioxane (2 mL), and the mixture was stirred at 0 °C for 1 h. The mixture was concentrated under reduced pressure to give intermediate A-1 (347 mg, 100% yield, 95% purity, HCl salt) as a yellow oil. MS (ESI) m / z = 220.0 [M+H] + .
[0345] Manufacturing Example 2: (1R)-1-[3-(difluoromethyl)-2-fluoro-phenyl]ethanamine (A-2)
[0346]
[0347] Step 1: Synthesis of 1-bromo-3-(difluoromethyl)-2-fluoro-benzene
[0348] To a solution of 3-bromo-2-fluoro-benzaldehyde (9 g, 44.33 mmol) in DCM (150 mL) was added DAST (Diethylaminosulfur trifluoride; 14.29 g, 88.67 mmol, 11.71 mL), and stirred at 25 °C for 1 h. Saturated NaHCO3 (50 mL) was added to the combined organic layer, and extracted with DCM (50 mL X 3). The mixture was washed with brine, dried over Na2SO4, and concentrated under reduced pressure to obtain a crude product. The organic layer was dehydrated over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (100% petroleum ether) to obtain 1-bromo-3-(difluoromethyl)-2-fluoro-benzene (3.9 g, 39.1% yield) as a colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.98 - 7.79 (m, 1H), 7.72 - 7.57 (m, 1H), 7.37 (s, 1H), 7.31 (br t,J= 7.8 Hz, 1H), 7.24 (s, 1H), 7.10 (s, 1H).
[0349] Step 2: Synthesis of 1-[3-(difluoromethyl)-2-fluoro-phenyl]ethanone
[0350] A mixture of 1-bromo-3-(difluoromethyl)-2-fluoro-benzene (17 g, 75.55 mmol), tributyl(1-ethoxyvinyl)stannane (28.65 g, 79.33 mmol, 26.80 mL) and Pd(PPh3)2Cl2 (2.65 g, 3.78 mmol) in dioxane (300 mL) was degassed and purged three times with N2, and the mixture was cooled to 100 o The mixture was stirred for 16 h at C under N2 atmosphere. The mixture was quenched with 4 N HCl (30 mL) and then cooled to 20 o C was stirred for 1 h. The mixture was poured into water (200 mL) and extracted with EtOAc (100 mL X 3). The organic layer was washed with brine (100 mL X 3), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (2% EtOAc in petroleum ether) to obtain 1-[3-(difluoromethyl)-2-fluoro-phenyl]ethanone (10 g, 70.35% yield) as a colorless oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.03-7.93 (m, 1H), 7.93-7.82 (m, 1H), 7.49-7.14 (m, 2H), 2.63-2.58 (m, 3H).
[0351] Step 3: Synthesis of (NZ,R)-N-[1-[3-(difluoromethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide
[0352] A mixture of 1-[3-(difluoromethyl)-2-fluoro-phenyl]ethanone (10 g, 53.15 mmol), 2-methylpropane-2-sulfinamide (6.44 g, 53.15 mmol), and Ti(OEt)4 (36.37 g, 159.45 mmol, 33.07 mL) in THF (80 mL) was degassed and purged three times with N2, and the mixture was stirred at 80 °C for 16 h under N2 atmosphere. The mixture was poured into water (100 mL), filtered, and the filtrate was extracted with EtOAc (100 mL X 3). The organic layer was washed with brine (50 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (35% EtOAc in petroleum ether) to give (NZ,R)-N-[1-[3-(difluoromethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (13.0 g, 81.65% yield, 97.25% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.90-7.81 (m, 1H), 7.81-7.73 (m, 1H), 7.47-7.40 (m, 1H), 7.29-7.10 (m, 1H), 2.71 (br s, 3H), 1.22 (s, 9H); MS (ESI) m / z = 292.1 [M+H] + .
[0353] Step 4: Synthesis of (R)-N-[(1R)-1-[3-(difluoromethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0354] A solution of (NZ,R)-N-[1-[3-(difluoromethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (13 g, 44.62 mmol) in THF (200 mL) and H2O (5 mL) was cooled to -70 °C, and NaBH4 (1.35 g, 35.70 mmol) was added in three batches, and the mixture was stirred at -70 °C for 2 h under N2 atmosphere. The mixture was quenched with saturated NH4Cl (200 mL) at 20 °C, diluted with EtOAc (150 mL), and extracted with EtOAc (150 mL X 3). The organic layer was dehydrated over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (30% EtOAc in petroleum ether) to give (R)-N-[(1R)-1-[3-(difluoromethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (4.4 g, 33.61% yield, 100% purity, 98.34% ee) as a colorless oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.74 (t,J= 7.2 Hz, 1H), 7.52 (t,J= 6.8 Hz, 1H), 7.37-7.33 (m, 1H), 7.33-7.06 (m, 1H), 5.88 (d,J= 8.0 Hz, 1H), 5.75 (s, 1H), 4.69 (quint,J= 7.0 Hz, 1H), 1.41 (d,J= 6.8 Hz, 3H), 1.10 (s, 9H); MS (ESI) m / z = 294.1 [M+H] + .
[0355] Step 5: Synthesis of (1R)-1-[3-(difluoromethyl)-2-fluoro-phenyl]ethanamine
[0356] A mixture of (R)-N-[(1R)-1-[3-(difluoromethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (2.00 g, 6.82 mmol) in 4 N HCl / dioxane (15 mL) was degassed and purged three times with N2, and the mixture was stirred at 25 °C for 2 h under N2 atmosphere. The mixture was concentrated under reduced pressure to give intermediate A-2 (1.5 g, 94.02% yield, 96.43% purity, HCl salt) as a white solid. MS (ESI) m / z = 190.1 [M+H] + .
[0357] Manufacturing Example 3: (1R)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanamine (A-3)
[0358]
[0359] Step 1: Synthesis of (NZ,S)-N-[1-[2-fluoro-3-(trifluoromethylphenyl]ethylidene]-2-methyl-propane-2-sulfinamide
[0360] A mixture of 1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanone (1.9 g, 9.22 mmol), (S)-2-methylpropane-2-sulfinamide (1.12 g, 9.22 mmol), and Ti(OEt)4 (6.31 g, 27.65 mmol, 5.73 mL) in THF (10 mL) was degassed and purged three times with N2, and the mixture was stirred at 80 °C for 16 h under N2 atmosphere. The mixture was poured into water (30 mL) and extracted with EtOAc (30 mL X 3). The organic layer was washed with brine (50 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (24% EtOAc in petroleum ether) to give (NZ,S)-N-[1-[2-fluoro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (2.08 g, 62.57% yield, 85.77% purity) as a yellow oil. MS (ESI) m / z = 310.1 [M+H]+ .
[0361] Step 2: Synthesis of (S)-N-[(1R)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0362] A solution of (NZ,S)-N-[1-[2-fluoro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (2.00 g, 6.47 mmol) in THF (15 mL) was cooled to -70 °C, L-selectride (1 M, 16.16 mL) was added, and the mixture was slowly warmed to 20 °C and stirred at 20 °C for 2 h. The reaction mixture was quenched with saturated NH4Cl aqueous solution (50 mL) at 20 °C, diluted with EtOAc (30 mL), and extracted with EtOAc (30 mL X 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (62% EtOAc in petroleum ether) to obtain the major product (S)-N-[(1R)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane2-sulfinamide (1.23 g, 56.49% yield, 92.35% purity, 98.28% ee) as a colorless oil. MS (ESI) m / z = 312.1 [M+H] + .
[0363] Step 3: Synthesis of (1R)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanamine
[0364] A mixture of (S)-N-[(1R)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (1.1 g, 3.53 mmol) and 4 N HCl / dioxane (5 mL) in dioxane (5 mL) was degassed and purged three times with N2, and the mixture was stirred at 25 °C for 2 h under N2 atmosphere. The mixture was concentrated under reduced pressure to give intermediate A-3 (850 mg, 96.04% yield, 97.25% purity, HCl) as a white solid. MS (ESI) m / z = 208.0 [M+H] + .
[0365] Manufacturing Example 4: 2-[3-[(1R)-1-aminoethyl]-2-chloro-phenyl]-2,2-difluoroethanol (A-4)
[0366]
[0367] Step 1: Synthesis of (2-chloro-3-iodo-phenyl)trimethylsilane
[0368] A solution of 1-chloro-2-iodo-benzene (27 g, 113.23 mmol, 370.37 uL) and TMSCl (14.76 g, 135.88 mmol, 17.24 mL) in THF (300 mL) was cooled to -78 °C, LDA (2 M, 67.94 mL) was added dropwise, and the mixture was stirred at -78 °C for 2 h. The mixture was quenched with water (300 mL) and extracted with EtOAc (300 mL X 3). The organic layer was washed with brine (500 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (0% EtOAc in petroleum ether) to give (2-chloro-3-iodo-phenyl)-trimethyl-silane (32 g, 90.98% yield) as a colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.99-7.94 (m, 1H), 7.47 (dd,J= 1.2, 7.2 Hz, 1H), 7.08-7.03 (m, 1H), 0.36-0.31 (m, 9H).
[0369] Step 2: Synthesis of 1-(2-chloro-3-iodophenyl)ethanone
[0370] To a solution of AlCl3 (16.48 g, 123.62 mmol, 6.76 mL) in DCM (200 mL) was slowly added dropwise acetyl chloride (9.70 g, 123.62 mmol, 8.82 mL) at 0 °C for 0.5 h, and (2-chloro-3-iodo-phenyl)trimethyl-silane (32 g, 103.02 mmol) in DCM (200 mL) was added. The mixture was stirred at 20 °C for 2 h and quenched with aqueous Na2CO3 solution (300 mL, 10%). The reaction mixture was poured into water (200 mL) and extracted with EtOAc (300 mL X 3). The organic layer was washed with brine (200 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (5% EtOAc in petroleum ether) to obtain 1-(2-chloro-3-iodophenyl)ethanone (13 g, 33.99% yield) as a colorless oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.07 (dd,J= 1.6, 8.0 Hz, 1H), 7.61 (dd,J= 1.2, 7.6 Hz, 1H), 7.19 (t,J= 7.6 Hz, 1H), 2.55 (s, 3H).
[0371] Step 3: Synthesis of 2-(2-chloro-3-iodophenyl)-2-methyl-1,3-dioxilane
[0372] A mixture of toluene (200 mL), 1-(2-chloro-3-iodo-phenyl)ethanone (13 g, 46.35 mmol), ethylene glycol (8.63 g, 139.04 mmol), and TsOH (798.11 mg, 4.63 mmol) was degassed and purged three times with N2, and the mixture was stirred at 125 °C for 16 h under N2 atmosphere. The mixture was poured into water (200 mL) and extracted with EtOAc (200 mL X 3). The organic layer was washed with brine (200 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (6% EtOAc in petroleum ether) to give 2-(2-chloro-3-iodophenyl)-2-methyl-1,3-dioxilane (14 g, 29.08% yield, 31.25% purity) as a colorless oil. MS (ESI) m / z = 324.9 [M+H] + .
[0373] Step 4: Synthesis of ethyl 2-[2-chloro-3-(2-methyl-1,3-dioxalan-2-yl)phenyl]-2,2-difluoroacetate
[0374] A mixture of 2-(2-chloro-3-iodo-phenyl)-2-methyl-1,3-dioxalane (14 g, 43.14 mmol), ethyl 2-bromo-2,2-difluoroacetate (17.51 g, 86.28 mmol, 11.08 mL), and Cu (8.22 g, 129.41 mmol, 917.82 μL) in DMSO (200 mL) was degassed and purged three times with N2, and the mixture was stirred at 80 °C for 16 h under N2 atmosphere. The mixture was poured into water (300 mL) and extracted with EtOAc (300 mL X 3). The organic layer was washed with brine (200 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (11% EtOAc in petroleum ether) to give ethyl 2-[2-chloro-3-(2-methyl-1,3-dioxalan-2-yl)phenyl]-2,2-difluoroacetate (6 g, 23.51% yield, 54.20% purity) as a colorless oil. MS (ESI) m / z = 321.0 [M+H] + .
[0375] Step 5: Synthesis of ethyl 2-(3-acetyl-2-chloro-phenyl)-2,2-difluoroacetate
[0376] To a solution of ethyl 2-[2-chloro-3-(2-methyl-1,3-dioxalan-2-yl)phenyl]-2,2-difluoroacetate (6 g, 18.71 mmol) in MeOH (200 mL) was added HCl (6 M, 15 mL), and the mixture was stirred at 40 °C for 1 h. The mixture was filtered under reduced pressure to obtain a residue, which was poured into water (50 mL) and extracted with EtOAc (30 mL X 3). The organic layer was washed with brine (20 mL × 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (8% EtOAc in petroleum ether) to give ethyl 2-(3-acetyl-2-chloro-phenyl)-2,2-difluoroacetate (6.4 g, 85.78% yield, 69.37% purity) as a colorless oil. MS (ESI) m / z = 277.0 [M+H] + .
[0377] Step 6: Synthesis of ethyl 2-[2-chloro-3-[(Z)-N-(1,1-dimethylethylsulfinyl)-C-methyl-carbonimidoyl]phenyl]-2,2-difluoroacetate
[0378] A mixture of ethyl 2-(3-acetyl-2-chloro-phenyl)-2,2-difluoroacetate (6 g, 21.69 mmol), 2-methylpropane-2-sulfinamide (3.94 g, 32.53 mmol), and Ti(OEt)4 (14.84 g, 65.06 mmol, 13.49 mL) in THF (100 mL) was degassed and purged three times with N2, and the mixture was stirred at 80 °C for 16 h under N2 atmosphere. The mixture was poured into water (80 mL), filtered, and extracted with EtOAc (50 mL X 6). The organic layer was washed with brine (30 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (29% MTBE in petroleum ether) to give ethyl 2-[2-chloro-3-[(Z)-N-(1,1-dimethylethylsulfinyl)-C-methyl-carbonimidoyl]phenyl]-2,2-difluoroacetate (5.2 g, 51.13% yield, 81% purity) as a light yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.92 - 7.76 (m, 1H), 7.74 - 7.52 (m, 2H), 4.42 - 4.27 (m, 2H), 3.34 (s, 3H), 1.24 - 1.18 (m, 9H), 1.13 (s, 3H); MS (ESI) m / z = 380.1 [M+H] + .
[0379] Step 7: Synthesis of (S)-N-[(1R)-1-[2-chloro-3-(1,1-difluoro-2-hydroxy-ethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0380] A mixture of ethyl 2-[2-chloro-3-[(Z)-N-(1,1-dimethylethylsulfinyl)-C-methyl-carbonimidoyl]phenyl]-2,2-difluoroacetate (2 g, 5.27 mmol) and L-selectride (1 M, 15.80 mL) in THF (50 mL) was degassed and purged three times with N2, and stirred at -70 °C for 5 h under N2 atmosphere. Saturated NH4Cl aqueous solution (100 mL) was added dropwise to the reaction mixture at -70 °C, and extracted with EtOAc (50 mL X 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. This was first purified by silica gel column chromatography (5% MeOH in DCM), and then the two diastereoisomers were separated and purified using prep-HPLC (Xtimate C18 150*40 mm*10 um, mobile phase: [water (NH3H2O)-ACN]; B%: 10%-55%, 20 min). MeCN was removed under reduced pressure, and the remaining solvent was removed by lyophilization to obtain the major product (S)-N-[(1R)-1-[2-chloro-3-(1,1-difluoro-2-hydroxy-ethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (1.4 g, 69.64% yield, 89% purity, 100% ee) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.72 (br d, J = 6.4 Hz, 1H), 7.55 - 7.41 (m, 2H), 5.70 (br t, J = 6.4 Hz, 1H), 5.60 (br d, J = 5.2 Hz, 1H), 4.91 (quint, J = 6.0 Hz, 1H), 4.02 (dt, J = 6.4, 14.4 Hz, 2H), 1.46 (br d, J = 6.4 Hz, 3H), 1.11 (s, 9H); MS (ESI) m / z = 340.1 [M+H] + .
[0381] Step 8: Synthesis of 2-[3-[(1R)-1-aminoethyl]-2-chloro-phenyl]-2,2-difluoroethanol
[0382] A mixture of (S)-N-[(1R)-1-[2-chloro-3-(1,1-difluoro-2-hydroxy-ethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (1.4 g, 4.12 mmol) in dioxane (10 mL) and 4 N HCl / dioxane (10 mL) was stirred at 20 °C for 2 h. The mixture was concentrated under reduced pressure to give intermediate A-4 (1.2 g, 88.77% yield, 82.93% purity, HCl salt) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.85 (br s, 3H), 7.96 (br d,J= 7.6 Hz, 1H), 7.68-7.62 (m, 1H), 7.62-7.55 (m, 1H), 5.75 (br s, 1H), 4.81 (br s, 1H), 4.03 (br t,J= 14.0 Hz, 2H), 1.53 (d,J= 6.8 Hz, 3H); MS (ESI) m / z = 236.1 [M+H] + .
[0383] Manufacturing Example 5: (R)-1-(2-fluoro-3-(1,1,2-trifluoroethyl)phenyl)ethan-1-amine (A-5)
[0384]
[0385] Step 1: Synthesis of (R)-(1-(3-(1,1-difluoro-2-hydroxyethyl)-2-fluorophenyl)ethyl)carbamate
[0386] To a solution of 2-{3-[(1R)-1-aminoethyl]-2-fluorophenyl}-2,2-difluoromethane-1-ol hydrochloride (500 mg, 1.96 mmol) in DCM (3.99 mL) were added di-tert-butyl dicarbonate (854 mg, 3.91 mmol) and DIPEA (0.68 mL, 3.91 mmol) at 0 °C, and the mixture was stirred at room temperature for 3 h. DCM was added, and the mixture was washed with water. The organic layer was dehydrated over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (Hex: EtOAc= 20: 1 to 10: 1) to obtain (R)-(1-(3-(1,1-difluoro-2-hydroxyethyl)-2-fluorophenyl)ethyl)carbamate (456 mg, 73% yield) as a colorless oil. MS (ESI) m / z = 264.04 [M+H] + .
[0387] Step 2: Synthesis of tert-butyl (R)-(1-(2-fluoro-3-(1,1,2-trifluoroethyl)phenyl)ethyl)carbamate
[0388] To a solution of (R)-(1-(3-(1,1-difluoro-2-hydroxyethyl)-2-fluorophenyl)ethyl)carbamate (221 mg, 0.692 mmol) in DCM (6.92 mL) was added DAST (0.37 mL, 2.77 mmol) at 0 °C under N2 atmosphere, warmed to room temperature, and stirred overnight. The mixture was quenched with saturated NaHCO3 and extracted with DCM. The organic layer was extracted with saturated NH4Cl and washed with brine. The organic layer was dehydrated over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. This was purified by silica gel column chromatography (hexane: EtOAc = 20:1 to 10:1) to obtain tert-butyl (R)-(1-(2-fluoro-3-(1,1,2-trifluoroethyl)phenyl)ethyl)carbamate (26 mg, 12% yield) as a colorless oil. MS (ESI) m / z = 265.99 [M+H] + .
[0389] Step 3: Synthesis of (R)-1-(2-fluoro-3-(1,1,2-trifluoroethyl)phenyl)ethan-1-amine
[0390] To a solution of tert-butyl (R)-(1-(2-fluoro-3-(1,1,2-trifluoroethyl)phenyl)ethyl)carbamate (56 mg, 0.174 mmol) in DCM (0.7 mL) was added TFA (0.15 mL) dropwise, and the mixture was stirred at 0 °C for 1 h. The mixture was warmed to room temperature and quenched with saturated NaHCO3. The organic solvent was removed by filtration under reduced pressure, and the aqueous layer was extracted with DCM. The organic layer was dehydrated over anhydrous Na2SO4 and concentrated under reduced pressure to give intermediate A-5 (34.5 mg, 89% yield) as a yellow oil. MS (ESI) m / z = 222.06 [M+H] + .
[0391] Manufacturing Example 6: (1R)-1-[3-(difluoromethyl)-5-nitro-phenyl]ethanamine (A-6)
[0392]
[0393] Step 1: Synthesis of 1-bromo-3-(difluoromethyl)-5-nitrobenzene
[0394] A mixture of 3-bromo-5-nitrobenzaldehyde (13.7 g, 59.56 mmol) and DAST (48.00 g, 297.81 mmol, 39.35 mL) in DCM (140 mL) was degassed and purged three times with N2, and stirred at 0 °C for 1 h. The mixture was warmed to 20 °C and stirred for 17 h under N2 atmosphere. The reaction mixture was poured onto ice and extracted with DCM (300 mL) and EtOAc (200 mL X 3). The combined organic layers were washed with brine (200 mL X 2), dehydrated over anhydrous Na2SO4, and filtered under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (0-10% EtOAc / petroleum ether) to obtain 1-bromo-3-(difluoromethyl)-5-nitrobenzene (14.27 g, 95.07% yield) as a colorless oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.57 (s, 1H), 8.40 (s, 1H), 8.29 (s, 1H), 7.34 - 7.05 (m, 1H).
[0395] Step 2: Synthesis of 1-[3-(difluoromethyl)-5-nitrophenyl]ethanone
[0396] A mixture of 1-bromo-3-(difluoromethyl)-5-nitrobenzene (12.27 g, 48.69 mmol), tributyl(1-ethoxyvinyl)stannane (19.5 g, 53.99 mmol, 18.22 mL), Pd(PPh3)2Cl2 (3.42 g, 4.87 mmol), and TEA (9.85 g, 97.38 mmol, 13.55 mL) in dioxane (120 mL) was degassed and purged with N2 three times, and the mixture was stirred at 80 °C for 12 h under N2 atmosphere. The mixture was quenched with 4 N HCl (24.34 mL) and stirred at 20 °C for 1 h. The mixture was poured into water (500 mL) and extracted with EtOAc (300 mL X 3). The organic layer was washed with brine (500 mL), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. KF (2.5 g) was slowly added dropwise to the aqueous layer and stirred. The crude product was purified by silica gel column chromatography (0–10% EtOAc / petroleum ether) to obtain 1-[3-(difluoromethyl)-5-nitrophenyl]ethanone (8.74 g, 83.43% yield) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.63 (s, 1H), 8.53 (s, 1H), 7.44 - 7.14 (m, 1H), 2.73 (s, 3H).
[0397] Step 3: Synthesis of (NE,R)-N-[1-[3-(difluoromethyl)-5-nitro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide
[0398] A mixture of 1-[3-(difluoromethyl)-5-nitrophenyl]ethanone (10 g, 46.48 mmol), (R)-2-methylpropane-2-sulfinamide (8.45 g, 69.72 mmol), and Ti(OEt)4 (31.81 g, 139.44 mmol, 28.91 mL) in THF (100 mL) was degassed and purged with N2 three times, and the mixture was stirred at 80 °C for 16 h under N2 atmosphere. The mixture was poured into water (200 mL X 3), filtered, and extracted with EtOAc (500 mL X 6). The organic layer was washed with brine (30 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (0–30% EtOAc / petroleum ether) to give (NE,R)-N-[1-[3-(difluoromethyl)-5-nitro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (12.83 g, 82.31% yield, 94.92% purity) as a yellow oil. MS (ESI) m / z = 319.1 [M+H] + .
[0399] Step 4: Synthesis of (R)-N-[(1R)-1-[3-(difluoromethyl)-5-nitro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0400] To a solution of (NE,R)-N-[1-[3-(difluoromethyl)-5-nitro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (4 g, 12.57 mmol) in THF (40 mL) and H2O (0.75 mL) was added NaBH4 (332.76 mg, 8.80 mmol) in three batches at -78 °C, and the mixture was stirred at -78 °C for 2 h under N2 atmosphere. The mixture was quenched with saturated NH4Cl (150 mL) at 20 °C, diluted with EtOAc (100 mL X 3), and extracted with EtOAc (100 mL X 3). The organic layer was dehydrated over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (0-25% EtOAc / petroleum ether) to give (R)-N-[(1R)-1-[3-(difluoromethyl)-5-nitro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (3.21 g, 79.26% yield, 99.39% purity, 99.00% ee) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.51 (s, 1H), 8.30 (s, 1H), 8.11 (s, 1H), 7.37 - 7.07 (m, 1H), 6.05 (d,J= 8.4 Hz, 1H), 4.69 - 4.60 (m, 1H), 1.45 (d,J= 6.8 Hz, 3H), 1.14 (s, 9H); MS (ESI) m / z = 321.1 [M+H] + .
[0401] Step 5: Synthesis of (1R)-1-[3-(difluoromethyl)-5-nitro-phenyl]ethanamine
[0402] A mixture of (R)-N-[(1R)-1-[3-(difluoromethyl)-5-nitro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (532 mg, 1.66 mmol) in 4 N HCl / dioxane (30 mL) was stirred at 0 °C for 2 h. The mixture was concentrated under reduced pressure to give intermediate A-6 (400 mg, 98.29% yield, 88.22% purity, HCl) as a brown solid. MS (ESI) m / z = 217.0 [M+H] + .
[0403] Manufacturing Example 7: (1R)-1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethanamine (A-7)
[0404]
[0405] Step 1: Synthesis of 1-bromo-2-fluoro-5-nitro-3-(trifluoromethyl)benzene
[0406] To a solution of 1-bromo-2-fluoro-3-(trifluoromethyl)benzene (10 g, 41.15 mmol) in H2SO4 (40 mL) was slowly added HNO3 (25.71 g, 408.01 mmol, 18.36 mL) dropwise at 0 °C, heated to 20 °C, and stirred for 3 h under a N2 atmosphere. The mixture was quenched with ice water (100 mL) and extracted with EtOAc (50 mL × 3). The organic layer was washed with brine (50 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica column chromatography (2% EtOAc in petroleum ether) to obtain 1-bromo-2-fluoro-5-nitro-3-(trifluoromethyl)benzene (5.9 g, 49.78% yield) as a colorless oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.95 (dd,J= 2.4, 5.2 Hz, 1H), 8.55 - 8.51 (m, 1H).
[0407] Step 2: Synthesis of 1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethanone
[0408] A mixture of 1-bromo-2-fluoro-5-nitro-3-(trifluoromethyl)benzene (5.9 g, 20.49 mmol), 1-tributyl(1-ethoxyvinyl)stannane (8.41 g, 23.29 mmol, 7.86 mL) and Pd(dppf)Cl2 (1.44 g, 2.05 mmol) in dioxane (50 mL) was degassed and purged with N2 three times, and stirred at 100 °C for 16 h under N2 atmosphere. After cooling the mixture to 0 °C, HCl solution (4 N, 50 mL) was added and stirred for 1 h. Water (100 mL) was added to the reaction mixture and extracted with EtOAc (100 mL X 3). The combined organic layer was dehydrated with anhydrous Na2SO4 and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (5% EtOAc in petroleum ether) to obtain 1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethanone (1.6 g, 31.10% yield) as a colorless oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.81 (dd,J= 2.8, 5.6 Hz, 1H), 8.71 (dd,J= 2.8, 5.2 Hz, 1H), 2.70 (d,J= 4.0 Hz, 3H).
[0409] Step 3: Synthesis of (NZ,R)-N-[1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyll-propane-2-sulfinamide
[0410] A mixture of 1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethanone (2.75 g, 10.95 mmol), (R)-2-methylpropane-2-sulfinamide (1.46 g, 12.05 mmol) and Ti(OEt)4 (7.49 g, 32.85 mmol, 6.81 mL) in THF (30 mL) was degassed and purged three times with N2, and the mixture was stirred at 80 °C for 16 h under N2 atmosphere. The mixture was poured into water (50 mL) and extracted with EtOAc (50 mL X 6). The organic layer was washed with brine (50 mL X 2), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (7% EtOAc in petroleum ether) to give (NZ,R)-N-[1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyll-propane-2-sulfinamide (3.43 g, 86.21% yield, 97.51% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.80 (br d,J= 2.4 Hz, 1H), 8.64 - 8.52 (m, 1H), 2.78 - 2.54 (m, 3H), 1.24 (s, 6H), 1.21 - 1.11 (m, 3H); MS (ESI) m / z = 354.9 [M+H] + .
[0411] Step 4: Synthesis of (R)-N-[(1R)-1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0412] A solution of (NZ,R)-N-[1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyll-propane-2-sulfinamide (3.43 g, 9.68 mmol) in THF (35 mL) and H2O (1 mL) was degassed and purged with N2 three times, then NaBH4 (230 mg, 6.08 mmol) was added at -70 °C, and the mixture was stirred at -70 °C for 2 h under N2 atmosphere. The mixture was quenched with saturated NH4Cl (50 mL) at 20 °C, diluted with EtOAc (50 mL), and extracted with EtOAc (50 mL X 3). The organic layer was dehydrated over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (20% EtOAc in petroleum ether) to give (R)-N-[(1R)-1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (1.72 g, 49.32% yield, 99.20% purity, 100% ee) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.83 (dd, J = 2.8, 5.6 Hz, 1H), 8.46 (dd, J = 2.8, 5.6 Hz, 1H), 6.14 (d, J =8.8 Hz, 1H), 4.83 - 4.73 (m, 1H), 1.48 (d, J = 6.8 Hz, 3H), 1.13 (s, 9H); MS (ESI) m / z = 356.9 [M+H]+.
[0413] Step 5: Synthesis of (1R)-1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethanamine
[0414] To a solution of (R)-N-[(1R)-1-[2-fluoro-5-nitro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (1.5 g, 4.21 mmol) in dioxane (10 mL) was added 4 N HCl / dioxane (10 mL), and the mixture was stirred at 20 °C for 2 h. The mixture was concentrated under reduced pressure to obtain intermediate A-7 (1.2 g, 88.77% yield, 82.93% purity, HCl) as a white solid. MS (ESI) m / z = 252.9 [M+H] + .
[0415] Manufacturing Example 8: (1R)-1-[2-methyl5-nitro-3-(trifluoromethyl)phenyl]ethanamine (A-8)
[0416]
[0417] Step 1: Synthesis of 1-bromo-2-methyl-5-nitro-3-(trifluoromethyl)benzene
[0418] To a solution of 1-bromo-2-methyl-3-(trifluoromethyl)benzene (10 g, 41.84 mmol) in H2SO4 (75 mL) was slowly added HNO3 (46.45 g, 737.15 mmol, 33.18 mL) dropwise at 0 °C, heated to 20 °C, and stirred for 2 h under a N2 atmosphere. The mixture was quenched with ice water (250 mL) and extracted with EtOAc (100 mL × 3). The organic layer was washed with brine (50 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica column chromatography (100% petroleum ether) to obtain 1-bromo-2-methyl-5-nitro-3-(trifluoromethyl)benzene (12 g, crude) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.71 (d,J= 2.0 Hz, 1H), 8.39 (d,J= 2.0 Hz, 1H), 2.59 (d,J= 1.2 Hz, 3H)
[0419] Step 2: Synthesis of 1-[2-methyl-5-nitro-3-(trifluoromethyl)phenyl]ethanone
[0420] A mixture of 1-bromo-2-methyl-5-nitro-3-(trifluoromethyl)benzene (12 g, 42.25 mmol), 1-tributyl(1-ethoxyvinyl)stannane (15.1 g, 41.81 mmol, 14.11 mL) and Pd(dppf)Cl2 (2.97 g, 4.22 mmol) in dioxane (100 mL) was degassed and purged with N2 three times, and stirred at 100 °C for 16 h under N2 atmosphere. After the mixture was cooled to 0 °C, HCl solution (2 N, 100 mL) was added and stirred for 1 h. Water (100 mL) was added to the reaction mixture and extracted with EtOAc (100 mL X 3). The combined organic layer was dehydrated with anhydrous Na2SO4 and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (10% EtOAc in petroleum ether) to obtain 1-[2-methyl-5-nitro-3-(trifluoromethyl)phenyl]ethanone (5.3 g, 50.75% yield) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.72 (d,J= 2.0 Hz, 1H), 8.47 (d,J= 2.0 Hz, 1H), 2.66 (s, 3H), 2.50 (s, 3H).
[0421] Step 3: Synthesis of (NZ,R)-2-methyl-N-[1-[2-methyl-5-nitro-3-(trifluoromethyl)phenyl]ethylidene]propane-2-sulfinamide
[0422] A mixture of 1-[2-methyl-5-nitro-3-(trifluoromethyl)phenyl]ethanone (5.3 g, 21.44 mmol), (R)-2-methylpropane-2-sulfinamide (2.86 g, 23.58 mmol) and Ti(OEt)4 (14.67 g, 64.32 mmol, 13.34 mL) in THF (55 mL) was degassed and purged with N2 three times, and the mixture was cooled to 80 oThe mixture was stirred for 16 h under N2 atmosphere at C. The mixture was poured into water (100 mL) and EtOAc (100 mL), filtered, and the filtrate was extracted with EtOAc (50 mL X 3). The organic layer was washed with brine (50 mL X 2), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (8% EtOAc in petroleum ether) to obtain (NZ,R)-2-methyl-N-[1-[2-methyl-5-nitro-3-(trifluoromethyl)phenyl]ethylidene]propane-2-sulfinamide (6.7 g, 88.90% yield, 99.67% purity) as a yellow oil. MS (ESI) m / z = 351.0 [M+H] + .
[0423] Step 4: Synthesis of (R)-2-methyl-N-[(1R)-1-[2-methyl-5-nitro-3-(trifluoromethyl)phenyl]ethyl]propane-2-sulfinamide
[0424] To a solution of (NZ,R)-2-methyl-N-[1-[2-methyl-5-nitro-3-(trifluoromethyl)phenyl]ethylidene]propane-2-sulfinamide (6.70 g, 19.12 mmol) in THF (80 mL) and H2O (2 mL) was added NaBH4 (230 mg, 6.08 mmol) at -78 o Added in 3 batches at C, -78 o 0 in C o After slowly heating to C, the mixture was stirred under N2 atmosphere for 3 hours. The mixture was cooled to 20 oQuenched with saturated NH4Cl (50 mL) at C, diluted with EtOAc (50 mL), and extracted with EtOAc (50 mL X 3). The organic layer was dehydrated over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (20% EtOAc / petroleum ether) to give (R)-2-methyl-N-[(1R)- 1-[2-methyl-5-nitro-3-(trifluoromethyl)phenyl]ethyl]propane-2-sulfinamide (1.4 g, 19.99% yield, 96.23% purity, 99.44% ee) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.59 (d,J= 2.4 Hz, 1H), 8.31 (d,J= 2.4 Hz, 1H), 5.74 (d,J= 6.0 Hz, 1H), 4.85 (quint,J= 6.4 Hz, 1H), 2.54 (s, 3H), 1.51 (d,J= 6.4 Hz, 3H), 1.12 (s, 9H); MS (ESI) m / z = 353.0 [M+H] + .
[0425] Step 5: Synthesis of (1R)-1-[2-methyl 5-nitro-3-(trifluoromethyl)phenyl]ethanamine
[0426] To a solution of (R)-2-methyl-N-[(1R)- 1-[2-methyl-5-nitro-3-(trifluoromethyl)phenyl]ethyl]propane-2-sulfinamide (1.40 g, 3.97 mmol) in dioxane (5 L) was added HCl / dioxane (5 mL) o Added in C, 20 o C for 2 h. The mixture was concentrated under reduced pressure, and MTBE (20 mL) was added to the residue to 20 o The mixture was stirred at C for 12 h. The mixture was filtered to obtain intermediate A-8 (1 g, 86.11% yield, 97.39% purity, HCl) as a white solid. MS (ESI) m / z = 248.9 [M+H] + .
[0427] Manufacturing Example 9: (1R)-1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethanamine (A-9)
[0428]
[0429] Step 1: Synthesis of 1-bromo-3-(difluoromethyl)-2-fluoro-5-nitrobenzene
[0430] To a solution of 1-bromo-3-(trifluoromethyl)-2-fluorobenzene (3.7 g, 16.44 mmol) in H2SO4 (30 mL) was slowly added HNO3 (14.51 g, 230.22 mmol, 10.36 mL) dropwise at 0 °C, heated to 20 °C, and stirred for 2 h. The mixture was quenched with ice water (120 mL) and extracted with EtOAc (40 mL × 3). The organic layer was washed with brine (120 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica column chromatography (100% petroleum ether) to obtain 1-bromo-3-(difluoromethyl)-2-fluoro-5-nitrobenzene (1.8 g, 40.54% yield) as a colorless oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.78 (br s, 1H), 8.47 (br d,J= 2.4 Hz, 1H), 7.34 (dt,J= 4.0, 53.4 Hz, 1H).
[0431] Step 2: Synthesis of 1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethanone
[0432] A mixture of 1-bromo-3-(difluoromethyl)-2-fluoro-5-nitrobenzene (1.8 g, 6.67 mmol), 1-tributyl(1-ethoxyvinyl)stenene (2.65 g, 7.33 mmol, 2.48 mL) and Pd(dppf)Cl2 (233.96 mg, 333.33 μmol) in dioxane (30 mL) was degassed and purged with N2 three times, and stirred at 100 °C for 16 h under N2 atmosphere. HCl solution (4 N, 30 mL) was added to the mixture, and 20 o C for 1 h. Water (50 mL) was added to the reaction mixture and extracted with EtOAc (50 mL X 3). The combined organic layers were washed with brine (50 mL X 3), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (2% EtOAc in petroleum ether) to give 1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethanone (1.42 g, 91.23% yield) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.72 - 8.68 (m, 1H), 8.68 - 8.64 (m, 1H), 7.39 (t,J= 53.2 Hz, 1H), 2.69 (d,J= 4.0 Hz, 3H).
[0433] Step 3: Synthesis of (NZ,R)-N-[1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide
[0434] A mixture of 1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethanone (1.4 g, 6.00 mmol), (R)-2-methylpropane-2-sulfinamide (727.80 mg, 6.00 mmol), and Ti(OEt)4 (4.11 g, 18.01 mmol, 3.74 mL) in THF (8 mL) was degassed, purged three times with N2, and stirred at 80 °C for 16 h under N2 atmosphere. The mixture was poured into water (50 mL) and extracted with EtOAc (50 mL X 3). The organic layer was washed with brine (20 mL X 2), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (35% EtOAc in petroleum ether) to give (NZ,R)-N-[1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (1.42 g, 70.29% yield) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.68 - 8.64 (m, 1H), 8.56 (br s, 1H), 7.51 - 7.24 (m, 1H), 2.76 (s, 3H), 1.24 (s, 9H).
[0435] Step 4: Synthesis of (R)-N-[(1R)-1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0436] To a solution of (NZ,R)-N-[1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (1.42 g, 4.22 mmol) in THF (20 mL) and H2O (0.75 mL) was added NaBH4 (127.78 mg, 3.38 mmol), and the mixture was stirred at -70 °C for 2 h under N2 atmosphere. The mixture was stirred for 20 oQuenched with saturated NH4Cl (30 mL) at C, diluted with EtOAc (30 mL), and extracted with EtOAc (30 mL X 3). The organic layer was dehydrated with anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (100% petroleum ether) to give (R)-N-[(1R)-1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (902 mg, 62.04% yield, 98.25% purity, 100% ee) as a colorless oil. MS (ESI) m / z = 339.1 [M+H] + .
[0437] Step 5: Synthesis of (1R)-1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethanamine
[0438] A mixture of (R)-N-[(1R)-1-[3-(difluoromethyl)-2-fluoro-5-nitro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (900 mg, 2.66 mmol) in 4 N HCl / dioxane (5 mL) was degassed and purged three times with N2, and stirred at 25 °C for 2 h under N2 atmosphere. The mixture was concentrated under reduced pressure to give Intermediate A-9 (700 mg, 96.58% yield, 99.33% purity, HCl) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.90 (br s, 4H), 8.52 (br d,J= 1.6 Hz, 1H), 7.38 (br t,J= 53.2 Hz, 1H), 4.77 (br s, 1H), 1.61 - 1.52 (m, 3H); MS (ESI) m / z = 235.1 [M+H] + .
[0439] Manufacturing Example 10: 3-[(1R)-1-aminoethyl]-5-(trifluoromethyl)amine (A-10)
[0440]
[0441] Step 1: Synthesis of 1-[3-nitro-5-(trifluoromethyl)phenyl]ethanone
[0442] A mixture of 1-bromo-3-nitro-5-(trifluoromethyl)benzene (50 g, 185.18 mmol), 1-tributyl(1-ethoxyvinyl)stannane (70.2 g, 194.38 mmol, 65.61 mL), Pd(dppf)Cl2 (13.00 g, 18.52 mmol), and TEA (37.48 g, 370.37 mmol, 51.55 mL) in dioxane (500 mL) was degassed and purged with N2 three times, then stirred at 80 °C for 16 h under N2 atmosphere. HCl solution (4 N, 200 mL) was added to the mixture, and stirred at 20 °C for 1 h. Water (200 mL) was added to the reaction mixture, and extracted with EtOAc (150 mL X 3). The combined organic layer was washed with brine (100 mL X 3), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (5% EtOAc in petroleum ether) to obtain 1-[3-nitro-5-(trifluoromethyl)phenyl]ethanone (66 g, 76.43% yield) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.85 (s, 1H), 8.73 (s, 1H), 8.63 (s, 1H), 2.76 (s, 3H).
[0443] Step 2: Synthesis of (NE,R)-2-methyl-N-[1-[3-nitro-5-(trifluoromethyl)phenyl]ethylidene]propane-2-sulfinamide
[0444] A mixture of 1-[3-nitro-5-(trifluoromethyl)phenyl]ethanone (66 g, 283.09 mmol), (R)-2-methylpropane-2-sulfinamide (44.60 g, 368.01 mmol), and Ti(OEt)4 (161.44 g, 707.72 mmol, 146.76 mL) in THF (650 mL) was degassed and purged with N2 three times, and the mixture was stirred at 85 °C for 16 h under N2 atmosphere. Water (200 mL) and EtOAc (200 mL) were poured into the mixture, filtered, and the filtrate was extracted with EtOAc (200 mL X 3). The organic layer was washed with brine (200 mL X 2), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (12% EtOAc in petroleum ether) to give (NE,R)-2-methyl-N-[1-[3-nitro-5-(trifluoromethyl)phenyl]ethylidene]propane-2-sulfinamide (77 g, 71.07% yield, 87.88% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.84 (s, 1H), 8.65 (s, 1H), 8.54 (s, 1H), 2.86 (s, 3H), 1.25 (s, 9H); MS (ESI) m / z = 336.9 [M+H] + ).
[0445] Step 3: Synthesis of (R)-2-methyl-N-[(1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethyl]propane-2-sulfinamide
[0446] To a solution of (NE,R)-2-methyl-N-[1-[3-nitro-5-(trifluoromethyl)phenyl]ethylidene]propane-2-sulfinamide (38.5 g, 114.47 mmol) in THF (350 mL) and H2O (7 mL) was added NaBH4 (3.27 g, 86.43 mmol) in three batches at -78 °C, and the mixture was stirred at -78 °C for 3 h under N2 atmosphere. The mixture was quenched with saturated NH4Cl (150 mL) at 20 °C, poured into water (200 mL), and extracted with EtOAc (200 mL X 3). The organic layer was washed with brine (100 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (15% EtOAc in petroleum ether) to give (R)-2-methyl-N-[(1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethyl]propane-2-sulfinamide (30 g, 32.01% yield, 82.663% purity, 100% ee) as a green solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.63 (s, 1H), 8.38 (s, 1H), 8.29 (s, 1H), 6.07 (d,J= 8.8 Hz, 1H), 4.72 - 4.65 (m, 1H), 1.45 (d,J= 6.8 Hz, 3H), 1.14 (s, 9H); MS (ESI) m / z = 338.9 [M+H] + .
[0447] Step 4: Synthesis of (1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethanamine
[0448] To a solution of the product (R)-2-methyl-N-[(1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethyl]propane-2-sulfinamide (30 g, 88.67 mmol) in dioxane (30 mL) was added 4 N HCl / dioxane (60 mL) and stirred at 20 °C for 3 h. The mixture was concentrated under reduced pressure, MTBE (100 mL) was added, and stirred at 20 °C for 12 h. It was filtered to obtain (1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethanamine (23 g, 91.02% yield, 94.96% purity, HCl) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.93 - 8.61 (m, 4H), 8.51 (s, 1H), 8.45 (s, 1H), 4.74 (q,J= 6.8 Hz, 1H), 1.58 (d,J= 6.8 Hz, 3H); MS (ESI) m / z = 234.9 [M+H] + .
[0449] Step 5: Synthesis of 3-[(1R)-1-aminoethyl]-5-(trifluoromethyl)amine
[0450] A mixture of (1R)-1-[3-nitro-5-(trifluoromethyl)phenyl]ethanamine (10 g, 42.70 mmol) and Pd / C (2 g, 10% purity) in MeOH (100 mL) was degassed and purged three times with N2, and the mixture was stirred at 40 °C for 6 h under a H2 atmosphere. The mixture was filtered and concentrated under reduced pressure to give Intermediate A-10 (8.5 g, 93.87% yield, 96.29% purity) as a yellow solid. It was used in the next reaction without further purification. 1 H NMR (400 MHz, DMSO-d6) δ 8.44 (br s, 3H), 6.97 (s, 1H), 6.84 (s, 2H), 5.75 (s, 2H), 4.30 (q,J= 6.8 Hz, 1H), 1.47 (d,J= 6.8 Hz, 3H); MS (ESI) m / z = 204.9 [M+H] + .
[0451] Manufacturing Example 11: (R)-1-(3-(1,1-difluoro-2-methoxyethyl)-2-fluorophenyl)ethan-1-amine (A-11)
[0452]
[0453] Step 1: Synthesis of tert-butyl (R)-(1-(3-(1,1-difluoro-2-methoxyethyl)-2-fluorophenyl)ethyl)carbamate
[0454] To a solution of tert-butyl(R)-(1-(3-(1,1-difluoro-2-hydroxyethyl)-2-fluorophenyl)ethyl)carbamate (87 mg, 0.272 mmol) in DCM (2.72 mL) were added Proton Sponge (117 mg, 0.545 mmol), trimethyloxonium tetrafluoroborate (80.6 mg, 0.545 mmol) and 4Å molecular sieves under nitrogen, and the mixture was stirred at 25 °C for 16 h. The reaction mixture was quenched with 1 M aqueous HCl and extracted with DCM. The combined organic layer was washed with brine, dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (25% EtOAc in hexane) to give tert-butyl(R)-(1-(3-(1,1-difluoro-2-methoxyethyl)-2-fluorophenyl)ethyl)carbamate (61 mg, 67% yield) as a colorless oil. MS (ESI) m / z = 278.02 [M+H] + .
[0455] Step 2: Synthesis of (R)-1-(3-(1,1-difluoro-2-methoxyethyl)-2-fluorophenyl)ethan-1-amine
[0456] To a solution of tert-butyl (R)-(1-(3-(1,1-difluoro-2-methoxyethyl)-2-fluorophenyl)ethyl)carbamate (61 mg, 0.183 mmol) in DCM (0.73 mL) was added trifluoroacetic acid (0.16 mL) at 0 °C. The mixture was then stirred at room temperature for 1 h. The reaction mixture was quenched with aqueous NaHCO3 solution and extracted with DCM. The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure to give intermediate A-11 (41 mg, 96% yield) as a yellow oil. MS (ESI) m / z = 234.08 [M+H] + .
[0457] Manufacturing Example 12: (1R)-1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethanamine (A-12)
[0458]
[0459] Step 1: Synthesis of 1-bromo-3-(1,1-difluoroethyl)-2-fluorobenzene
[0460] A solution of 1-(3-bromo-2-fluoro-phenyl)ethanone (4 g, 18.43 mmol) and DAST (23.77 g, 147.44 mmol, 19.48 mL) in DCM (60 mL) was degassed and purged three times with N2, and stirred at 50 °C for 60 h under N2 atmosphere. The reaction mixture was slowly quenched with ice water (40 mL) and basified (pH = 7-8) with saturated NaHCO3. The aqueous layer was extracted with DCM (50 mL × 3), and the organic layer was washed with brine (20 mL X 3). The organic layer was dehydrated over anhydrous Na2SO4 and filtered under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (0% EA in petroleum ether) to obtain 1-bromo-3-(1,1-difluoroethyl)-2-fluorobenzene (3.5 g, 79.45% yield) as a colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.89 (br t,J= 7.2 Hz, 1H), 7.60 (br t,J= 7.2 Hz, 1H), 7.29 (t,J= 8.0 Hz, 1H), 2.02 (t,J= 19.2 Hz, 3H).
[0461] Step 2: Synthesis of 1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethanone
[0462] A mixture of 1-bromo-3-(1,1-difluoroethyl)-2-fluorobenzene (3.5 g, 14.64 mmol), 1-tributyl(1-ethoxyvinyl)stannane (5.66 g, 15.67 mmol, 5.29 mL), TEA (2.96 g, 29.28 mmol, 4.08 mL) and Pd(dppf)Cl2 (1.03 g, 1.46 mmol) in dioxane (40 mL) was degassed, purged three times with N2, and stirred at 80 °C for 16 h under N2 atmosphere. HCl solution (4N, 60 mL) was added to the mixture, and stirred at 25 °C for 1 h. Water (30 mL) was added to the reaction mixture, and extracted with EtOAc (50 mL X 3). The combined organic layers were washed with brine (50 mL X 3). After washing and dehydration with anhydrous Na2SO4, the residue was concentrated under reduced pressure, and purified by silica gel column chromatography (3% EtOAc in petroleum ether) to obtain 1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethanone (2.5 g, 84.45% yield) as a colorless oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.95 (br t,J= 7.2 Hz, 1H), 7.82 (br t,J= 7.2 Hz, 1H), 7.44 (t,J= 7.6 Hz, 1H), 2.62 (d,J= 4.0 Hz, 3H), 2.05 (t,J= 19.2 Hz, 3H).
[0463] Step 3: Synthesis of (NE,S)-N-[1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide
[0464] A mixture of 1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethanone (2.7 g, 13.35 mmol), (S)-2-methylpropane-2-sulfinamide (2.43 g, 20.03 mmol), and Ti(OEt)4 (9.14 g, 40.06 mmol, 8.31 mL) in THF (40 mL) was degassed, purged three times with N2, and stirred at 80 °C for 16 h under N2 atmosphere. The mixture was poured into water (50 mL), filtered, and extracted with EtOAc (60 mL X 3). The organic layer was washed with brine (40 mL X 2), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (5% EtOAc in petroleum ether) to give (NE,S)-N-[1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (3.4 g, 76.29% yield, 91.5% purity) as a yellow oil. MS (ESI) m / z = 306.2 [M+H] + .
[0465] Step 4: Synthesis of (S)-N-[(1R)-1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethyl]-2-methylpropane-2-sulfinamide
[0466] To a solution of (NE,S)-N-[1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (3.4 g, 11.13 mmol) in THF (50 mL) was added L-selectride (1 M, 27.84 mL) at -70 °C, degassed, and purged three times with N2, and the mixture was stirred at -70 °C for 3 h under N2 atmosphere. The reaction mixture was slowly dropwise added saturated NH4Cl aqueous solution (80 mL) at -70 °C to quench, dilute with EtOAc (50 mL), and extracted with EtOAc (40 mL X 5). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (25% EtOAc in petroleum ether) to give the major product (S)-N-[(1R)-1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethyl]-2-methylpropane-2-sulfinamide (2.3 g, 65.86% yield, 98% purity, 99.3% ee) as a light yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.63 (t,J= 6.8 Hz, 1H), 7.51 - 7.40 (m, 1H), 7.33 - 7.26 (m, 1H), 5.54 (d,J= 5.6 Hz, 1H), 4.72 (quint,J= 6.8 Hz, 1H), 2.00 (t,J= 19.2 Hz, 3H), 1.49 (d,J= 6.8 Hz, 3H), 1.09 (s, 9H); MS (ESI) m / z = 308.0 [M+H] + .
[0467] Step 5: Synthesis of (1R)-1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethanamine
[0468] A solution of (S)-N-[(1R)-1-[3-(1,1-difluoroethyl)-2-fluoro-phenyl]ethyl]-2-methylpropane-2-sulfinamide (500 mg, 1.63 mmol) and HCl / dioxane (4 N, 25 mL) in dioxane (2 mL) was degassed and purged three times with N2, and the mixture was stirred at 25 °C for 0.5 h under N2 atmosphere. The mixture was concentrated under reduced pressure to give intermediate A-12 (350 mg, 89.78% yield, HCl) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.75 (br s, 3H), 7.88 (t,J= 7.2 Hz, 1H), 7.59 (t,J= 7.2 Hz, 1H), 7.41 (t,J= 7.6 Hz, 1H), 4.66 (br d,J= 5.2 Hz, 1H), 2.02 (t,J= 19.2 Hz, 3H), 1.56 - 1.53 (m, 3H); MS (ESI) m / z = 204.1 [M+H] + .
[0469] Manufacturing Example 13: 2-[3-[(1R)-1-aminoethyl]-2-methyl-phenyl]-2,2-difluoro-ethanol (A-13)
[0470]
[0471]
[0472] Step 1: Synthesis of 1-(2-methyl-3-nitro-phenyl)ethanone
[0473] A mixture of 1-bromo-methyl-3-nitro-benzene (10 g, 46.29 mmol), 1-tributyl(1-ethoxyvinyl)stannane (19.85 g, 54.96 mmol, 18.55 mL) and Pd(PPh3)2Cl2 (3.25 g, 4.63 mmol) in dioxane (50 mL) was degassed and purged with N2 three times, then stirred at 100 °C for 12 h under N2 atmosphere. Water (100 mL) was added to the reaction mixture and extracted with EtOAc (100 mL X 3). The combined organic layer was dehydrated with anhydrous Na2SO4 and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (20% EtOAc in petroleum ether) to obtain 1-(2-methyl-3-nitro-phenyl)ethanone (8.0 g, 96.46% yield) as a yellow oil. The aqueous layer was adjusted to pH = 9 with aqueous NaOH solution, and NaClO (100 mL) was slowly added while stirring. 1 H NMR (400 MHz, DMSO-d6) δ 8.05 - 7.89 (m, 2H), 7.56 (t, J= 8.0 Hz, 1H), 2.60 (s, 3H), 2.37 (s, 3H).
[0474] Step 2: Synthesis of 1-(3-amino-2-methyl-phenyl)ethanone
[0475] To a solution of 1-(2-methyl-3-nitro-phenyl)ethanone (9.2 g, 51.35 mmol) in EtOH (100 mL) and H2O (20 mL) were added Fe (28.67 g, 513.47 mmol) and NH4Cl (27.47 g, 513.47 mmol). The mixture was degassed, purged with N2 three times, and stirred at 80 °C for 12 h under nitrogen conditions. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. Water (100 mL) was poured into the reaction mixture, and the mixture was extracted with EtOAc (100 mL × 3). The combined organic layer was washed with brine (100 mL), dried over Na2SO4, and concentrated under reduced pressure to give the crude product 1-(3-amino-2-methyl-phenyl)ethanone (6.8 g, 88.77% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 6.98 (t,J= 7.6 Hz, 1H), 6.84 (dd,J= 1.2, 7.6 Hz, 1H), 6.77 (dd,J=1.2, 8.0 Hz, 1H), 5.05 (s, 2H), 2.46 (s, 3H), 2.06 (s, 3H).
[0476] Step 3: Synthesis of 1-(3-iodo-2-methyl-phenyl)ethanone
[0477] To a suspension of 1-(3-amino-2-methyl-phenyl)ethanone (6.5 g, 43.57 mmol) in H2SO4 (95.68 g, 975.55 mmol, 21.6 mL) was added an aqueous solution of NaNO2 (3.01 g, 43.57 mmol) (220 mL) at 0 °C and stirred for 1 hour. The mixture was added to an aqueous solution of KI (21.70 g, 130.71 mmol) (220 mL) and stirred at 20 °C for 18 hours. 100 mL of water was added to the reaction mixture and extracted with EtOAc (100 mL × 3). The organic layer was washed with brine (100 mL), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica column chromatography (6% EtOAc in petroleum ether) to obtain 1-(3-iodo-2-methyl-phenyl)ethanone (8.2 g, 72.37% yield) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.99 (dd,J= 1.2, 8.0 Hz, 1H), 7.67 (d,J= 7.6 Hz, 1H), 7.07 (t,J= 7.6 Hz, 1H), 2.53 (s, 3H), 2.41 (s, 3H).
[0478] Step 4: Synthesis of ethyl 2-(3-acetyl-2-methyl-phenyl)-2,2-difluoroacetate
[0479] A mixture of 1-(3-iodo-2-methyl-phenyl)ethanone (4 g, 15.38 mmol), ethyl 2-bromo-2,2-difluoroacetate (3.43 g, 16.92 mmol, 2.17 mL), and Cu (2.93 g, 46.14 mmol, 327.24 μL) in DMSO (40 mL) was degassed and purged with N2 three times, and the mixture was stirred at 80 °C for 16 h under N2 atmosphere. The mixture was poured into water (100 mL) and extracted with EtOAc (100 mL X 3). The organic layer was washed with brine (100 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (1-2% EtOAc in petroleum ether) to give ethyl 2-(3-acetyl-2-methyl-phenyl)-2,2-difluoroacetate (3.4 g, 74.11% yield, 85.91% purity) as a colorless oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.86 (d,J= 7.6 Hz, 1H), 7.72 (d,J= 7.6 Hz, 1H), 7.49 (t,J= 7.6 Hz, 1H), 4.34 (q,J= 7.2 Hz, 2H), 2.57 (s, 3H), 2.29 (s, 3H), 1.22 (t,J= 7.2 Hz, 3H); MS (ESI) m / z = 257.0 [M+H] + .
[0480] Step 5: Synthesis of ethyl 2-[3-[(Z)-N-[(R)-tert-butylsulfinyl]-C-methyl-carbonimidoyl]-2-methyl-phenyl)-2,2-difluoroacetate
[0481] A mixture of ethyl 2-(3-acetyl-2-methyl-phenyl)-2,2-difluoroacetate (3.4 g, 13.27 mmol), (R)-2-methylpropane-2-sulfinamide (1.77 g, 14.60 mmol), and Ti(OEt)4 (9.08 g, 39.81 mmol, 8.25 mL) in THF (40 mL) was degassed and purged three times with N2, and stirred at 80 °C for 12 h under N2 atmosphere. Water (50 mL) and EtOAc (50 mL) were poured into the mixture, and it was extracted with EtOAc (50 mL X 3). The combined organic layers were washed with brine (50 mL X 2), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (12% EtOAc in petroleum ether) to give ethyl 2-[3-[(Z)-N-[(R)-tert-butylsulfinyl]-C-methyl-carbonimidoyl]-2-methyl-phenyl)-2,2-difluoroacetate ((2.6 g, 48.82% yield, 89.56% purity) as a yellow oil. MS (ESI) m / z = 360.0 [M+H] + .
[0482] Step 6: Synthesis of (R)-N-[(1R)-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-methyl-phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0483] A mixture of ethyl-2-[3-[(Z)-N-[(R)-tert-butylsulfinyl]-C-methyl-carbonimidoyl]-2-methyl-phenyl)-2,2-difluoroacetate (2.6 g, 7.23 mmol) and NaBH4 (830 mg, 21.94 mmol) in THF (30 mL) and H2O (1 mL) was degassed, purged three times with N2, and stirred at -70 °C for 2 h under N2 atmosphere. The mixture was quenched with saturated NH4Cl (50 mL) at 20 °C, diluted with EtOAc (50 mL), and extracted with EtOAc (50 mL X 3). The organic layer was dehydrated over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. This was separated and purified using prep-HPLC (YMC-Triart Prep C18 250*50 mm*10 um, mobile phase: [water (NH3H2O+NH4HCO3)-MeCN]; B%: 20%-50%, 20 min). MeCN was removed under reduced pressure, and the remaining solvent was removed by lyophilization to obtain the major product (R)-N-[(1R)-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-methyl-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (900 mg, 38.08% yield, 97.77% purity, 100% ee) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.61 (d,J= 7.6 Hz, 1H), 7.39 - 7.34 (m, 1H), 7.28 (t,J= 7.2 Hz, 1H), 5.73 - 5.60 (m, 2H), 4.69 (quint,J= 6.8 Hz, 1H), 3.88 (dt,J= 6.4, 14.8 Hz, 2H), 2.37 (s, 3H), 1.37 (d,J= 6.8 Hz, 3H), 1.11 - 1.06 (m, 9H); MS (ESI) m / z = 320.0 [M+H] + .
[0484] Step 7: Synthesis of 2-[3-[(1R)-1-aminoethyl]-2-methyl-phenyl]-2,2-difluoroethanol
[0485] To (R)-N-[(1R)-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-methyl-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (150 mg, 469.62 μmol) in dioxane (2 mL) was added HCl / dioxane (4 N, 4 mL) dropwise at 0 °C, and the mixture was stirred at 0 °C for 2 h. The mixture was concentrated under reduced pressure to obtain intermediate A-13 (115 mg, 57.48% yield, 50.52% purity) as a yellow solid. MS (ESI) m / z = 216.0 [M+H] + .
[0486] Manufacturing Example 14: 2-[3-[(1R)-1-amino-1-deuterio-ethyl]-2-fluoro-phenyl]-2,2-difluoro-ethanol (A-14)
[0487]
[0488] Step 1: Synthesis of ethyl 2-(3-bromo-2-fluoro-phenyl)-2,2-difluoro-acetate
[0489] To a solution of 1-bromo-2-fluoro-3-iodo-benzene (11 g, 36.56 mmol, 1 eq) in DMSO (200 mL) were added copper solid (6.97 g, 109.67 mmol, 777.82 μL) and ethyl 2-bromo-2,2-difluoro-acetate (22.26 g, 109.67 mmol, 14.13 mL). The reaction mixture was stirred at 85 °C for 16 h under N2 atmosphere. After the reaction mixture was filtered, water (80 mL) was added to the filtrate, and the mixture was extracted with EtOAc (80 mL X 3). The organic layer was washed with brine (60 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (10% EtOAc in petroleum ether) to give ethyl 2-(3-bromo-2-fluoro-phenyl)-2,2-difluoro-acetate (9.3 g, 77.07% yield, 90% purity) as a white oil. 1H NMR (400 MHz, DMSO-d6) δ 8.02-7.95 (m, 1H), 7.75-7.69 (m, 1H), 7.37 (t,J= 8.0 Hz, 1H), 4.40-4.31 (m, 2H), 1.23 (t,J= 7.2 Hz, 3H).
[0490] Step 2: Synthesis of 2-(3-bromo-2-fluoro-phenyl)-2,2-difluoro-ethanol
[0491] To a solution of ethyl 2-(3-bromo-2-fluoro-phenyl)-2,2-difluoro-acetate (8.8 g, 29.62 mmol) in THF (140 mL) was slowly added LiBH4 (2 M, 20.74 mL) at 0 °C under N2 atmosphere. The reaction mixture was then stirred at 50 °C for 2 h under N2 atmosphere. Aqueous NH4Cl solution (80 mL) was slowly added to the mixture, and extracted with EtOAc (60 mL X 3). The organic layer was washed with brine (80 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (6% EtOAc in petroleum ether) to give 2-(3-bromo-2-fluoro-phenyl)-2,2-difluoro-ethanol (7.3 g, 96.63% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.89 (t,J= 7.2 Hz, 1H), 7.61-7.52 (m, 1H), 7.29 (t,J= 8.0 Hz, 1H), 5.76-5.70 (m, 1H), 3.96-3.88 (m, 2H).
[0492] Step 3: Synthesis of 1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethanone
[0493] A mixture of tributyl(1-ethoxyvinyl)stannane (8.24 g, 22.82 mmol, 7.71 mL), TEA (3.17 g, 31.37 mmol, 4.37 mL) and Pd(PPh3)2Cl2 (1.10 g, 1.57 mmol) in a solution of 2-(3-bromo-2-fluoro-phenyl)-2,2-difluoro-ethanol (4 g, 15.68 mmol) in dioxane (50 mL) was degassed, purged three times with N2, and stirred at 80 °C for 12 h under N2 atmosphere. To the mixture, HCl solution (50 ml, 1 M) was added while stirring at 25 °C, and stirred at 25 °C for 1 h. Water (30 mL) was added to the reaction mixture and extracted with EtOAc (50 mL X 3). The combined organic layer was washed with brine (80 mL X 3), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (12% EtOAc in petroleum ether) to obtain 1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethanone (3.33 g, 90.43% yield, 92.93% purity) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.99-7.91 (m, 1H), 7.82-7.74 (m, 1H), 7.43 (t,J= 8.0 Hz, 1H), 5.73 (t,J= 6.8 Hz, 1H), 3.95 (dt,J= 6.8, 14.3 Hz, 2H), 2.60 (d,J= 4.4 Hz, 3H); MS (ESI) m / z = 218.9 [M+H] + .
[0494] Step 4: Synthesis of (NZ,R)-N-[1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide
[0495] To a solution of 1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethanone (3.33 g, 15.26 mmol) in THF (35 mL) were added (R)-2-methylpropane-2-sulfinamide (2.77 g, 22.89 mmol) and Ti(OEt)4 (10.44 g, 45.79 mmol, 9.50 mL), and the mixture was stirred at 70 °C for 12 h under N2 atmosphere. The mixture was poured into water (50 mL) and extracted with EtOAc (50 mL X 3). The organic layer was washed with brine (50 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (20% EtOAc in petroleum ether) to give (NZ, R)-N-[1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (4.3 g, 85.90% yield, 97.99% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.79 (br t,J= 7.2 Hz, 1H), 7.68 (br t,J= 6.8 Hz, 1H), 7.41 (br t,J= 7.6 Hz, 1H), 5.75-5.71 (m, 1H), 3.93 (dt,J= 6.4, 14.0 Hz, 2H), 2.69 (br d,J= 1.6 Hz, 3H), 1.22 (s, 9H); MS (ESI) m / z = 322.1 [M+H] + .
[0496] Step 5: Synthesis of (R)-N-[(1R)-1-deuterio-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0497] To a solution of (NZ,R)-N-[1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (4.3 g, 13.38 mmol) in THF (80 mL) and D2O (1.6 mL) was added NaBD4 (506.23 mg) at -70 °C, and the mixture was stirred at -70 °C for 2 h under N2 atmosphere. TLC (PE:EA = 1 / 1) confirmed that the reaction had proceeded completely. The mixture was quenched with saturated NH4Cl aqueous solution (50 mL) and extracted with (50 mL X 3). The organic layer was washed with brine (80 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (20% EtOAc / petroleum ether) to give (R)-N-[(1R)-1-deuterio-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (4.2 g, 81.28% yield, 84% purity) as a yellow oil. MS (ESI) m / z = 325.0 [M+H] + .
[0498] Step 6: Synthesis of (R)-N-[(1S)-1-deuterio-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0499] (R)-N-[(1R)-1-deuterio-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide was purified by prep-HPLC column: Welch Xtimate C18 250*50mm*10um; mobile phase: [water (NH3H2O+NH4HCO3)-ACN]; 5%-55% B, 20 min). The solvent was concentrated under reduced pressure, and the residue was lyophilized to obtain (R)-N-[(1S)-1-deuterio-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (700 mg, 16.28% yield, 100% purity), peak 1) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.64 (t,J= 6.8 Hz, 1H), 7.48-7.39 (m, 1H), 7.33-7.26 (m, 1H), 5.70 (t,J= 6.4 Hz, 1H), 5.52 (s, 1H), 3.90 (dt,J= 6.4, 14.4 Hz, 2H), 1.48 (s, 3H), 1.09 (s, 9H); MS (ESI) m / z = 325.2 [M+H] + .
[0500] Step 7: Synthesis of 2-[3-[(1R)-1-amino-1-deuterio-ethyl]-2-fluoro-phenyl]-2,2-difluoro-ethanol
[0501] To (R)-N-[(1S)-1-deuterio-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (1.14 g, 3.51 mmol) in dioxane (5 mL) was added HCl / dioxane (20 mL) at 0 °C, and the mixture was stirred at 20 °C for 2 h. The mixture was concentrated under reduced pressure to obtain Intermediate A-14 (900 mg, 94.78% yield, 95% purity, hydrochloride) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 8.73 (br s, 2H), 7.87 (t,J= 6.8 Hz, 1H), 7.57 (t,J= 7.2 Hz, 1H), 7.44-7.37 (m, 1H), 3.92 (br t,J= 14.2 Hz, 2H), 1.54 (s, 3H), 1.10 (s, 1H).
[0502] Manufacturing Example 15: (1R)-1-[2-chloro-3-(trifluoromethyl)phenyl]ethanamine (A-15)
[0503]
[0504] Step 1: Synthesis of 1-[2-chloro-3-(trifluoromethyl)phenyl]ethanone
[0505] A mixture of tributyl(1-ethoxyvinyl)stannane (12.520 g, 34.67 mmol, 11.71 mL), TEA (6.24 g, 61.67 mmol, 8.58 mL), and Pd(PPh3)2Cl2 (1.10 g, 1.57 mmol) in a solution of 1-bromo-2-chloro-3-(trifluoromethyl)benzene (4 g, 15.68 mmol) in dioxane (140 mL) was added, degassed, purged three times with N2, and stirred at 80 ℃ for 16 h under N2 atmosphere. TLC (PE:EA = 10 / 1) confirmed that the reaction had proceeded completely. HCl solution (80 mL, 1 M) was added to the mixture while stirring at 25 ℃, and stirred at 25 ℃ for 1 h. Water (120 mL) was added to the reaction mixture and extracted with EtOAc (150 mL X 3). The combined organic layers were washed with brine (150 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a residue. The aqueous layer was stirred while slowly adding saturated KF aqueous solution (200 mL), and then stirred at 25 °C for 1 hour. This was purified by column chromatography (6% EtOAc in petroleum ether) to obtain 1-[2-chloro-3-(trifluoromethyl)phenyl]ethanone (4.2 g, 58.13% yield, 95% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.97 (d, J= 8.0 Hz, 1H), 7.92 (d, J= 7.6 Hz, 1H), 7.71-7.63 (m, 1H), 2.61 (s, 3H).
[0506] Step 2: Synthesis of (NE,R)-N-[1-[2-chloro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide
[0507] To a solution of 1-[2-chloro-3-(trifluoromethyl)phenyl]ethanone (4.2 g, 18.87 mmol) in THF (60 mL) were added (S)-2-methylpropane-2-sulfinamide (3.43 g, 28.30 mmol) and Ti(OEt)4 (12.91 g, 56.61 mmol, 11.74 mL), and the mixture was stirred at 80 °C for 16 h under N2 atmosphere. TLC (PE:EA = 10 / 1) confirmed that the reaction had proceeded completely. The mixture was poured into water (40 mL), the reaction mixture was filtered, and the filtrate was extracted with EtOAc (60 mL X 3). The organic layer was washed with brine (80 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (6% EtOAc in petroleum ether) to give (NE,R)-N-[1-[2-chloro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (5.15 g, 75.40% yield, 90% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.98 (br d,J= 7.6 Hz, 1H), 7.91 (br d,J= 7.6 Hz, 1H), 7.82 (br d,J= 7.6 Hz, 1H), 2.71 (s, 3H), 1.26 (s, 9H); MS (ESI) m / z = 326.0 [M+H] + .
[0508] Step 3: Synthesis of N-[(1R)-1-[2-chloro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0509] To a solution of (NE,R)-N-[1-[2-chloro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (5.15 g, 15.81 mmol) in THF (100 mL) was slowly added dropwise L-selectride (1 M, 31.62 mL) at -70 °C for 0.5 h, and the mixture was stirred at -70 °C for 2 h under N2 atmosphere. The reaction mixture was slowly added dropwise to saturated NH4Cl aqueous solution (60 mL) at 20 °C under N2 atmosphere, quenched, diluted with EtOAc (80 mL) and extracted with EtOAc (80 mL X 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (13% EtOAc in petroleum ether) to obtain the desired peak 2 product, N-[(1R)-1-[2-chloro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (2 g, 78.17% yield, 89.89% purity, ee = 95.96%) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.89 (d,J= 8.0 Hz, 1H), 7.76 (d,J= 6.8 Hz, 1H), 7.63-7.54 (m, 1H), 5.66 (d,J= 5.6 Hz, 1H), 4.93 (t,J= 6.4 Hz, 1H), 1.48 (d,J= 6.8 Hz, 3H), 1.10 (s, 9H).
[0510] Step 4: Synthesis of (1R)-1-[2-chloro-3-(trifluoromethyl)phenyl]ethanamine
[0511] To a solution of N-[(1R)-1-[2-chloro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (200 mg, 610.14 μmol) in dioxane (1 mL) was added dropwise HCl / dioxane (1 mL), and the mixture was stirred at 25 °C for 2 h. TLC (PE:EtOAC = 1:1) showed that all the starting material had been consumed and one new spot was identified. The mixture was concentrated under reduced pressure to give intermediate A-15 (136 mg, 99.68% yield) as a yellow solid. MS (ESI) m / z = 224.1 [M+H] + .
[0512] Manufacturing Example 16: [1-[3-[(1R)-1-aminoethyl]-2-fluorophenyl]cyclopropyl] methanol (A-16)
[0513]
[0514] Step 1: Synthesis of 1-(3-bromo-2-fluoro-phenyl)cyclopropanecarbonitrile
[0515] A solution of 2-(3-bromo-2-fluoro-phenyl)acetonitrile (4.4 g, 20.56 mmol) and 1,2-dibromoethane (5.02 g, 26.72 mmol, 2.02 mL) in THF (80 mL) was purged three times with N2, and then NaH (1.07 g, 26.72 mmol, 60% purity) was added at 0 °C. The mixture was then stirred at 20 °C for 16 h under N2 atmosphere. Saturated NH4Cl aqueous solution was poured into the mixture, and extracted with EtOAc (30 mL X 3). The organic layer was washed with brine (50 mL), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (9% EtOAc in petroleum ether) to obtain 1-(3-bromo-2-fluoro-phenyl)cyclopropanecarbonitrile (4.6 g, 75.50% yield, 81% purity) as a yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 7.74 (ddd,J= 1.6, 6.8, 8.0 Hz, 1H), 7.57 - 7.38 (m, 1H), 7.18 (dt,J= 0.8, 8.0 Hz, 1H), 1.86 - 1.60 (m, 2H), 1.57 - 1.41 (m, 2H).
[0516] Step 2: Synthesis of 1-(3-bromo-2-fluoro-phenyl)cyclopropanecarboxylate
[0517] A solution of 1-(3-bromo-2-fluoro-phenyl)cyclopropanecarbonitrile (4.69 g, 19.54 mmol) in ethanol (80 mL) and sulfuric acid (10 mL) was purged three times with N2, and the mixture was stirred at 90 °C for 48 h under a N2 atmosphere. TLC (PE:EA = 10:1) confirmed that the reaction had proceeded completely. Water (20 mL) was added to the mixture, and extracted with EtOAc (20 mL X 3). The organic layer was washed with brine (100 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (2% EtOAc in petroleum ether) to obtain 1-(3-bromo-2-fluoro-phenyl)cyclopropanecarboxylate (3.74 g, 66.68% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.63 (ddd,J= 1.6, 6.8, 8.0 Hz, 1H), 7.40 - 7.29 (m, 1H), 7.20 - 7.02 (m, 1H), 4.04 (q,J= 7.2 Hz, 2H), 1.64 - 1.47 (m, 2H), 1.29 - 1.23 (m, 2H), 1.08 (t,J= 7.2 Hz, 3H).
[0518] Step 3: Synthesis of ethyl 1-(3-acetyl-2-fluoro-phenyl)cyclopropanecarboxylate
[0519] A mixture of tributyl(1-ethoxyvinyl)stannane (9.82 g, 27.20 mmol, 9.19 mL) and Pd(PPh3)2Cl2 (1.78 g, 2.54 mmol) in a solution of 1-(3-bromo-2-fluoro-phenyl)cyclopropanecarboxylate (7.3 g, 25.42 mmol) in dioxane (100 mL) was degassed, purged three times with N2, and stirred at 80 ℃ for 16 h under N2 atmosphere. TLC (PE:EA = 3:1) confirmed that the reaction had proceeded completely. The mixture was quenched by adding 4 N HCl solution (30 mL) and stirred at 20 ℃ for 1 h. TLC (PE:EA = 5:1) confirmed that all intermediates had disappeared and that the reaction had proceeded completely. Water (100 mL) was added to the reaction mixture and extracted with EtOAc (100 mL X 3). The combined organic layers were washed with brine (100 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a residue. The aqueous layer was stirred while slowly adding saturated aqueous KF solution (150 mL), and then stirred at 25 °C for 1 hour. This was purified by column chromatography (3% EtOAc in petroleum ether) to obtain ethyl 1-(3-acetyl-2-fluoro-phenyl)cyclopropanecarboxylate (4.6 g, 72.29% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.78 - 7.68 (m, 1H), 7.65 - 7.54 (m, 1H), 7.26 (dt,J= 1.2, 7.6 Hz, 1H), 4.04 (dq,J= 1.2, 7.2 Hz, 2H), 2.58 (dd,J= 1.2, 4.4 Hz, 3H), 1.62 - 1.49 (m, 2H), 1.32 - 1.22 (m, 2H), 1.09 (dt,J= 1.2, 7.2 Hz, 3H).
[0520] Step 4: Synthesis of ethyl 1-[3-[(Z)-N-[(R)-tert-butylsulfinyl]-C-methylcarbonimidoyl]-2-fluoro-phenyl]cyclopropanecarboxylate
[0521] To a solution of ethyl 1-(3-acetyl-2-fluoro-phenyl)cyclopropanecarboxylate (2 g, 7.99 mmol) in THF (25 mL) were added (R)-2-methylpropane-2-sulfinamide (968.58 mg, 7.99 mmol) and Ti(OEt)4 (5.47 g, 23.97 mmol, 4.97 mL), degassed, and purged three times with N2. The mixture was then stirred at 80 °C for 16 h under N2 atmosphere. The mixture was poured into water (50 mL), the reaction mixture was filtered, and the filtrate was extracted with EtOAc (50 mL X 3). The organic layer was washed with brine (100 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (6% EtOAc in petroleum ether) to give ethyl 1-[3-[(Z)-N-[(R)-tert-butylsulfinyl]-C-methylcarbonimidoyl]-2-fluoro-phenyl]cyclopropanecarboxylate (2.3 g, 73.28% yield, 90% purity) as a yellow oil. MS (ESI) m / z = 354.3 [M+H] + .
[0522] Step 5: Synthesis of ethyl 1-[3-[(1R)-1-[[(S)-tert-butylsulfinyl]amino]ethyl]-2-fluorophenyl]cyclopropanecarboxylate
[0523] To a solution of ethyl 1-[3-[(Z)-N-[(R)-tert-butylsulfinyl]-C-methylcarbonimidoyl]-2-fluoro-phenyl]cyclopropanecarboxylate (1.1 g, 3.11 mmol) in THF (20 mL) was slowly added dropwise L-selectride (1 M, 5.91 mL) at -78 °C under N2 atmosphere, and the mixture was stirred at -78 °C for 2 h under N2 atmosphere. The reaction mixture was slowly dropped into saturated NH4Cl aqueous solution (20 mL) at 20 °C under N2 atmosphere, quenched, added to water (20 mL), and extracted with EtOAc (20 mL X 3). The organic layer was washed with brine (10 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (19% EtOAc in petroleum ether) to give ethyl 1-[3-[(1R)-1-[[(S)-tert-butylsulfinyl]amino]ethyl]-2-fluorophenyl]cyclopropanecarboxylate (440 mg, 36.99% yield, 93% purity, ee = 95.12%) as a colorless oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.46 - 7.33 (m, 1H), 7.25 - 7.17 (m, 1H), 7.15 - 7.05 (m, 1H), 5.45 (d,J= 6.0 Hz, 1H), 4.74 - 4.57 (m, 1H), 4.01 (dq,J= 2.0, 7.2 Hz, 2H), 1.51 (s, 2H), 1.47 (d,J= 6.8 Hz, 3H), 1.22 - 1.16 (m, 2H), 1.11 - 1.09 (m, 9H), 1.08 - 1.04 (m, 3H); MS (ESI) m / z = 356.1 [M+H] + .
[0524] Step 6: Synthesis of ethyl 1-[3-[(1R)-1-aminoethyl]-2-fluoro-phenyl]cyclopropanecarboxylate
[0525] To a solution of ethyl 1-[3-[(1R)-1-[[(S)-tert-butylsulfinyl]amino]ethyl]-2-fluorophenyl]cyclopropanecarboxylate (250 mg, 703.30 μmol) in dioxane (1 mL) was added dropwise HCl / dioxane (1 mL), degassed, and purged three times with N2. The mixture was then stirred at 0°C under N2 atmosphere for 1 h. LCMS confirmed complete consumption of the starting material. The mixture was concentrated under reduced pressure to afford the crude product ethyl 1-[3-[(1R)-1-aminoethyl]-2-fluoro-phenyl]cyclopropanecarboxylate (200 mg, 96.75% yield, 97.9% purity, hydrochloride) as a white solid, which was used in the next reaction without further purification. MS (ESI) m / z = 252.2 [M+H] + .
[0526] Step 7: Synthesis of [1-[3-[(1R)-1-aminoethyl]-2-fluorophenyl]cyclopropyl]methanol
[0527] To a solution of ethyl 1-[3-[(1R)-1-aminoethyl]-2-fluoro-phenyl]cyclopropanecarboxylate (200 mg, 795.87 μmol) in THF (3 mL) was added LiAlH4 (90.62 mg, 2.39 mmol) at -10 °C, and the mixture was then stirred at -10 °C for 2 h. The mixture was quenched with aqueous NaOH solution (15%, 0.6 mL) at 20 °C, filtered, and the filtrate concentrated under reduced pressure to give intermediate A-16 (165 mg, 74.30% yield, 75% purity) as a yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 7.47 (dt,J= 1.6, 7.2 Hz, 1H), 7.21 (dt,J= 1.6, 7.2 Hz, 1H), 7.15 - 7.08 (m, 1H), 4.68 (br t,J= 5.6 Hz, 1H), 4.30 (q,J= 6.4 Hz, 1H), 3.50 (br d,J= 5.6 Hz, 2H), 1.29 (d,J= 6.4 Hz, 3H), 0.91 - 0.85 (m, 2H), 0.73 - 0.68 (m, 2H).
[0528] Manufacturing Example 17: (1R)-1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethanamine (A-17)
[0529]
[0530] Step 1: Synthesis of 1-bromo-2-fluoro-3-isopropenyl-benzene
[0531] A solution of t-BuOK (5.17 g, 46.08 mmol, 1 eq) and methyl (triphenyl) phosphonium bromide (16.46 g, 46.08 mmol) in THF (100 mL) was stirred at 20 °C for 1 h. Then, a solution of 1-(3-bromo-2-fluoro-phenyl)ethanone (10 g, 46.08 mmol) in THF (100 mL) was added to the reaction mixture, and the mixture was stirred at 60 °C for 16 h under N2 atmosphere. Water (80 mL) was poured into the mixture, and it was extracted with EtOAc (80 mL X 3). The organic layer was washed with brine (100 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (petroleum ether) to obtain 1-bromo-2-fluoro-3-isopropenyl-benzene (7.5 g, 68.12% yield, 90% purity) as a white oil. 1H NMR (400 MHz, DMSO-d6) δ 7.66 - 7.49 (m, 1H), 7.36 (dt,J= 1.6, 7.4 Hz, 1H), 7.16 - 7.10 (m, 1H), 5.31 (d,J= 0.8 Hz, 1H), 5.22 (s, 1H), 2.08 (d,J= 0.8 Hz, 3H).
[0532] Step 2: Synthesis of 1-bromo-2-fluoro-3-(1-methylcyclopropyl)benzene
[0533] TFA (7.95 g, 69.75 mmol, 5.18 mL) was slowly added dropwise to a solution of diethylzinc (1 M, 69.75 mL) at 0 °C for 20 min. The mixture was then stirred at 0 °C for 20 min, and then a solution of CH2I2 (18.68 g, 69.75 mmol, 5.63 mL) in DCM (45 mL) was slowly added dropwise at 0 °C. The mixture was then stirred at 0 °C for 20 min, and then 1-bromo-2-fluoro-3-isopropenyl-benzene (3 g, 13.95 mmol) was slowly added dropwise at 0 °C. The mixture was stirred at 25 °C for 12 h. It was confirmed that the reaction had proceeded completely by TLC (PE:EA = 10:1). Water (30 mL) was poured into the mixture, and it was extracted with DCM (30 mL X 3). The organic layer was washed with brine (50 mL), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (petroleum ether) to obtain 1-bromo-2-fluoro-3-(1-methylcyclopropyl)benzene (2.7 g, 76.04% yield, 90% purity) as a colorless liquid. 1H NMR (400 MHz, DMSO-d6) δ 7.53 (ddd,J= 1.6, 6.4, 8.0 Hz, 1H), 7.32 (dt,J= 1.6, 7.2 Hz, 1H), 7.06 (dt,J= 0.8, 7.8 Hz, 1H), 1.29 (s, 3H), 0.78 - 0.75 (m, 2H), 0.73 - 0.70 (m, 2H).
[0534] Step 3: Synthesis of 1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethanone
[0535] A solution of 1-bromo-2-fluoro-3-(1-methylcyclopropyl)benzene (4 g, 17.46 mmol) in dioxane (60 mL) was added to a mixture of tributyl(1-ethoxyvinyl)stannane (6.62 g, 18.33 mmol, 6.19 mL) and Pd(PPh3)2Cl2 (612.77 mg, 873.03 μmol), degassed, purged with N2 three times, and stirred at 100 °C for 16 h under N2 atmosphere. 4 N HCl solution (10 mL) was added to the mixture, and stirred at 20 °C for 1 h. The reaction mixture was added to water (50 mL) and extracted with EtOAc (30 mL X 3). The combined organic layer was washed with brine (30 mL X 3), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a residue. This was purified by column chromatography (petroleum ether) to obtain 1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethanone (2.1 g, 60.69% yield, 97% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.64 (dt,J= 2.0, 7.6 Hz, 1H), 7.56 (dt,J= 2.0, 7.2 Hz, 1H), 7.21 (t,J= 7.6 Hz, 1H), 2.58 (d,J= 4.4 Hz, 3H), 1.32 (s, 3H), 0.79 - 0.76 (m, 2H), 0.74 - 0.71 (m, 2H); MS (ESI) m / z = 193.0 [M+H]+ .
[0536] Step 4: Synthesis of (NE, S)-N-[1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide
[0537] To a solution of 1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethanone (2 g, 10.40 mmol) in THF (30 mL) were added (S)-2-methylpropane-2-sulfinamide (1.51 g, 12.49 mmol) and Ti(OEt)4 (4.75 g, 20.81 mmol, 4.32 mL), degassed, and purged three times with N2. The mixture was then stirred at 80 °C for 5 h under a N2 atmosphere. The mixture was poured into water (20 mL), the reaction mixture was filtered, and the filtrate was extracted with EtOAc (20 mL X 3). The organic layer was washed with brine (20 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (2% EtOAc in petroleum ether) to give (NE, S)-N-[1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (2.5 g, 77.44% yield, 95.209% purity) as a yellow oil. MS (ESI) m / z = 296.2 [M+H] + .
[0538] Step 5: Synthesis of (S)-N-[(1R)-1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0539] To a solution of (NE, S)-N-[1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (2.5 g, 8.46 mmol) in THF (40 mL) was slowly added dropwise L-selectride (1 M, 12.69 mL) at -78 °C under N2 atmosphere for 0.5 h, and the mixture was stirred at -78 °C for 3 h under N2 atmosphere. The reaction mixture was quenched by slowly adding dropwise saturated NH4Cl aqueous solution (50 mL) at -78 °C under N2 atmosphere, diluted with EtOAc (60 mL), and extracted with EtOAc (60 mL X 3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (6% EtOAc in petroleum ether) to give (S)-N-[(1R)-1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (2.3 g, 76.19% yield, 83.38% purity, ee = 98.7%) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.34 - 7.25 (m, 1H), 7.19 (dt,J= 1.6, 7.6 Hz, 1H), 7.09 - 7.02 (m, 1H), 5.40 (d,J= 6.0 Hz, 1H), 4.67 (q,J= 6.4 Hz, 1H), 1.46 (d,J= 8.0 Hz, 3H), 1.28 (s, 3H), 1.09 (s, 9H), 0.74 - 0.70 (m, 2H), 0.68 (m, 2H); MS (ESI) m / z = 298.2 [M+H] + .
[0540] Step 6: Synthesis of (1R)-1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethanamine
[0541] To a solution of (S)-N-[(1R)-1-[2-fluoro-3-(1-methylcyclopropyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (200 mg, 672.43 μmol) in dioxane (2 mL) was added dropwise HCl / dioxane (2 mL), degassed, and purged three times with N2. The mixture was then stirred at 25 °C under N2 atmosphere for 2 h. The mixture was concentrated under reduced pressure to obtain a crude product, which was treated with MTBE (2 mL) at 25 °C for 20 min to give intermediate A-17 (120 mg, 73.02% yield, 94% purity, hydrochloride) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.53 (br s, 3H), 7.52 - 7.47 (m, 1H), 7.35 (dt,J= 1.6, 7.2 Hz, 1H), 7.22 - 7.17 (m, 1H), 4.61 (br s, 1H), 1.51 (d,J= 6.8 Hz, 3H), 1.31 (s, 3H), 0.74 (br d,J= 10.0 Hz, 4H); MS (ESI) m / z = 194.0 [M+H] + .
[0542] Manufacturing Example 18: (1R)-1-Deuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanamine (A-18)
[0543]
[0544] Step 1: Synthesis of (NZ,R)-N-[1-[2-fluoro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide
[0545] To a solution of 1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanone (3 g, 14.55 mmol) in THF (50 mL) were added Ti(OEt)4 (9.96 g, 43.66 mmol, 9.05 mL) and (R)-2-propane-2-sulfinamide (2.65 g, 21.83 mmol), and the mixture was stirred at 70 °C for 12 h under N2 atmosphere. The mixture was poured into water (60 mL), the reaction mixture was filtered, and the filtrate was extracted with EtOAc (60 mL X 3). The organic layer was washed with brine (50 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (8% EtOAc in petroleum ether) to give (NZ,R)-N-[1-[2-fluoro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (4.36 g, 90.10% yield, 93.03% purity) as a yellow oil. 1 H NMR (400MHz, DMSO-d6) δ 7.99 (br t,J= 7.2 Hz, 1H), 7.92 (br t,J= 7.2 Hz, 1H), 7.51 (br t,J= 8.0 Hz, 1H), 2.72 (br d,J= 1.2 Hz, 3H), 1.22 (s, 9H); MS (ESI) m / z = 310.1[M+H] +
[0546] Step 2: Synthesis of (R)-N-[(1R)-1-deuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0547] To a solution of (NZ,R)-N-[1-[2-fluoro-3-(trifluoromethyl)phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (500 mg, 1.62 mmol) in THF (10 mL) and D2O (0.2 mL) was added NaBD4 (61.15 mg, 1.62 mmol) at -70 °C, and the mixture was stirred at -70 °C for 4 h under N2 atmosphere. The mixture was quenched with saturated NH4Cl (50 mL) and poured into water (30 mL). The mixture was extracted with EtOAc (40 mL X 3), and the organic layer was washed with brine (40 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (18% EtOAc / petroleum ether) to give (R)-N-[(1R)-1-deuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (330 mg, 48.42% yield, 74.08% purity, 98.06% ee) as a yellow oil. 1 H NMR (400MHz, DMSO-d6) δ 7.89 (br t,J= 7.2 Hz, 1H), 7.70-7.62 (m, 1H), 7.42 (t,J= 8.0 Hz, 1H), 5.91 (s, 1H), 1.42 (s, 3H), 1.10 (s, 9H). MS (ESI) m / z = 312.9[M+H] + .
[0548] Step 3: Synthesis of (1R)-1-deuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]dethanamine
[0549] To a solution of (R)-N-[(1R)-1-deuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]-2-methyl-propane-2-sulfinamide (330 mg, 1.06 mmol) in dioxane (4 mL) at 0 °C was added 4N HCl / dioxane (4 mL), and the mixture was stirred at 0 °C for 1 h. The mixture was concentrated under reduced pressure to give intermediate A-18 (200 mg, 90.93% yield, 90% purity) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.80 (br s, 3H), 8.09 (t,J= 7.2 Hz, 1H), 7.82 (t,J= 7.2 Hz, 1H), 7.52 (t,J= 8.0 Hz, 1H), 1.56 (s, 3H); MS (ESI) m / z = 209.1 [M+H] + .
[0550] Manufacturing Example 19: (1R)-2,2,2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]enamine (A-19)
[0551]
[0552] Step 1: Synthesis of (NE, S)-N-[[2-fluoro-3-(trifluoromethyl)phenyl]methylene]-2-methyl-propane-2-sulfinamide
[0553] To a solution of 2-fluoro-3-(trifluoromethyl)benzaldehyde (5 g, 26.03 mmol, 3.59 mL) in THF (60 mL) were added (S)-2-methylpropane-2-sulfinamide (4.73 g, 39.04 mmol) and Ti(OEt)4 (17.81 g, 78.08 mmol, 16.19 mL), degassed, and purged three times with N2. The mixture was then stirred at 80 °C for 3 h under a N2 atmosphere. The mixture was poured into water (40 mL), and the reaction mixture was filtered and extracted with EtOAc (100 mL X 3). The organic layer was washed with brine (40 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (5% EtOAc in petroleum ether) to give (NE, S)-N-[[2-fluoro-3-(trifluoromethyl)phenyl]methylene]-2-methyl-propane-2-sulfinamide (7.3 g, 93.75% yield, 98.7% purity) as a white solid. MS (ESI) m / z = 295.9 [M+H] + .
[0554] Step 2: Synthesis of (S)-2-methyl-N-[(1R)-2,2,2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]propane-2-sulfinamide
[0555] To a solution of (NE, S)-N-[[2-fluoro-3-(trifluoromethyl)phenyl]methylene]-2-methyl-propane-2-sulfinamide (1.00 g, 3.39 mmol) in THF (15 mL) was slowly added dropwise iodo(trideuteriomethyl)magnesium (1 M, 5.08 mL) at -40 °C. The mixture was then stirred at -40 °C for 6 h, then warmed to 23 °C and stirred for 12 h. The mixture was quenched by slowly adding dropwise saturated NH4Cl aqueous solution (20 mL) at 0 °C, and extracted with EtOAc (30 mL X 3). The organic layer was washed with brine (10 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (9% EtOAc in petroleum ether) to give (S)-2-methyl-N-[(1R)-2,2,2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]propane-2-sulfinamide (65 mg, 3.69% yield, 60.5% purity, ee = 98.26%) as a yellow oil. MS (ESI) m / z = 314.9 [M+H] + .
[0556] Step 3: Synthesis of (1R)-2,2,2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanamine
[0557] To a solution of (S)-2-methyl-N-[(1R)-2,2,2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]propane-2-sulfinamide (65 mg, 206.77 μmol) in dioxane (1 mL) at 0 °C was added HCl / dioxane (4 M, 1 mL), degassed, and purged three times with N2. The mixture was then stirred at 25 °C for 1 h under N2 atmosphere. The mixture was concentrated under reduced pressure to give intermediate A-19 (50 mg, 78.43% yield, 80% purity, hydrochloride) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ 8.50 (br s, 3H), 7.97 (t,J= 7.2 Hz, 1H), 7.84 (t,J= 7.2 Hz, 1H), 7.54 (t,J= 8.0 Hz, 1H), 4.71 (br d,J= 5.2 Hz, 1H); MS (ESI) m / z = 314.3 [M+H] + .
[0558] Manufacturing Example 20: 2-[3-[(1R)-1-aminoethyl]-2-fluoro-phenyl]-1, 1-dideuterio-2, 2-difluoro-ethanol (A-20)
[0559]
[0560] Step 1: Synthesis of ethyl 2-(3-bromo-2-fluoro-phenyl)-2,2-difluoro-acetate
[0561] To a solution of ethyl 2-bromo-2,2-difluoro-acetate (14.17 g, 69.79 mmol, 8.99 mL, 3 eq) in DMSO (200 mL) were added copper (4.43 g, 69.79 mmol, 494.98 μL, 3 eq) and 1-bromo-2-fluoro-3-iodo-benzene (7 g, 23.26 mmol, 1 eq). The reaction mixture was stirred at 85 °C for 16 h under N2 atmosphere. TLC (PE:EA = 1:0) confirmed the complete consumption of reactant 1 and the formation of one major spot. The reaction mixture was filtered, and water (80 mL) was added to the filtrate, followed by extraction with EtOAc (80 mL X 3). The organic layer was washed with brine (60 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (0-10% ethyl acetate / petroleum ether) to obtain ethyl 2-(3-bromo-2-fluoro-phenyl)-2,2-difluoro-acetate (5.68 g, 78.08% yield, 95% purity) as a colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.99 (t,J= 7.2 Hz, 1H), 7.75 - 7.70 (m, 1H), 7.37 (t,J= 8.0 Hz, 1H), 4.36 (q,J= 7.2 Hz, 2H), 1.23 (t,J= 7.2 Hz, 3H).
[0562] Step 2: Synthesis of 2-(3-bromo-2-fluoro-phenyl)-1, 1-dideuterio-2,2-difluoro-ethanol
[0563] To a solution of ethyl 2-(3-bromo-2-fluoro-phenyl)-2,2-difluoro-acetate (3 g, 10.10 mmol) in THF (40 mL) / D2O (0.8 mL) was added NaBD4 (496.68 mg, 13.13 mmol) at -78 °C, and the reaction mixture was stirred at 25 °C for 4 h under N2 atmosphere. Saturated NH4Cl aqueous solution (50 mL) was slowly added to the mixture at 20 °C, quenched, and water (30 mL) was added, followed by extraction with EtOAc (40 mL X 3). The organic layer was washed with brine (50 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (0-11% EtOAc / PE) to give 2-(3-bromo-2-fluoro-phenyl)-1, 1-dideuterio-2,2-difluoro-ethanol (2.27 g, 87.45% yield) as an off-white oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.95 - 7.85 (m, 1H), 7.64 - 7.50 (m, 1H), 7.29 (t,J= 8.0 Hz, 1H), 5.70 (s, 1H).
[0564] Step 3: Synthesis of 1-[3-(2, 2-dideuterio-1, 1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethanone
[0565] A mixture of tributyl(1-ethoxyvinyl)stannane (4.33 g, 11.99 mmol, 4.05 mL), TEA (1.63 g, 16.11 mmol, 2.24 mL), and Pd(PPh3)2Cl2 (565.24 mg, 805.31 μmol) in dioxane (40 mL) was degassed and purged with N2 three times, and stirred at 80 °C for 16 h under N2 atmosphere. To the mixture, aqueous HCl solution (80 ml, 1 M) was added while stirring at 25 °C, and the mixture was stirred at 25 °C for 1 h. Water (40 mL) was added to the reaction mixture and extracted with EtOAc (20 mL X 3). The combined organic layers were washed with brine (40 mL X 3), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a residue. Saturated KF aqueous solution (60 mL) was slowly added, and then stirred at 25 °C for 1 h. The residue was purified by silica gel column chromatography (0-14% EtOAc / PE) to obtain 1-[3-(2, 2-dideuterio-1, 1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethanone (1.6 g, 90.23% yield) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.99 - 7.90 (m, 1H), 7.83 - 7.73 (m, 1H), 7.43 (t,J= 7.6 Hz, 1H), 5.70 (s, 1H), 4.04 (s, 1H), 2.60 (d,J= 4.4 Hz, 3H); MS (ESI) m / z = 221.1 [M+H] + .
[0566] Step 4: Synthesis of (NZ,R)-N-[1-[3-(2, 2-dideuterio-1, 1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide
[0567] To a solution of 1-[3-(2, 2-dideuterio-1, 1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethanone (230 mg, 1.04 mmol) in THF (5 mL) were added (R)-2-methylpropane-2-sulfinamide (189.91 mg, 1.57 mmol) and Ti(OEt)4 (714.83 mg, 3.13 mmol, 649.85 μL), and the mixture was stirred at 70 °C for 16 h under N2 atmosphere. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL X 3). The organic layer was washed with brine (20 mL X 2), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (0-20% EtOAc / PE) to give (NZ,R)-N-[1-[3-(2, 2-dideuterio-1, 1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (250 mg, 72.31% yield, 97.7% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.79 (br t,J= 6.8 Hz, 1H), 7.68 (br t,J= 6.8 Hz, 1H), 7.41 (br t,J= 7.6 Hz, 1H), 5.70 (s, 1H), 2.69 (br d,J= 1.6 Hz, 3H), 1.22 (s, 9H); MS (ESI) m / z = 324.0 [M+H] + .
[0568] Step 5: Synthesis of (R)-N-[(1R)-1-[3-(2,2-dideuterio-1, 1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide
[0569] To a solution of (NZ,R)-N-[1-[3-(2, 2-dideuterio-1, 1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethylidene]-2-methyl-propane-2-sulfinamide (250 mg, 773.11 μmol) in THF (5 mL) and H2O (0.1 mL) was added NaBH4 (29.25 mg, 773.11 μmol) at -70 °C, and the mixture was stirred at -70 °C for 4 h under N2 atmosphere. The mixture was quenched with saturated NH4Cl aqueous solution (20 mL) at 20 °C, water (20 mL) was added, and then extracted with EtOAc (20 mL X 3). The organic layer was washed with brine (30 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (0-45% EtOAc / PE) and prep-HPLC (column: Welch Xtimate C18 40*200mm 7um; mobile phase: [water (NH3H2O + NH4HCO3)-ACN]; gradient: 16%-56% B over 25 min). The solvent was concentrated under reduced pressure, and the residue was lyophilized to obtain (R)-N-[(1S)-1-[3-(2, 2-dideuterio-1, 1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (30 mg, 11.93% yield, 100% purity, ee = 100%) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.63 (br t,J= 7.2 Hz, 1H), 7.43 (t,J= 7.2 Hz, 1H), 7.38 - 7.22 (m, 1H), 6.04 (br d,J= 1.6 Hz, 1H), 5.53 (d,J= 5.6 Hz, 1H), 4.71 (br t,J= 6.4 Hz, 1H), 2.54 (s, 1H), 1.48 (d,J= 6.8 Hz, 3H), 1.09 (s, 9H); LC / MS (ESI) m / z = 326.2 [M+H] +. Additionally, the desired product (R)-N-[(1R)-1-[3-(2, 2-dideuterio-1, 1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (90 mg, 276.59 μmol, 35.78% yield, 100% purity, ee = 99.96%) was obtained as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.70 (t,J= 7.2Hz, 1H), 7.47 - 7.40 (m, 1H), 7.34 - 7.26 (m, 1H), 5.86 (d,J= 7.6 Hz, 1H), 4.68 (t,J= 7.2 Hz, 1H), 1.40 (d,J= 6.8 Hz, 3H), 1.10 (s, 9H); MS (ESI) m / z = 326.2 [M+H] + .
[0570] Step 6: Synthesis of 2-[3-[(1R)-1-aminoethyl]-2-fluoro-phenyl]-1, 1-dideuterio-2, 2-difluoro-ethanol
[0571] To a solution of (R)-N-[(1R)-1-[3-(2, 2-dideuterio-1, 1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]-2-methyl-propane-2-sulfinamide (90 mg, 276.59 μmol) in dioxane (1 mL) was added HCl / dioxane (4 mL). The mixture was then stirred at 25 °C for 2 h. LCMS showed complete consumption of the starting material and the value of the desired compound was confirmed. The mixture was concentrated under reduced pressure to give intermediate A-20 (60 mg, 94.14% yield, 96% purity) as an off-white oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.66 (br s, 2H), 7.84 (t,J= 7.2 Hz, 1H), 7.58 (t,J= 6.8 Hz, 1H), 7.46 - 7.34 (m, 1H), 4.75 - 4.56 (m, 1H), 1.54 (d,J= 6.4 Hz, 3H).
[0572] Manufacturing Example 21: (+ / -)-1, 2, 2, 2-tetradeuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanamine (A-21)
[0573]
[0574] Step 1: Synthesis of 2,2,2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanol
[0575] To a solution of (2-fluoro-3-(trifluoromethyl)benzaldehyde (1 g, 5.21 mmol, 717.88 μL) in THF (20 mL) was slowly added iodo(trideuteriomethyl)magnesium (1 M, 10.41 mL) dropwise at -78 °C under N2 atmosphere, and the mixture was stirred at -78 °C for 3 h. Saturated NH4Cl aqueous solution (20 mL) was slowly added dropwise to the mixture, quenched, and extracted with EtOAc (30 mL X 3). The organic layer was washed with brine (30 mL), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (2% EtOAc in petroleum ether) to obtain 2, 2, 2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanol (900 mg, (81.88% yield, 95% purity) was obtained as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.85 (t,J= 7.2 Hz, 1H), 7.64 (t,J= 6.8 Hz, 1H), 7.40 (t,J= 8.0 Hz, 1H), 5.49 (d,J= 4.4 Hz, 1H), 5.03 (br d,J= 4.4 Hz, 1H).
[0576] Step 2: Synthesis of 2,2,2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanone
[0577] To a solution of 2,2,2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanol (900 mg, 4.26 mmol) in DCM (10 mL) was added (1,1-diacetoxy-3-oxo-1,2-benziodoxol-1-yl) acetate (2.17 g, 5.11 mmol, 1.58 mL) at 0 °C. The mixture was then warmed to 25 °C and stirred at 25 °C for 1 h. Saturated aqueous Na2CO3 solution (20 mL) was added to the mixture, and the mixture was extracted with DCM (20 mL X 3). The organic layer was washed with brine (30 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (1% EtOAc in petroleum ether) to obtain 2, 2, 2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanone (630 mg, 70.67% yield, 90% purity) as a white oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.13-8.05 (m, 1H), 7.85-7.77 (m, 1H), 7.35 (t,J= 8.0 Hz, 1H).
[0578] Step 3: Synthesis of 1, 2, 2, 2-tetradeuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanol
[0579] To a solution of 2,2,2-trideuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanone (530 mg, 2.53 mmol) in THF (8 mL) and D2O (0.16 mL) was added NaBD4 (95.87 mg, 2.53 mmol) at -70 °C under N2 atmosphere, and the mixture was stirred at -70 °C for 4 h under N2 atmosphere. The mixture was quenched with saturated NH4Cl aqueous solution (10 mL) and extracted with EtOAc (10 mL X 3). The organic layer was washed with brine (20 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (5% EtOAc in petroleum ether) to obtain 1, 2, 2, 2-tetradeuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanol (430 mg, 79.98% yield, 95% purity) as a white oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.85 (t,J= 7.2 Hz, 1H), 7.64 (t,J= 7.2 Hz, 1H), 7.40 (t,J= 8.0 Hz, 1H), 5.48 (s, 1H).
[0580] Step 4: Synthesis of 2-chloro-N-[1, 2, 2, 2-tetradeuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]acetamide
[0581] To a solution of 1,2,2,2-tetradeuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanol (400 mg, 1.89 mmol) in 2-chloroacetonitrile (2.92 g, 38.65 mmol, 2.45 mL) was slowly added sulfuric acid (2.22 g, 22.62 mmol, 1.21 mL) at 0 °C. The mixture was then stirred at 25 °C for 2 h under N2 atmosphere. The mixture was quenched with cold water (10 mL), adjusted to pH = 10-13 with saturated NaOH aqueous solution, and extracted with DCM (10 mL X 3). The organic layer was washed with brine (30 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (8% EtOAc in petroleum ether) to obtain 2-chloro-N-[1, 2, 2, 2-tetradeuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]acetamide (510 mg, 71.05% yield, 75.55% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.86 (s, 1H), 7.69 (td,J= 7.6, 15.2 Hz, 2H), 7.41 (t,J= 8.0 Hz, 1H), 4.09 (s, 2H); MS (ESI) m / z = 287.9 [M+H] + .
[0582] Step 5: Synthesis of (+ / -)-1, 2, 2, 2-tetradeuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethanamine
[0583] To a solution of 2-chloro-N-[1, 2, 2, 2-tetradeuterio-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]acetamide (250 mg, 869.04 μmol) in acetic acid (0.6 mL) were added thiourea (72.77 mg, 955.94 μmol) and ethanol (3 mL), and the mixture was stirred at 90 °C for 2 h. The mixture was diluted with water (5 mL), adjusted to pH = 9-10 with saturated NaOH aqueous solution, and extracted with EtOAc (5 mL X 3). The organic layer was washed with brine (10 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product. This was purified by silica gel column chromatography (58% EtOAc in petroleum ether) to obtain intermediate A-21 (180 mg, 73.38% yield, 74.82% purity) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.81 (br s, 1H), 8.05 (br t,J= 7.2 Hz, 1H), 7.76 (br t,J= 7.2 Hz, 1H), 7.48 (t,J= 8.0 Hz, 1H); MS (ESI) m / z = 212.0 [M+H] + .
[0584] Manufacturing Example 22: 2-[3-[(1R)-1-amino-2,2,2-trideuterio-ethyl]-2-fluoro-phenyl]-2,2-difluoro-ethanol (A-22)
[0585]
[0586] Step 1: Synthesis of 2,2-difluoro-2-(2-fluoro-3-vinyl-phenyl)ethanol
[0587] To a solution of 2-(3-bromo-2-fluoro-phenyl)-2,2-difluoro-ethanol (3 g, 11.76 mmol) in dioxane (40 mL) and H2O (5 mL) were added 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxoborolane (4.53 g, 29.41 mmol), Cs2CO3 (15.33 g, 47.05 mmol), and Pd(PPh3)4 (2.04 g, 1.76 mmol). The mixture was degassed, purged with nitrogen three times, and stirred at 90 °C under nitrogen for 3 h. The reaction mixture was filtered and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (4% EtOAc in petroleum ether) to obtain 2,2-difluoro-2-(2-fluoro-3-vinyl-phenyl)ethanol (1.44 g, 57.52% yield, 95% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.81 (t,J= 7.2 Hz, 1H), 7.47 (t,J= 6.8 Hz, 1H), 7.33-7.27 (m, 1H), 6.88 (dd,J= 11.2, 17.6 Hz, 1H), 5.98 (d,J= 18.0 Hz, 1H), 5.69 (t,J= 6.4 Hz, 1H), 5.50 (d,J= 11.2 Hz, 1H), 3.97-3.87 (m, 2H).
[0588] Step 2: Synthesis of 3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-benzaldehyde
[0589] To a solution of 2,2-difluoro-2-(2-fluoro-3-vinyl-phenyl)ethanol (1.44 g, 7.12 mmol) in THF (16 mL) and H2O (4 mL) were added dipotassium dioxido(dioxo)osmium dihydrate (262.44 mg, 712.26 μmol) and NaIO4 (5.94 g, 27.78 mmol) at 0 °C. The reaction mixture was degassed, purged with nitrogen three times, and stirred under nitrogen at 15 °C for 2 h. The reaction mixture was filtered, and the filtrate was poured into H2O (4 mL) and extracted with DCM (20 mL × 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (7% EtOAc in petroleum ether) to obtain 3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-benzaldehyde (990 mg, 64.68% yield, 95% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 10.26 (s, 1H), 8.03-7.95 (m, 1H), 7.88 (dt,J= 1.6, 7.6 Hz, 1H), 7.50 (t,J= 7.6 Hz, 1H), 5.83-5.71 (m, 1H), 4.09-3.81 (m, 2H).
[0590] Step 3: Synthesis of (NZ,S)-N-[[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]methylene]-2-methyl-propane-2-sulfinamide
[0591] Using commercially available (S)-2-methylpropane-2-sulfinamide, (NZ,S)-N-[[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]methylene]-2-methyl-propane-2-sulfinamide (850 mg, 93.01% yield, 97.19% purity) was obtained as a yellow oil in the same manner as in step 1 of Preparation Example 19. MS (ESI) m / z = 308.0 [M+H] + .
[0592] Step 4: Synthesis of (S)-2-methyl-N-[(1R)-2,2,2-trideuterio-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]propane-2-sulfinamide
[0593] (S)-2-Methyl-N-[(1R)-2,2,2-trideuterio-1-[3-(1,1-difluoro-2-hydroxy-ethyl)-2-fluoro-phenyl]ethyl]propane-2-sulfinamide (250 mg, 30.79% yield, 98.53% purity) was obtained as a yellow oil by the same method as in step 2 of Preparation Example 19 using commercially available iodo(trideuteriomethyl)magnesium (1 M in THF). MS (ESI) m / z = 327.0 [M+H] + .
[0594] Step 5: Synthesis of 2-[3-[(1R)-1-amino-2,2,2-trideuterio-ethyl]-2-fluoro-phenyl]-2,2-difluoro-ethanol
[0595] Intermediate A-22 (160 mg, 64.60% yield, 80% purity, hydrochloride) was obtained as a yellow oil using the same method as step 3 of Manufacturing Example 19. 1H NMR (400 MHz, DMSO-d6) δ 8.75 (br s, 3H), 7.87 (t,J= 6.8 Hz, 1H), 7.57 (t,J= 6.8 Hz, 1H), 7.40 (t,J= 8.0 Hz, 1H), 5.99-5.44 (m, 1H), 4.63 (br d,J= 4.0 Hz, 1H), 3.93 (br t,J= 14.4 Hz, 2H); MS (ESI) m / z = 223.1 [M+H] + .
[0596] Manufacturing Example 22-1: (1R)-1-[2-fluoro-3-(1,1,2-trifluoroethyl)phenyl]ethanamine (A-23)
[0597]
[0598] Step 1: Synthesis of tert-butyl N-[(1R)-1-[3-(1,1-difluoro-2-hydroxyethyl)-2-fluorophenyl]ethyl]carbamate
[0599] A mixture of intermediate A-1 (1 g, 3.91 mmol, HCl), Boc2O (1.71 g, 7.82 mmol, 1.80 mL), and DIEA (1.01 g, 7.82 mmol, 1.36 mL) in DCM (11 mL) was degassed and purged with nitrogen three times. The mixture was then stirred at 25 °C for 3 h under a nitrogen atmosphere. The mixture was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (15% EA in PE) to give tert-butyl N-[(1R)-1-[3-(1,1-difluoro-2-hydroxyethyl)-2-fluorophenyl]ethyl]carbamate (848 mg, 59.75% yield, 88% purity) as a colorless oil. 1H NMR (400 MHz, DMSO-d6) δ 7.60 - 7.50 (m, 2H), 7.44 - 7.39 (m, 1H), 7.30 - 7.26 (m, 1H), 5.70 (t, J = 6.4 Hz, 1H), 4.92 (br t, J = 7.2 Hz, 1H), 3.91 (dt, J = 6.4, 14.4 Hz, 2H), 1.36 (s, 9H), 1.29 (d, J = 7.2 Hz, 3H); MS (ESI) m / z = 264.0 [M+H-56] + .
[0600] Step 2: Synthesis of tert-butyl N-[(1R)-1-[2-fluoro-3-(1,1,2-trifluoroethyl)phenyl]ethyl]carbamate
[0601] To a solution of tert-butyl N-[(1R)-1-[3-(1,1-difluoro-2-hydroxyethyl)-2-fluorophenyl]ethyl]carbamate (400 mg, 1.25 mmol), N,N-diethylethanamine;trihydrofluoride (605.82 mg, 3.76 mmol, 612.56 μL), and N,N-diethylethanamine (760.54 mg, 7.52 mmol, 1.05 mL) in anhydrous THF (10 mL) was slowly added NfT (1.14 g, 3.76 mmol, 661.57 μL) dropwise at 20 °C. The mixture was then stirred at 50 °C for 36 h. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (5% EtOAc in PE) to obtain tert-butyl N-[(1R)-1-[2-fluoro-3-(1,1,2-trifluoroethyl)phenyl]ethyl]carbamate (346 mg, 82.84% yield, 96.37% purity) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 7.66 - 7.54 (m, 2H), 7.51 - 7.46 (m, 1H), 7.37 - 7.32 (m, 1H), 5.03 (t,J= 13.8 Hz, 1H), 4.96 - 4.87 (m, 2H), 1.36 (s, 9H), 1.30 (d,J= 7.2 Hz, 3H); MS (ESI) m / z = 266.0 [M+H-56] + .
[0602] Step 3: Synthesis of (1R)-1-[2-fluoro-3-(1,1,2-trifluoroethyl)phenyl]ethanamine
[0603] A mixture of N-[(1R)-1-[2-fluoro-3-(1,1,2-trifluoroethyl)phenyl]ethyl]carbamate (346 mg, 1.08 mmol) in HCl / dioxane (4N, 2 mL) and dioxane (2 mL) was degassed and purged with nitrogen three times. The mixture was then stirred at 20 °C for 1 h under a nitrogen atmosphere. The reaction mixture was concentrated under reduced pressure to give intermediate A-23 (248 mg, 78.66% yield, 88% purity, HCl) as a white solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.66 (br s, 3H), 7.92 (t,J= 7.2 Hz, 1H), 7.66 (t,J= 6.8 Hz, 1H), 7.53 - 7.43 (m, 1H), 5.11 - 4.89 (m, 2H), 4.68 (q,J= 6.8 Hz, 1H), 1.55 (d,J= 6.8 Hz, 3H); MS (ESI) m / z = 221.9 [M+H] + .
[0604] Manufacturing Example 23: 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)triazole (T-8)
[0605]
[0606] Step 1: Synthesis of 1-(trideuteriomethyl)triazole
[0607] To a solution of 1H-triazole (1.99 g, 28.74 mmol, 1.67 mL) in THF (25 mL) were added K2CO3 (7.95 g, 57.49 mmol) and trideuterio(iodo)methane (5 g, 34.49 mmol, 2.15 mL), and the mixture was stirred at 25 °C for 12 h. The reaction mixture was poured into water (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to give the crude intermediate T-7 (1.18 g, 47.56% yield) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.06 (s, 1H), 7.70 (s, 1H).
[0608] Step 2: Synthesis of [3-(trideuteriomethyl)triazol-4-yl]boronic acid
[0609] To a solution of intermediate T-7 (600 mg, 6.97 mmol) in THF (10 mL) was slowly added n-BuLi (2.5 M, 3.07 mL) under nitrogen at 0 °C. The reaction mixture was stirred at -20 °C for 1 h and then cooled to -78 °C. 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.56 g, 8.36 mmol, 1.71 mL) was slowly added to the reaction mixture at -78 °C. After 15 min, the reaction mixture was warmed to 0 °C for 1 h. The reaction mixture was quenched with an aqueous ammonium salt solution. The reaction mixture was concentrated under reduced pressure to give the crude product intermediate T-8 (2.2 g) as a white solid. MS (ESI) m / z = 131.2 [M+H] + .
[0610] Manufacturing Example 24: 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)triazole (T-5)
[0611]
[0612] To a solution of 1-methyltriazole (2 g, 24.07 mmol) in THF (20 mL) was slowly added n-BuLi (2.5 M, 10.59 mL) under nitrogen at 0 °C. The reaction mixture was stirred at -20 °C for 1 h and then cooled to -78 °C. 2-Isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (15.37 g, 28.88 mmol, 5.89 mL) was slowly added to the reaction mixture at -78 °C. After 15 min, the reaction mixture was warmed to 0 °C for 1 h. The reaction mixture was quenched with an aqueous ammonium salt solution (100 mg, 6 mL). The reaction mixture was concentrated under reduced pressure to give the crude intermediate T-5 (7.9 g) as a pale yellow solid, which was used in the next reaction without purification. MS (ESI) m / z = 210.2 [M+H] + .
[0613] Manufacturing Example 25: Tributyl-(3-methyltriazol-4-yl)stanane (T-3)
[0614]
[0615] A solution of 1-methyltriazole (3 g, 36.10 mmol) in THF (30 mL) was cooled to -78 °C, n-BuLi (2.5 M, 16.17 mL) was slowly added, and the reaction mixture was stirred at -78 °C for 2 h. Subsequently, tributyl(chloro)stannane (16.94 g, 52.04 mmol, 14 mL) was slowly added to the reaction mixture, and the mixture was stirred at -78 °C for 1 h under nitrogen conditions. Water was slowly added to the reaction mixture at 0 °C, quenched, and extracted with EtOAc (70 mL × 3). The combined organic layers were washed with brine (50 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude intermediate T-3 (17.35 g, 34.97 mmol, 96.85% yield, 75% purity) as a pale yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 7.58 (br s, 1H), 4.06 - 4.00 (m, 3H), 1.50 - 1.44 (m, 4H), 1.28 (br d,J= 7.2 Hz, 8H), 1.19 - 1.12 (m, 6H), 0.87 - 0.82 (m, 9H).
[0616] Manufacturing Example 26: Tributyl-[3-(trideuteriomethyl)triazol-4-yl]stanane (T-9)
[0617]
[0618] A solution of 1-(trideuteriomethyl)triazole (1 g, 11.61 mmol) in THF (20 mL) was cooled to -78 °C, n-BuLi (2.5 M, 5.20 mL) was slowly added, and the reaction mixture was stirred at -78 °C for 1 h. Subsequently, tributyl(chloro)stannane (5.22 g, 16.03 mmol, 4.31 mL) was slowly added to the reaction mixture, and the mixture was stirred at -78 °C for 1 h under nitrogen conditions. The reaction mixture was quenched by slowly adding NH4Cl aqueous solution (20 mL) at 0 °C, and extracted with EtOAc (40 mL×3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to give the crude product, intermediate T-9 (4 g, 10.66 mmol), as a yellow oil. It was used in the next reaction without further purification. 1 H NMR (400 MHz, DMSO-d6) δ 7.60 (s, 1H), 1.49 (m, 4H), 1.35 - 1.21 (m, 8H), 1.19 - 1.09 (m, 6H), 0.88 - 0.83 (m, 9H).
[0619] Manufacturing Example 27: Tributyl-(3-ethyltriazol-4-yl)stanane (T-11)
[0620]
[0621] A solution of 1-ethyltriazole (500 mg, 5.15 mmol) in THF (10 mL) was cooled to -78 °C, n-BuLi (2.5 M, 2.31 mL) was slowly added, and the reaction mixture was stirred at -78 °C for 2 h. Subsequently, tributyl(chloro)stannane (2.14 g, 6.57 mmol, 1.77 mL) was slowly added to the reaction mixture, and the mixture was stirred at -78 °C for 1 h under nitrogen conditions. An aqueous ammonium salt solution (20 mL) was slowly added to the reaction mixture at 0 °C, quenched, and extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine (10 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to obtain intermediate T-11 (2.4 g, 90.54% yield, 75% purity) as a pale yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.58 (s, 1H), 4.33 (q,J= 7.2 Hz, 2H), 1.37-1.21 (m, 12H), 1.20-1.13 (m, 6H), 0.86 (d,J= 8.0 Hz, 12H).
[0622] Manufacturing Example 27-1: Tributyl-(3-cyclopropyl-4-yl)stanane (T-14)
[0623]
[0624] Step 1: Synthesis of 1-cyclopropyltriazole
[0625] To a solution of 4-methylbenzenesulfonohydrazide (5 g, 26.85 mmol) in methanol (50 mL) was added 2,2-dimethoxyacetaldehyde (4.89 g, 28.19 mmol, 4.25 mL). The reaction mixture was stirred at 25 °C for 2 h. Then, acetic acid (1.61 g, 26.85 mmol, 1.54 mL) and cyclopropanamine (1.53 g, 26.85 mmol, 1.86 mL) were added to the reaction mixture, and the mixture was stirred at 75 °C for 14 h. The reaction mixture was concentrated under reduced pressure to obtain a residue, which was purified by silica gel column chromatography (10% EtOAc in petroleum ether) to give 1-cyclopropyltriazole (6 g, 49.15% yield, 90% purity) as a yellow oil. 1 H NMR (400 MHz, DMSO-d6) δ 8.13 (s, 1H), 7.69 (d,J= 0.8 Hz, 1H), 4.02 - 3.92 (m, 1H), 1.15 - 1.08 (m, 4H).
[0626] Step 2: Synthesis of tributyl-(3-cyclopropyltriazol-4-yl)stannane
[0627] A solution of 1-cyclopropyltriazole (200 mg, 1.83 mmol) in THF (4 mL) was cooled to -78 °C, n-BuLi (2.5 M, 1.10 mL) was slowly added, and the reaction mixture was stirred at -78 °C for 2 h. Subsequently, tributyl(chloro)stannane (1.14 g, 3.50 mmol, 942.15 μL) was slowly added to the reaction mixture, and the mixture was stirred at -78 °C for 1 h under nitrogen conditions. The reaction mixture was quenched by slowly adding an aqueous ammonium salt solution (10 mL) at 0 °C, and extracted with EtOAc (15 mL × 3). The combined organic layers were washed with brine (10 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to obtain intermediate T-14 (1 g, 95.93% yield, 70% purity) as a white oil.1 H NMR (400 MHz, DMSO-d6) δ 7.59 (s, 1H), 3.71 (tt,J= 3.6, 7.2 Hz, 1H), 1.53 - 1.46 (m, 6H), 1.29 - 1.27 (m, 6H), 1.10 - 1.05 (m, 10H), 0.87 (s, 9H).
[0628] Manufacturing Example 27-2: Tributyl-(3-isopropyltriazol-4-yl)stanane (T-15)
[0629]
[0630] Intermediate T-15 (1 g, 97.21% yield, 70% purity) was obtained as a white oil using the same method as step 2 of Preparation Example 27-1 using commercially available 2,2-dimethoxyacetaldehyde and benzyloxyethanamine. 1 H NMR (400 MHz, DMSO-d6) δ 7.55 (s, 1H), 4.52 (td,J= 6.8, 13.2 Hz, 1H), 1.48 (s, 12H), 1.29 (br d,J= 7.6 Hz, 6H), 1.14 - 1.09 (m, 6H), 0.86 (d,J= 7.6 Hz, 9H).
[0631] Manufacturing Example 27-3: [3-(2-Benzyloxyethyl)triazol-4-yl]-tributyl-stannane (T-16)
[0632]
[0633] Intermediate T-16 (720 mg, crude product) was obtained as a yellow oil in the same manner as in Preparation Example 27-1 using commercially available 2,2-dimethoxyacetaldehyde and benzyloxyethanamine. This was used in the next reaction without further purification. 1H NMR (400 MHz, DMSO-d6) δ 7.82 (s, 1H), 7.40 - 7.37 (m, 3H), 7.33 (br d,J= 6.0 Hz, 2H), 4.71 (t,J= 5.2 Hz, 2H), 4.58 (s, 2H), 3.94 (t,J= 5.2 Hz, 2H), 1.59 - 1.55 (m, 6H), 1.37 (m, 6H), 1.19 (m, 6H), 0.96 - 0.95 (m, 6H).
[0634] Manufacturing Example 27-4: Tert-Butyl 3-(5-(tributylstannyl)-1H-1,2,3-triazol-1yl)azetidine-1-carboxylate (T-17)
[0635]
[0636] Intermediate T-17 (720 mg, crude product) was obtained as a yellow oil in the same manner as in Preparation Example 27-1 using commercially available 2,2-dimethoxyacetaldehyde and tert-butyl 3-aminoazetidine-1-carboxylate. This was used in the next reaction without further purification. 1 H NMR (400 MHz, DMSO-d6) δ 8.36 (d, J = 1.2 Hz, 1H), 7.80 (d, J = 0.8 Hz, 1H), 5.50 (tt, J = 5.2, 8.0 Hz, 1H), 4.39 (br t, J = 8.6 Hz, 2H), 4.17 (br s, 2H), 1.41 (s, 9H).
[0637] Manufacturing Example 27-5: 1-(Oxetan-3-yl)-5-(tributylstannyl)-1H-1,2,3-triazole (T-18)
[0638]
[0639] Intermediate T-18 (600 mg, 1.45 mmol, 90.64% yield) was obtained as a yellow oil in the same manner as in Preparation Example 27-1 using commercially available 2,2-dimethoxyacetaldehyde and 3-aminooxetane. This was used in the next reaction without further purification.1 H NMR (400 MHz, DMSO-d6) δ 7.67 (s, 1H), 5.64 - 5.53 (m, 1H), 5.00 (d,J= 6.8 Hz, 4H), 1.48 - 1.42 (m, 6H), 1.28 (br d,J= 7.6 Hz, 6H), 1.17 - 1.11 (m, 6H), 0.87 - 0.84 (m, 9H).
[0640] Manufacturing Example 27-6: Tributyl-(3-cyclobutyltriazol-4-yl)stanane (T-19)
[0641]
[0642] Intermediate T-19 (1.06 g, 79.18% yield) was obtained as a yellow oil in the same manner as in Preparation Example 27-1 using commercially available 2,2-dimethoxyacetaldehyde and cyclobutanamine. This was used in the next reaction without further purification. 1 H NMR (400 MHz, DMSO-d6) δ 7.58 (s, 1H), 4.81 (quin,J= 8.2 Hz, 1H), 2.74 - 2.58 (m, 2H), 2.47 - 2.40 (m, 2H), 1.91 (td,J= 4.8, 10.0 Hz, 2H), 1.50 - 1.42 (m, 7H), 1.30 - 1.26 (m, 6H), 1.18 - 1.13 (m, 6H), 0.87 - 0.84 (m, 9H).
[0643] Manufacturing Example 27-7: 1-(2,2-difluorocyclopropyl)triazole (T-20)
[0644]
[0645] Step 1: Synthesis of vinyl 4-methylbenzenesulfonate
[0646] n-BuLi (2.5 M in hexane, 18.46 mL) was added to anhydrous THF (70 mL) under nitrogen conditions, and the mixture was stirred at 35 °C for 4 h. After cooling to -78 °C, a solution of 4-methylbenzenesulfonyl chloride (8 g, 41.96 mmol) in anhydrous THF (20 mL) was added dropwise over 0.5 h. The resulting mixture was stirred at -78 °C for 1 h, warmed to 25 °C, and stirred for 1 h. The reaction mixture was poured into H2O (50 mL) and extracted with EtOAc (50 mL × 3). The combined organic layers were washed with brine (50 mL × 2), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (5% EtOAc in petroleum ether) to obtain vinyl 4-methylbenzenesulfonate (4.3 g, 51.69% yield) as a clear oil. 1 H NMR (400 MHz, DMSO-d6) δ 7.82 (d,J= 8.4 Hz, 2H), 7.51 (d,J= 8.0 Hz, 2H), 6.73 (dd,J= 5.6, 13.2 Hz, 1H), 4.94 (dd,J= 2.4, 13.2 Hz, 1H), 4.82 (dd,J= 2.4, 5.6 Hz, 1H), 2.43 (s, 3H).
[0647] Step 2: Synthesis of (2,2-difluorocyclopropyl) 4-methylbenzenesulfonate
[0648] To a mixture of vinyl 4-methylbenzenesulfonate (3.5 g, 7.66 mmol) and NaF (74.13 μL, 1.77 mmol) in o-xylene (2 mL) was added trimethylsilyl 2,2-difluoro-2-fluorosulfonyl-acetate (3.5 g, 17.66 mmol) dropwise over 2 h at 120 °C. The mixture was stirred at 120 °C for 2 h. The reaction mixture was concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (5% EtOAc in petroleum ether) to give (2,2-difluorocyclopropyl) 4-methylbenzenesulfonate (3.77 g, 82.49% yield, 95.9% purity) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.85 (d,J= 8.4 Hz, 2H), 7.53 (d,J= 8.0 Hz, 2H), 4.63 (ddt,J= 2.4, 4.8, 9.2 Hz, 1H), 2.44 (s, 3H), 2.11 - 1.93 (m, 1H), 1.83 (tdd, J = 5.2, 10.4, 16.8 Hz, 1H).
[0649] Step 3: Synthesis of 1-(2,2-difluorocyclopropyl)triazole
[0650] To a solution of 1H-triazole (1.63 mL, 28.20 mmol) in DMF (40 mL) was added NaH (1.13 g, 28.20 mmol, 60% purity) in three portions under nitrogen. The reaction mixture was stirred at 20 °C for 1 h under nitrogen. Then, (2,2-difluorocyclopropyl) 4-methylbenzenesulfonate (3.5 g, 14.10 mmol) in DMF (10 mL) was added dropwise over 15 min, and the mixture was stirred at 80 °C for 5 h under nitrogen. After quenching with H2O (30 mL) at 20 °C, the mixture was extracted with EtOAc (50 mL × 4). The combined organic layers were washed with brine (20 mL × 3), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (50% DCM in PE) to obtain intermediate T-20 (400 mg, 16.8% yield, 86.02% purity) as a yellow oil. MS (ESI) m / z = 146.1 [M+H] + .
[0651] Manufacturing Example 27-8: Tert-Butyl 4-(5-tributylstannyltriazol-1-yl)piperidine-1-carboxylate (T-21)
[0652]
[0653] Intermediate T-21 (3 g, 95.08% yield, 85% purity) was obtained as a yellow oil in the same manner as in Preparation Example 27-1 using commercially available 2,2-dimethoxyacetaldehyde and 4-methylbenzenesulfonhydrazide. This was used in the next reaction without further purification. 1H NMR (400 MHz, DMSO-d6) δ 7.58 (s, 1H), 4.34 (br t,J= 10.8 Hz, 1H), 4.14 - 4.04 (m, 2H), 2.94 (br s, 2H), 1.98 (s, 2H), 1.94 - 1.87 (m, 2H), 1.53 - 1.45 (m, 6H), 1.42 (s, 9H), 1.31 - 1.26 (m, 6H), 1.20 - 1.15 (m, 6H), 0.87 - 0.83 (m, 9H).
[0654] Manufacturing Example 27-9: Tert-Butyl (S)-3-(5-(tributylstannyl)-1H-1,2,3-triazol-1-yl)pyrrolidine-1-carboxylate (T-22)
[0655]
[0656] Intermediate T-22 (890 mg, 12.35% yield, 71% purity) was obtained as a yellow oil in the same manner as in Preparation Example 27-1 using commercially available 2,2-dimethoxyacetaldehyde and tert-butyl (3S)-3-aminopyrrolidine-1-carboxylate. This was used in the next reaction without further purification. 1 H NMR (400 MHz, CDCl3) δ 7.73 (s, 1H), 7.59 (s, 1H), 5.21 (br s, 1H), 3.91 (dd,J= 6.4, 12.0 Hz, 1H), 3.82 - 3.72 (m, 1H), 3.59 (br s, 2H), 2.53 - 2.40 (m, 2H), 1.46 (s, 9H); MS (ESI) m / z = 239.1 [M+H] + .
[0657] Manufacturing Example 28: 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-1)
[0658]
[0659] Step 1: Synthesis of 3-bromo-5-(3-methyltriazol-4-yl)pyridine
[0660] A solution of 3,5-dibromopyridine (10.92 g, 46.10 mmol), tributyl-(3-methyltriazol-4-yl)stannane (22.3 g, 59.92 mmol), and Pd(PPh3)2Cl2 (3.24 g, 4.61 mmol) in toluene (200 mL) was purged with nitrogen three times and stirred at 90 °C under nitrogen for 16 h. Water (150 mL) was poured into the reaction mixture, and the mixture was extracted with EtOAc (200 mL x 3). The combined organic layer was washed with brine (200 mL x 3), dried over Na2SO4, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (80% EA in petroleum ether) to obtain 3-bromo-5-(3-methyltriazol-4-yl)pyridine (4.4 g, 39.93% yield) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.83-8.83 (m, 1H), 8.40 (t, J= 2.0 Hz, 1H), 8.09 (s, 1H), 7.66-7.49 (m, 1H), 4.13 (s, 3H); MS (ESI) m / z = 153.0 [M+H] + .
[0661] Step 2: Synthesis of [5-(3-methyltriazol-4-yl)-3-pyridyl]boronic acid
[0662] A solution of 3-bromo-5-(3-methyltriazol-4-yl)pyridine (6.76 g, 28.28 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxoborolan-2-yl)-1,3,2-dioxoborolane (14.36 g, 56.55 mmol), Pd(dppf)Cl2 (2.31 g, 2.83 mmol), and KOAc (5.55 g, 56.55 mmol) in dioxane (120 mL) was purged with nitrogen three times and stirred at 100 °C for 16 h under nitrogen conditions. The reaction mixture was filtered and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (3% MeOH in DCM) to obtain [5-(3-methyltriazol-4-yl)-3-pyridyl]boronic acid (intermediate P-11, 6.76 g, 78.52% yield, 67% purity) as a dark brown solid. MS (ESI) m / z = 205.1 [M+H] + .
[0663] Step 3: Synthesis of methyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0664] A solution of methyl 6-oxo-1H-pyridazine-3-carboxylate (3.78 g, 24.51 mmol), [5-(3-methyltriazol-4-yl)-3-pyridyl]boronic acid (5 g, 24.51 mmol), Cu(OAc)2 (4.45 g, 24.51 mmol), TEA (4.96 g, 49.02 mmol, 6.82 mL), and pyridine (3.88 g, 49.02 mmol, 3.96 mL) in MeCN (100 mL) was replaced with oxygen three times and stirred at 90 °C under oxygen conditions for 16 h. The reaction mixture was filtered and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (3% MeOH in DCM) to obtain methyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (1.83 g, 5.27 mmol, 21.51% yield, 89.98% purity) as a dark brown solid. MS (ESI) m / z = 312.9 [M+H] + .
[0665] Step 4: Synthesis of 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0666] To a solution of methyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (1.0 g, 3.20 mmol) in THF (4 mL) and H2O (2 mL) was added NaOH (256.16 mg, 6.40 mmol). After three nitrogen exchanges, the mixture was stirred at 25 °C under nitrogen for 16 h. The mixture was adjusted to pH = 2-3 using 1 N HCl aqueous solution, and the solid was filtered to obtain intermediate 4-1 (725 mg, 74.01% yield, 97.5% purity) as a yellow solid. MS (ESI) m / z = 299.0 [M+H] + .
[0667] Manufacturing Example 28-1: 1-[5-(3-ethyltriazol-4-yl)-3-pyridyl]-5-methyl-6-oxo-pyridazine-3-carboxylic acid (4-9)
[0668]
[0669] Intermediate 4-9 (86 mg, crude product) was obtained as a pale yellow solid using the same method as in Preparation Example 28 using 3,5-dibromopyridine and intermediate T-4. MS (ESI) m / z = 327.1 [M+H] + .
[0670] Manufacturing Example 28-2: (2-Fluoro-5-(1-methyl-1H-1,2,3-triazol-5-yl)pyridin-3-yl)boronic acid (P-20)
[0671]
[0672] Intermediate P-20 was obtained as a pale yellow solid using the same method as steps 1 and 2 of Preparation Example 28 using 3-bromo-2-fluoro-5-iodopyridine and intermediate T-3. MS (ESI) m / z = 223.1 [M+H] + .
[0673] Manufacturing Example 28-3: (2-Fluoro-5-(1-trideuteriomethyltriazol-5-yl)pyridin-3-yl]boronic acid (P-21)
[0674]
[0675] Intermediate P-21 was obtained as a pale yellow solid using the same method as steps 1 and 2 of Preparation Example 28 using 3-bromo-2-fluoro-5-iodopyridine and intermediate T-9. MS (ESI) m / z = 226.1 [M+H] + .
[0676] Manufacturing Example 28-4: (2-Fluoro-5-(1-cyclopropyltriazol-5-yl)pyridin-3-yl]boronic acid (P-22)
[0677]
[0678] Intermediate P-22 was obtained as a pale yellow solid using the same method as steps 1 and 2 of Preparation Example 28 using 3-bromo-2-fluoro-5-iodopyridine and intermediate T-14. MS (ESI) m / z = 249.1 [M+H] + .
[0679] Manufacturing Example 29: Methyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (3-1): Alternative method
[0680]
[0681] Step 1: Synthesis of methyl 1-(5-bromo-3-pyridyl)-6-oxo-pyridazine-3-carboxylate
[0682] A solution of methyl 6-oxo-1H-pyridazine-3-carboxylate (5 g, 32.44 mmol), 3-bromo-5-(4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl)pyridine (9.21 g, 32.44 mmol), Cu(OAc)2 (2.95 g, 16.22 mmol), boric acid (4.01 g, 64.88 mmol), and 4A MS (1 g) in MeCN (120 mL) was replaced with oxygen three times and stirred at 90 °C under oxygen conditions for 16 h. Water (30 mL) was poured into the reaction mixture, and the mixture was extracted with EtOAc (30 mL x 3). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (58% DCM in petroleum ether) to obtain methyl 1-(5-bromo-3-pyridyl)-6-oxo-pyridazine-3-carboxylate (2.2 g, 21.54% yield, 98.49% purity) as a white solid. MS (ESI) m / z = 312.0 [M+H] + .
[0683] Step 2: Synthesis of methyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0684] A solution of methyl 1-(5-bromo-3-pyridyl)-6-oxo-pyridazine-3-carboxylate (2.2 g, 7.09 mmol), tributyl-(3-methyltriazol-4-yl)stannane (7.92 g, 21.28 mmol), and Pd(PPh3)2Cl2 (497.95 mg, 709.44 μmol) in toluene (20 mL) was purged with nitrogen three times and stirred at 100 °C under nitrogen for 16 h. The reaction mixture was filtered, and the filtrate was poured with water (20 mL), and extracted with EtOAc (50 mL x 3). The combined organic layer was washed with brine (20 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (2% MeOH in DCM) to obtain intermediate 3-1 (1.0 g, 32.50% yield, 72% purity) as a white solid. MS (ESI) m / z = 327.1 [M+H] + .
[0685] Manufacturing Example 30: 6-Oxo-1-[5-[3-(trideuteriomethyl)triazol-4-yl]-3-pyridyl]pyridazine-3-carboxylic acid (4-2)
[0686]
[0687] Step 1: Synthesis of methyl 6-oxo-1-[5-[3-(trideuteriomethyl)triazol-4-yl]-3-pyridyl]pyridazine-3-carboxylate
[0688] A solution of 1-(5-bromo-3-pyridyl)-6-oxo-pyridazine-3-carboxylate (1 g, 3.22 mmol), tributyl-[3-(trideuteriomethyl)triazol-4-yl]stannane (3.63 g, 9.67 mmol), and Pd(PPh3)2Cl2 (226.34 mg, 322.47 μmol) in toluene (10 mL) was purged with nitrogen three times and stirred at 100 °C under nitrogen for 16 h. Water (20 mL) was poured into the reaction mixture, and the mixture was extracted with EtOAc (30 mL x 3). The combined organic layer was washed with brine (20 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (5% MeOH in DCM) to obtain methyl 6-oxo-1-[5-[3-(trideuteriomethyl)triazol-4-yl]-3-pyridyl]pyridazine-3-carboxylate (420 mg, 30.57% yield, 74% purity) as a yellow solid. MS (ESI) m / z = 316.1 [M + H] + .
[0689] Step 2: Synthesis of 6-oxo-1-[5-[3-(trideuteriomethyl)triazol-4-yl]-3-pyridyl]pyridazine-3-carboxylic acid
[0690] To a solution of methyl 6-oxo-1-[5-[3-(trideuteriomethyl)triazol-4-yl]-3-pyridyl]pyridazine-3-carboxylate (420 mg, 1.33 mmol) in THF (8 mL) and H2O (2 mL) was added NaOH (79.92 mg, 2.00 mmol). After three nitrogen exchanges, the mixture was stirred under nitrogen at 25 °C for 2 h. The mixture was adjusted to pH = 6-7 with 1 N HCl aqueous solution and concentrated under reduced pressure to give intermediate 4-2 (420 mg, 65.93% yield, 63% purity) as a yellow solid. MS (ESI) m / z = 302.1 [M + H] + .
[0691] Manufacturing Example 31: 1-[5-(3-Ethyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-3)
[0692]
[0693] Step 1: Synthesis of 1-[5-(3-ethyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0694] A solution of 1-(5-bromo-3-pyridyl)-6-oxo-pyridazine-3-carboxylate (260 mg, 838.43 μmol), tributyl-(3-ethyltriazol-4-yl)stannane (485.66 mg, 1.26 mmol), and Pd(PPh3)2Cl2 (58.85 mg, 83.84 μmol) in toluene (5 mL) was purged with nitrogen three times and stirred at 100 °C under nitrogen for 16 h. Water (30 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (10 mL x 3). The combined organic layer was washed with brine (10 mL x 5), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (3% MeOH in DCM) to give 1-[5-(3-ethyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (110 mg, 13.67% yield, 34% purity) as a yellow oil. MS (ESI) m / z = 327.1 [M + H] + .
[0695] Step 2: Synthesis of 1-[5-(3-ethyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0696] To a solution of 1-[5-(3-ethyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (110 mg, 337.10 umol) in THF (3 mL) was added LiOH .H2O (28.29 mg, 674.21 μmol) and H2O (1 mL) were added and stirred at 20 °C for 1 h. The reaction mixture was concentrated under reduced pressure to obtain a crude product, which was purified by prep-HPLC (column: Welch Xtimate C18 150*30 mm*5 μm; mobile phase: [water (HCl)-MeCN]; B%: 0%-26%, 25 min). Most of the MeCN was concentrated under reduced pressure, and the residual solvent was dried using a lyophilizer to obtain intermediate 4-3 (47 mg, 44.65% yield, 100% purity) as a white solid. MS (ESI) m / z = 313.0 [M + H] + .
[0697] Manufacturing Example 32: 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridine-3-carboxylic acid (4-4)
[0698]
[0699] Step 1: Synthesis of ethyl 1-(5-bromo-3-pyridyl)-6-oxo-pyridine-3-carboxylate
[0700] A solution of ethyl 6-oxo-1H-pyridine-3-carboxylate (535.17 mg, 3.20 mmol), 3-bromo-5-(4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl)pyridine (1 g, 3.52 mmol), Cu(OAc)2 (290.75 mg, 1.60 mmol), 4A MS (500 mg, 3.20 mmol), and boric acid (395.92 mg, 6.40 mmol) in MeCN (15 mL) was replaced with oxygen three times and stirred at 90 °C under oxygen conditions for 16 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (30% EtOAc in petroleum ether) to obtain ethyl 1-(5-bromo-3-pyridyl)-6-oxo-pyridine-3-carboxylate (87 mg, 7.65% yield, 90.95% purity) as a white solid. MS (ESI) m / z = 322.9 [M + H] + .
[0701] Step 2: Synthesis of ethyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridine-3-carboxylate
[0702] A solution of ethyl 1-(5-bromo-3-pyridyl)-6-oxo-pyridine-3-carboxylate (87 mg, 269.23 μmol), tributyl-(3-methyltriazol-4-yl)stannane (250.48 mg, 673.08 μmol), and Pd(dppf)Cl2 (19.70 mg, 26.92 μmol) in toluene (2 mL) was purged with nitrogen three times and stirred at 100 °C for 16 h under nitrogen conditions. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (2% MeOH in DCM) to obtain ethyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridine-3-carboxylate (30 mg, 32.07% yield, 93.62% purity) as a white solid. MS (ESI) m / z = 326.1 [M + H] + .
[0703] Step 3: Synthesis of 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridine-3-carboxylic acid
[0704] To a solution of ethyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridine-3-carboxylate (30 mg, 92.22 μmol) in THF (1 mL) and H2O (0.5 mL) was added NaOH (7.38 mg, 184.43 μmol). After three nitrogen exchanges, the mixture was stirred under nitrogen at 25 °C for 1 h. The pH of the mixture was adjusted to 5-6 using 1 N HCl aqueous solution, and the organic layer was concentrated under reduced pressure to obtain intermediate 4-4 (25 mg, crude) as a yellow oil. MS (ESI) m / z = 298.0 [M + H] + .
[0705] Manufacturing Example 33: 3-Methyl-5'-(1-methyl-1H-1,2,3-triazol-5-yl)-2-oxo-2H-[1,3'-bipyridine]-5-carboxylic acid (4-5)
[0706]
[0707] Step 1: Synthesis of ethyl 5'-bromo-3-methyl-2-oxo-2H-[1,3'-bipyridine]-5-carboxylate
[0708] To a solution of ethyl 5-methyl-6-oxo-1,6-dihydronicotinate (500 mg, 2.76 mmol) in MeCN (21.2 mL) were added 5-bromo-3-pyridineboronic acid pinacol ester (1.18 mg, 4.14 mmol), Cu(OAc)2 (501 mg, 2.76 mmol), and pyridine (0.89 mL, 11 mmol), and the mixture was stirred at 90 °C for 16 h. Water was added to the reaction mixture, and it was extracted with EtOAc. The combined organic layer was washed with copper(II) sulfate pentahydrate, dried over Na2SO4, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (50% EtOAc in hexane) to obtain ethyl 5'-bromo-3-methyl-2-oxo-2H-[1,3'-bipyridine]-5-carboxylate (460 mg, 49% yield) as a white solid. 1 H NMR (400 MHz, CDCl3) δ ppm 8.77 (d, J = 2.0 Hz, 1H), 8.60 (d, J = 2.4 Hz, 1H), 8.06 (d, J = 2.4 Hz, 1H), 8.01 (t, J = 2.0 Hz, 1H), 7.84 (d, J = 0.8 Hz, 1H), 4.34 (q, J = 7.0 Hz, 2H), 2.22 (s, 3H), 1.37 (t, J = 7.2 Hz, 3H); MS (ESI) m / z = 336.95, 338.95 [M+H] + .
[0709] Step 2: Synthesis of ethyl 3-methyl-5'-(1-methyl-1H-1,2,3-triazol-5-yl)-2-oxo-2H-[1,3'-bipyridine]-5-carboxylate
[0710] A solution of ethyl 5'-bromo-3-methyl-2-oxo-2H-[1,3'-bipyridine]-5-carboxylate (300 mg, 0.890 mmol), tributyl (1-methyl-1H-1,2,3-triazol-5-yl)stannane (993 mg, 2.67 mmol), TEA (124 μL, 0.890 mmol), and Pd(PPh3)2Cl2 (62.6 mg, 0.089 mmol) in toluene (8.9 mL) was purged with nitrogen three times and stirred at 100 °C under nitrogen for 17 h. Water (30 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL x 5), dried over Na2SO4 and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (17% EtOAc in hexane) to give ethyl 3-methyl-5'-(1-methyl-1H-1,2,3-triazol-5-yl)-2-oxo-2H-[1,3'-bipyridine]-5-carboxylate (81 mg, 27% yield) as a white solid. 1 H NMR (400 MHz, CDCl3) δ 8.79 (d,J= 2.0 Hz, 1H), 8.74 (d,J= 2.4 Hz, 1H), 8.16 (d,J= 2.0 Hz, 1H), 7.97 (t,J= 2.2 Hz, 1H), 7.87-7.86 (m, 2H), 4.36 (q,J= 7.2 Hz, 2H), 4.18 (s, 3H), 2.24 (s, 3H), 1.37 (t,J= 7.2 Hz, 3H); MS (ESI) m / z = 340.07 [M+H] + .
[0711] Step 3: Synthesis of 3-methyl-5'-(1-methyl-1H-1,2,3-triazol-5-yl)-2-oxo-2H-[1,3'-bipyridine]-5-carboxylic acid
[0712] To a solution of 5'-bromo-3-methyl-2-oxo-2H-[1,3'-bipyridine]-5-carboxylate (81 mg, 0.239 mmol) in THF (2.39 mL) were added LiOH·H2O (30 mg, 0.716 mmol) and H2O (1.19 mL), and the mixture was stirred at 25 °C for 1 h. The reaction mixture was poured into water, and the mixture was adjusted to pH = 1 with 1 N HCl aqueous solution, and the solid was filtered to obtain intermediate 4-5 (73 mg, 98% yield) as a white solid. MS (ESI) m / z = 312.04 [M+H] + .
[0713] Manufacturing Example 34: 1-[5-(2-methylpyrazol-3-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-6)
[0714]
[0715] A solution of methyl 1-(5-bromo-3-pyridyl)-6-oxo-pyridazine-3-carboxylate (500 mg, 1.61 mmol), (2-methylpyrazol-3-yl)boronic acid (406.06 mg, 3.22 mmol), K2CO3 (557.09 mg, 4.03 mmol), and Pd(PPh3)4 (186.32 mg, 161.24 μmol) in dioxane (5 mL), H2O (0.5 mL) was purged with nitrogen three times and stirred at 100 °C under nitrogen for 16 h. The reaction mixture was concentrated under reduced pressure to remove the solvent, and then diluted with water (10 mL). The pH was adjusted to 3-4 by adding 1 N HCl aqueous solution, and then extracted with EtOAc (20 mL × 3). The organic layer was washed with brine (30 mL), dried over Na2SO4, and concentrated under reduced pressure to obtain intermediate 4-6 (835 mg, crude) as a brown solid. MS (ESI) m / z = 298.1 [M+H] + .
[0716] Manufacturing Example 35: 5-Methyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-7)
[0717]
[0718] Step 1: Synthesis of methyl 5-methyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0719] A solution of methyl 5-methyl-6-oxo-1H-pyridazine-3-carboxylate (200 mg, 1.19 mmol), [5-(3-methyltriazol-4-yl)-3-pyridyl]boronic acid (242.63 mg, 1.19 mmol), Cu(OAc)2 (216.03 mg, 1.19 mmol), TEA (240.71 mg, 2.38 mmol, 331.11 μL), and pyridine (188.17 mg, 2.38 mmol, 192.01 μL) in MeCN (5 mL) was purged with nitrogen three times and stirred at 90 °C under nitrogen for 16 h. Water (30 mL) was added to the reaction mixture, and it was extracted with EtOAc (30 mL × 3). The organic layer was washed with brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (1% MeOH in DCM) to obtain methyl 5-methyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (305 mg, 69.15% yield, 88% purity) as a yellow solid. MS (ESI) m / z = 327.1 [M+H] + .
[0720] Step 2: Synthesis of 5-methyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0721] To a solution of methyl 5-methyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (305 mg, 934.70 μmol) in THF (4 mL) was added LiOH. H2O (117.67 mg, 2.80 mmol) and H2O (2 mL) were added and stirred at 25 °C for 16 h. The reaction mixture was concentrated under reduced pressure to remove the solvent and diluted with water (10 mL). The pH was adjusted to 3-4 by adding 1 N HCl aqueous solution and extracted with EtOAc (20 mL × 3). The organic layer was washed with brine (30 mL), dried over Na2SO4, and concentrated under reduced pressure to give intermediate 4-7 (63 mg, 20.29% yield, 94% purity) as a white solid. MS (ESI) m / z = 313.1 [M+H] + .
[0722] Manufacturing Example 35-1: 5-Methyl-1-[5-(3-methyltriazol-4-yl)-2-fluoro-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-82)
[0723]
[0724] Intermediate 4-82 was obtained as a yellow solid in the same manner as in Preparation Example 35 using intermediate P-20 and methyl 5-bromo-6-oxo-1,6-dihydropyridazine-3-carboxylate (C-6). MS (ESI) m / z = 395.1 [M+H] + .
[0725] Manufacturing Example 36: 5-Deuterio-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (4-33)
[0726]
[0727] Step 1: Synthesis of methyl 1-(5-bromo-3-pyridyl)-5-deuterio-6-oxo-pyridazine-3-carboxylate
[0728] A solution of methyl 5-deuterio-6-oxo-1H-pyridazine-3-carboxylate (95 mg, 612.39 μmol), 3-bromo-5-(4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl)pyridine (P-1, 521.68 mg, 1.84 mmol), Cu(OAc)2 (111.23 mg, 612.39 μmol), TEA (185.90 mg, 1.84 mmol, 255.71 μL), and pyridine (145.32 mg, 1.84 mmol, 148.29 μL) in MeCN (4 mL) was replaced with oxygen three times and stirred at 90 °C under oxygen conditions for 16 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (30% EtOAc in petroleum ether) to obtain methyl 1-(5-bromo-3-pyridyl)-5-deuterio-6-oxo-pyridazine-3-carboxylate (105 mg, 43.54% yield, 79% purity) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 8.84 (d, J= 2.0 Hz, 2H), 8.39 (t, J= 2.0 Hz, 1H), 7.95 - 7.91 (s, 1H), 3.88 (s, 3H); MS (ESI) m / z = 312.8 [M+H] + .
[0729] Step 2: Synthesis of methyl 5-deuterio-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0730] A solution of methyl 1-(5-bromo-3-pyridyl)-5-deuterio-6-oxo-pyridazine-3-carboxylate (105 mg, 337.50 μmol), tributyl-(3-methyltriazol-4-yl)stannane (220.00 mg, 591.18 μmol), and Pd(PPh3)2Cl2 (23.69 mg, 33.75 μmol) in dioxane (3 mL) was purged with nitrogen three times and stirred at 105 °C for 5 h under nitrogen conditions. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (2% MeOH in PE) to obtain methyl 5-deuterio-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (100 mg, 53.62% yield, 56.7% purity) as a yellow solid. MS (ESI) m / z = 314.3 [M+H] + .
[0731] Step 3: Synthesis of 5-deuterio-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0732] A solution of methyl 5-deuterio-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (50 mg, 159.60 μmol, 1 eq) and NaOH (12.77 mg, 319.19 μmol, 2 eq) in THF (1 mL) and H2O (0.5 mL) was stirred at 25 °C for 1 h under nitrogen after purging the mixture three times. The mixture was adjusted to pH = 5-6 with 1 N HCl aqueous solution and concentrated under reduced pressure to give intermediate 4-33 (40 mg, 57.45% yield, 68.6% purity) as a yellow solid, which was used in the next reaction without further purification. MS (ESI) m / z = 299.9 [M+H] + .
[0733] Manufacturing Example 36-1: 1-[5-(3-Cyclopropyltriazol-4-yl)-3-pyridyl]-5-deuterio-6-oxo-pyridazine-3-carboxylic acid (4-36)
[0734]
[0735] Intermediate 4-36 (20 mg, 79.12% yield, 98.6% purity) was obtained as a yellow solid using the same method as steps 2 and 3 of Preparation Example 36 using intermediate 3-20 and T-14. MS (ESI) m / z = 326.1 [M+H] + .
[0736] Manufacturing Example 36-2: 1-[3-(3-isopropyltriazol-4-yl)phenyl]-5-methyl-6-oxo-pyridazine-3-carboxylic acid (4-37)
[0737]
[0738] Step 1: Synthesis of methyl 1-(5-bromo-3-pyridyl)-5-methyl-6-oxo-pyridazine-3-carboxylate
[0739] A solution of methyl 5-methyl-6-oxo-1H-pyridazine-3-carboxylate (600 mg, 3.57 mmol), 3-bromo-5-(4,4,5,5-tetramethyl1,3,2-dioxaborolan-2-yl)pyridine (1.01 g, 3.57 mmol), Cu(OAc)2 (1.30 g, 7.14 mmol), TEA (722.14 mg, 7.14 mmol, 993.31 μL) and pyridine (564.50 mg, 7.14 mmol, 576.02 μL) in MeCN (15 mL) was replaced with oxygen three times and stirred at 90 °C under oxygen conditions for 16 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (80% EtOAc in petroleum ether) to obtain methyl 1-(5-bromo-3-pyridyl)-5-methyl-6-oxo-pyridazine-3-carboxylate (intermediate 3-23, 200 mg, 13.83% yield, 80% purity) as a yellow solid. MS (ESI) m / z = 325.9 [M+H] + .
[0740] Step 2: Synthesis of 1-[3-(3-isopropyltriazol-4-yl)phenyl]-5-methyl-6-oxo-pyridazine-3-carboxylic acid
[0741] A solution of methyl 1-(5-bromo-3-pyridyl)-5-methyl-6-oxo-pyridazine-3-carboxylate (200 mg, 617.04 μmol), tributyl-(3-isopropyltriazol-4-yl)stannane (600 mg, 1.50 mmol) and Pd(PPh3)2Cl2 (86.62 mg, 123.41 μmol) in dioxane (5 mL) was purged with nitrogen three times and stirred under nitrogen at 105 °C for 16 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by prep-HPLC (Column: Welch Xtimate C18 40*200 mm 7 μm; Mobile phase: [water (hydrochloride)-ACN]; 0%-38% B, 20.5 min). After acetonitrile was concentrated under reduced pressure, the residual solvent was lyophilized to obtain intermediate 4-37 (30 mg, 13.63% yield, 95.15% purity) as a yellow solid. MS (ESI) m / z = 341.0 [M+H] + .
[0742] Manufacturing Example 36-3: 1-[5-(3-Cyclopropyltriazol-4-yl)-3-pyridyl]-5-methyl-6-oxo-pyridazine-3-carboxylic acid (4-39)
[0743]
[0744] Intermediate 4-39 (40 mg, 25.04% yield, 98% purity) was obtained as a dark brown solid using the same method as step 2 of Preparation Example 36-2 using intermediate 3-23 and T-14. MS (ESI) m / z = 339.1 [M+H] + .
[0745] Manufacturing Example 36-4: 1-[5-(3-Cyclopropyltriazol-4-yl)-3-pyridyl]-5-ethyl-6-oxo-pyridazine-3-carboxylic acid (4-41)
[0746]
[0747] Intermediate 4-41 (90 mg, 38.44% yield, 89% purity) was obtained as a yellow oil using the same method as in Manufacturing Example 36-2 using intermediates C-9 and P-1. MS (ESI) m / z = 353.0 [M+H] + .
[0748] Manufacturing Example 36-5: 1-[5-(3-isopropyltriazol-4-yl)-3-pyridyl]-5-ethyl-6-oxo-pyridazine-3-carboxylic acid (4-40)
[0749]
[0750] Intermediate 4-40 (90 mg, 74.48% yield, 79.6% purity) was obtained as a yellow oil using intermediate 3-22 (obtained from step 1 of Preparation Example 36-5) and intermediate T-15 in the same manner as in Preparation Example 36-1. MS (ESI) m / z = 355.1 [M+H] + .
[0751] Manufacturing Example 36-6: 5-Ethyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-31)
[0752]
[0753] Step 1: Synthesis of methyl 5-ethyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0754] A solution of 5-bromo-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (46 mg, 117.59 μmol), Cs2CO3 (76.63 mg, 235.19 μmol), Pd(dppf)Cl2 (3.44 mg, 4.70 μmol), and triethyl borate (1 M in THF, 470.37 μL) in THF (3 mL) was purged with nitrogen three times and stirred at 70 °C for 12 h under nitrogen conditions. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (3% DCM in MeOH) to obtain methyl 5-ethyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (26 mg, 32.48% yield, 50% purity) as a white solid. MS (ESI) m / z = 340.6 [M+H] + .
[0755] Step 2: Synthesis of 5-ethyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0756] Intermediate 4-31 (20 mg, 48.14% yield, 60% purity) was obtained as a yellow solid using the same method as in step 3 of Preparation Example 36 using intermediate methyl 5-ethyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate. MS (ESI) m / z = 326.9 [M+H] + .
[0757] Manufacturing Example 36-7: 1-[5-(3-Methyltriazol-4-yl)-3-pyridyl]-6-oxo-5-phenyl-pyridazine-3-carboxylic acid (4-26)
[0758]
[0759] Step 1: Synthesis of methyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-5-phenyl-pyridazine-3-carboxylate
[0760] A solution of 5-bromo-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (intermediate 3-8, 30 mg, 76.69 μmol), phenylboronic acid (28.05 mg, 230.07 μmol), Pd(dppf)Cl2 (5.61 mg, 7.67 μmol), Na2CO3 (16.26 mg, 153.38 μmol), and H2O (0.4 mL) in dioxane (4 mL) was degassed and purged with nitrogen three times. The mixture was then stirred at 80 °C for 1 h under a nitrogen atmosphere. The mixture was purified by silica column chromatography (7% MeOH in DCM) to give methyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-5-phenyl-pyridazine-3-carboxylate (intermediate 3-28, 58 mg, 97.36% yield, 100% purity) as a yellow oil. MS (ESI) m / z = 389.1[M+H] + .
[0761] Step 2: Synthesis of 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-5-phenyl-pyridazine-3-carboxylic acid
[0762] Intermediate 4-26 (55 mg, 98.38% yield, 62% purity) was obtained as a yellow solid using the same method as step 2 of Preparation Example 36-1 using Intermediate 3-28. MS (ESI) m / z = 375.1 [M+H] + .
[0763] Manufacturing Example 36-8: 5-(Cyclohexen-1-yl)-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-28)
[0764]
[0765] Intermediate 4-28 (56 mg, 75.46% yield, 76.66% purity) was obtained as a yellow solid in the same manner as in Preparation Example 36-7 using intermediate 3-8 and commercially available cyclohexene-1-yl boronic acid. MS (ESI) m / z = 379.2 [M+H] + .
[0766] Manufacturing Example 36-9: 5-Cyano-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-24)
[0767]
[0768] Step 1: Synthesis of methyl 5-cyano-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0769] To a solution of methyl 5-bromo-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (200 mg, 511 μmol), DPPF (56.69 mg, 102 μmol), and Pd2(dba)3 (46.82 mg, 51.1 μmol) in DMA (3 mL) were added Zn(CN)2 (70 mg, 596 μmol) and Zn (40 mg, 611 μmol). The mixture was then purged with nitrogen three times and stirred at 120 °C for 2 h under nitrogen. The reaction mixture was filtered, and the filtrate was poured into water (20 mL) and extracted with EtOAc (15 mL x 4). The combined organic layers were washed with brine (10 mL x 3), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product. The aqueous layer was quenched by adding 1N HCl aqueous solution (5 mL) and stirred overnight. The residue was purified by silica gel column chromatography (0–100% ethyl acetate / petroleum ether) to obtain methyl 5-cyano-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (73 mg, 25.23% yield, 59.6% purity) as a dark brown oil. MS (ESI) m / z = 338.1 [M+H] + .
[0770] Step 2: Synthesis of 5-cyano-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0771] LiBr (29.89 mg, 344 μmol) was added to a solution of H2O (1 mL) in MeCN (1 mL) at -10 °C over 1 min. The mixture was then stirred at -10 °C for 1 h to obtain solution A. Methyl 5-cyano-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (43 mg, 127 μmol) and DIEA (39.97 μL, 229 μmol) were slowly added dropwise to solution A at -10 °C and stirred at 20 °C for 1 h. The reaction mixture was poured into water (5 mL), 1 N HCl aqueous solution was added to adjust the pH to 4, and then extracted with EtOAc (10 mL x 3). The combined organic layer was washed with brine (5 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to obtain intermediate 4-24 (25 mg, 60.06% yield, 99% purity) as a brown oil. MS (ESI) m / z = 323.9 [M+H] + .
[0772] Manufacturing Example 36-10: 5-Acetyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine 3-carboxylic acid (4-34)
[0773]
[0774] Step 1: Synthesis of methyl 5-acetyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0775] To a solution of methyl 5-bromo-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (410 mg, 1.05 mmol) in dioxane (6 mL) were added tributyl(1-ethoxyvinyl)stannane (454.23 mg, 1.26 mmol, 424.91 μL), TEA (212.12 mg, 2.10 mmol, 291.77 μL), and Pd(PPh3)2Cl2 (73.57 mg, 104.81 μmol). The mixture was then stirred at 120 °C for 18 h under N2 atmosphere. HCl solution (50 ml, 1 M) was added to the mixture while stirring at 20 °C, and the mixture was stirred at 20 °C for 2.5 h. Water (10 mL) was added to the reaction mixture and extracted with EtOAc (20 mL X 3). The combined organic layers were washed with brine (10 mL X 3), dehydrated with anhydrous Na2SO4, and concentrated under reduced pressure to obtain a residue. The aqueous layer was slowly added with saturated KF aqueous solution (15 mL) under stirring, and the mixture was stirred at 25 °C for 1 h. This was purified by silica gel column chromatography (2% MeOH in DCM) to obtain methyl 5-acetyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (200 mg, 21.54% yield, 40% purity) as a yellow solid. MS (ESI) m / z = 355.1 [M+H] + .
[0776] Step 2: Synthesis of 5-acetyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0777] Intermediate 4-34 (80 mg, 41.57% yield, 99.8% purity) was obtained as a yellow solid using the same method as in step 3 of Preparation Example 36 using methyl 5-acetyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate. MS (ESI) m / z = 340.9 [M+H] + .
[0778] Manufacturing Example 36-11: 5-(Hydroxymethyl)-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-25)
[0779]
[0780] Step 1: Synthesis of methyl 5-(hydroxymethyl)-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0781] To a solution of methyl 5-bromo-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (50 mg, 127.82 μmol) in dioxane (3 mL) were added Xphos-Pd-G2 (10.06 mg, 12.78 μmol) and tributylstannylmethanol (123.12 mg, 383.46 μmol). The mixture was then stirred at 80 °C for 2 h. The mixture was purified by silica gel column chromatography (5% MeOH in DCM) to give methyl 5-(hydroxymethyl)-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (21 mg, 44.03% yield, 91.74% purity) as a yellow oil. MS (ESI) m / z = 343.0 [M+H] + .
[0782] Step 2: Synthesis of 5-(hydroxymethyl)-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0783] Intermediate 4-25 (20 mg, 99.31% yield, 96% purity) was obtained as a yellow solid in the same manner as in step 3 of Preparation Example 36 using methyl 5-(hydroxymethyl)-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate. MS (ESI) m / z = 329.0 [M+H] + .
[0784] Manufacturing Example 36-12: 5-Cyclohexyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-29)
[0785]
[0786] Step 1: Synthesis of methyl 5-cyclohexyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0787] To a solution of intermediate 3-24 (26 mg, 66.26 μmol) in dioxane (4 mL) and ethanol (4 mL) was added Pd(OH)2 (13.96 mg, 19.88 μmol, 20% purity) under a nitrogen atmosphere. The mixture was purged with hydrogen several times under reduced pressure. The mixture was then stirred at 45 °C under hydrogen conditions (20 Psi) for 16 h. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography (3% DCM in MeOH) to give methyl 5-cyclohexyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (30 mg, 98.56% yield, 85.860% purity) as a white solid. MS (ESI) m / z = 395.0 [M+H] + .
[0788] Step 2: Synthesis of 5-cyclohexyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0789] Intermediate 4-29 (30 mg, 93.19% yield, 89.880% purity) was obtained as a yellow solid using the same method as in step 3 of Preparation Example 36 using methyl 5-cyclohexyl-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate. MS (ESI) m / z = 380.7 [M+H] + .
[0790] Manufacturing Example 36-13: 1-[5-[3-(1-tert-butoxycarbonylazetidin-3-yl)triazol-4-yl]-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-66)
[0791]
[0792] Intermediate 4-66 (380 mg, 69.96% purity, 71.36% yield) was obtained as a yellow oil in the same manner as in Preparation Example 36-1 using methyl 1-(5-bromopyridin-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (2-1) and intermediate T-17. MS (ESI) m / z = 340.0 [M+H] + .
[0793] Manufacturing Example 36-14: 1-[5-[3-(oxetan-3-yl)triazol-4-yl]-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-35)
[0794]
[0795] Intermediate 4-35 (27 mg, 32.53 μmol, 38.42 yield, 41% purity) was obtained as a pale yellow solid using the same method as in Manufacturing Example 36-1 using Intermediate 2-1 and Intermediate T-18. MS (ESI) m / z = 341.0 [M+H] + .
[0796] Manufacturing Example 36-15: 1-[5-(3-Cyclobutyl-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-43)
[0797]
[0798] Intermediate 4-43 (50 mg, 81.13% yield, 93.48% purity) was obtained as a yellow solid using the same method as in Manufacturing Example 36-1 using Intermediate 2-1 and Intermediate T-19. MS (ESI) m / z = 339.0 [M+H] + .
[0799] Manufacturing Example 37: 1-[6-(methylamino)-5-(1-methyl-1H-1,2,3-triazol-5-yl)-3-pyridyl]-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (4-44)
[0800]
[0801] Step 1: Synthesis of methyl 1-(5-bromo-6-fluoro-3-pyridyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate
[0802] Intermediate 3-30 (213 mg, 100%) was obtained as a white solid in the same manner as in step 1 of Preparation Example 33 using methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (C-1) and P-7. 1 H NMR (400 MHz, CDCl3) δ 8.54 (dd,J= 2.4, 1.2 Hz, 1H), 8.37 (dd,J= 7.6, 2.4 Hz, 1H), 7.95 (d,J= 9.6 Hz, 1H), 7.12 (d,J= 10.0 Hz, 1H), 3.40 (s, 3H); MS (ESI) m / z = 327.9 [M+H] + , 329.9 [M+3H] + .
[0803] Step 2: Synthesis of methyl 1-[6-fluoro-5-(1-methyl-1H-1,2,3-triazol-5-yl)-3-pyridyl]-6-oxo-1,6-dihydropyridazine-3-carboxylate
[0804] Intermediate 3-21 (145 mg, 67%) was obtained as a white solid using the same method as step 2 of Preparation Example 33 using Intermediate 3-30 and T-3. 1H NMR (400 MHz, CDCl3) δ 8.73 (q,J= 7.3 Hz, 1H), 8.24 (dd,J= 8.0, 2.8 Hz, 1H), 7.99 (d,J= 9.6 Hz, 1H), 7.89 (s, 1H), 7.15 (d,J= 9.6 Hz, 1H), 4.13 (d,J= 1.2 Hz, 3H), 4.00 (s, 3H); MS (ESI) m / z = 331.0 [M+H] + .
[0805] Step 3: Synthesis of methyl 1-[6-(methylamino)-5-(1-methyl-1H-1,2,3-triazol-5-yl)-3-pyridyl]-6-oxo-1,6-dihydropyridazine-3-carboxylate
[0806] A solution of intermediate 3-21 (70 mg, 0.212 mmol) in methylamine (1 M in THF, 1.1 mL) was stirred at 60 °C for 16 h under a N2 atmosphere. Methylamine (1 M in THF, 1.1 mL) was further added to the reaction mixture, which was stirred at 60 °C for 2 h. The reaction mixture was then concentrated under reduced pressure and crystallized from DCM and hexane to yield methyl 1-[6-(methylamino)-5-(1-methyl-1H-1,2,3-triazol-5-yl)-3-pyridyl]-6-oxo-1,6-dihydropyridazine-3-carboxylate (63 mg, 87%) as a yellow solid. The obtained compound was used in the next reaction without further purification. MS (ESI) m / z = 342.0 [M+H] + .
[0807] Step 4: Synthesis of 1-[6-(methylamino)-5-(1-methyl-1H-1,2,3-triazol-5-yl)-3-pyridyl]-6-oxo-1,6-dihydropyridazine-3-carboxylic acid
[0808] Intermediate 4-44 (25 mg, 41%) was obtained as a yellow solid in the same manner as in step 3 of Preparation Example 33 using intermediate methyl 1-[6-(methylamino)-5-(1-methyl-1H-1,2,3-triazol-5-yl)-3-pyridyl]-6-oxo-1,6-dihydropyridazine-3-carboxylate. MS (ESI) m / z = 328.0 [M+H] + .
[0809] Manufacturing Example 38: 1-[5-(1-Methyl-1H-1,2,3-triazol-5-yl)-6-morpholine-3-pyridyl]-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (4-45)
[0810]
[0811] Step 1: Synthesis of methyl 1-[5-(1-methyl-1H-1,2,3-triazol-5-yl)-6-morpholino-3-pyridyl]-6-oxo-1,6-dihydropyridazine-3-carboxylate
[0812] Intermediate 3-21 (65 mg, 0.197 mmol), morpholine (25.5 μL, 0.295 mmol), and Na2CO3 (42 mg, 0.394 mmol) in MeCN (0.5 mL) were placed in a microwave vial and stirred at 90°C for 17.5 h. The mixture was then cooled to room temperature and diluted with EtOAc. The solid was filtered through a pad of Celite and washed with EtOAc. The filtrate was concentrated under reduced pressure, and it was purified by silica gel column chromatography to give methyl 1-[5-(1-methyl-1H-1,2,3-triazol-5-yl)-6-morpholino-3-pyridyl]-6-oxo-1,6-dihydropyridazine-3-carboxylate (54 mg, 69%) as a yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.67 (d,J= 2.8 Hz, 1H), 7.95 (d,J= 9.6 Hz, 1H), 7.81 (s, 1H), 7.79 (d,J= 2.8 Hz, 1H), 7.11 (d,J= 10.0 Hz, 1H), 4.04 (s, 3H), 3.99 (s, 3H), 3.66 (t,J= 4.6 Hz, 4H), 3.14 (t,J= 4.8 Hz, 4H); MS (ESI) m / z = 398.1 [M+H] + .
[0813] Step 2: Synthesis of 1-[5-(1-methyl-1H-1,2,3-triazol-5-yl)-6-morpholino-3-pyridyl]-6-oxo-1,6-dihydropyridazine-3-carboxylic acid
[0814] Intermediate 4-45 (33 mg, 63%) was obtained as a yellow solid in the same manner as in step 3 of Preparation Example 33 using intermediate methyl 1-[5-(1-methyl-1H-1,2,3-triazol-5-yl)-6-morpholino-3-pyridyl]-6-oxo-1,6-dihydro-3-pyridazinecarboxylate. MS (ESI) m / z = 384.1 [M+H] + .
[0815] Manufacturing Example 39: Methyl 5-fluoro-6-oxo-1,6-dihydropyridine-3-carboxylate (C-5)
[0816]
[0817] Step 1: Synthesis of 3-fluoro-5-(methoxycarbonyl)pyridine 1-oxide
[0818] To a solution of methyl 5-fluoronicotinate (1 g, 6.45 mmol) in DCM (14.3 mL) was added urea hydrogen peroxide (1.27 g, 13.5 mmol) and trifluoroacetic anhydride (4.66 mL, 33.5 mmol) under nitrogen at 0 °C. The reaction mixture was then stirred at 25 °C for 17 h. After the reaction mixture was cooled to 0 °C, aqueous NaHCO3 solution was added, and extracted with DCM. The combined organic layers were washed with aqueous sodium bisulfate solution, dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (5% MeOH in DCM) to give 3-fluoro-5-(methoxycarbonyl)pyridine 1-oxide (245 mg, 22% yield) as a pale yellow solid. 1 H NMR (400 MHz, CDCl3) δ 9.07 (s, 1H), 8.67 (s, 1H), 8.01 (ddd,J= 8.6, 2.8,1.6 Hz, 1H), 3.99 (s, 3H); MS (ESI) m / z = 171.95 [M+H] + .
[0819] Step 2: Synthesis of methyl 5-fluoro-6-oxo-1,6-dihydropyridine-3-carboxylate
[0820] A solution of 3-fluoro-5-(methoxycarbonyl)pyridine 1-oxide (394 mg, 2.30 mmol) in acetic anhydride (11.3 mL) was stirred at 140 °C under nitrogen for 17 h. The reaction mixture was quenched by the addition of aqueous NaHCO3 solution and extracted with EtOAc. The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (5% MeOH in DCM) to give intermediate C-5 (129 mg, 33% yield) as a white solid. 1H NMR (400 MHz, CDCl3) δ 12.81 (brs, 1H), 8.07-8.08 (m, 1H), 7.77 (dd,J= 10.4, 2.2 Hz, 1H), 3.89 (s, 3H).
[0821] Manufacturing Example 40: Methyl 5-deuterio-6-oxo-1H-pyridazine-3-carboxylate (C-8)
[0822]
[0823] A solution of methyl 6-oxo-1H-pyridazine-3-carboxylate (200 mg, 1.30 mmol) and Pt / C (163.59 mg, 38.93 μmol, 5% purity) in D2O (4 mL), isopropanol (0.2 mL), and cyclohexane (1.8 mL) was degassed and purged with argon three times. The mixture was then stirred at 80 °C under argon in a 50 mL autoclave for 24 h. The reaction mixture was diluted with DCM (20 mL), filtered, and the filter cake was washed with DCM (20 mL x 2) and concentrated under reduced pressure to give intermediate C-8 (100 mg, 49.68% yield) as a brown solid. 1 H NMR (400 MHz, DMSO-d6) δ 7.89 (s, 1H), 3.91 (s, 3H); MS (ESI) m / z = 155.9 [M+H] + .
[0824] Manufacturing Example 41: Methyl 5-ethyl-6-oxo-1H-pyridazine-3-carboxylate (C-9)
[0825]
[0826] A solution of methyl 5-bromo-6-oxo-1H-pyridazine-3-carboxylate (46 mg, 117.59 μmol), Cs2CO3 (6.99 g, 21.46 mmol), Pd(dppf)Cl2 (3.14 g, 4.29 mmol), and triethyl borate (1 M, 107.29 mL) in THF (60 mL) was purged with nitrogen three times and stirred at 65 °C for 16 h under nitrogen conditions. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (1% DCM in MeOH) to give intermediate C-9 (930 mg, 42.82% yield, 90% purity) as a dark brown solid. MS (ESI) m / z = 183.1 [M+H] + .
[0827] Manufacturing Example 42: 3-Fluoro-5'-(1-methyl-1H-1,2,3-triazol-5-yl)-2-oxo-2H-[1,3'-bipyridine]-5-carboxylic acid (4-8)
[0828]
[0829] Intermediate 4-8 (12.8 mg, 58% yield) was synthesized using the same method as steps 1 and 3 of Preparation Example 33 using Intermediate C-5 of Preparation Example 39. MS (ESI) m / z = 316.06 [M+H] + .
[0830] Manufacturing Example 42-1: 5-Bromo-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-10)
[0831]
[0832] Step 1: Synthesis of methyl 5-bromo-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0833] Intermediate 3-8 (137 mg, 13.78% yield, 93% purity) was obtained as a yellow solid using the same method as step 1 of Manufacturing Example 36-2 using intermediate C-6 and intermediate P-11. MS (ESI) m / z = 391.0, 392.9 [M+H] + .
[0834] Step 2: Synthesis of 5-bromo-1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0835] Intermediate 4-10 (90 mg, crude product) was obtained as a brown solid using the same method as step 2 of 36-9 using intermediate 3-8. MS (ESI) m / z = 376.9, 379.0 [M+H] + .
[0836] Manufacturing Example 42-2: 3-Bromo-5'-(1-methyl-1H-1,2,3-triazol-5-yl)-2-oxo-2H-[1,3'-bipyridine]-5-carboxylic acid (4-11)
[0837]
[0838] Intermediate 4-11 (52 mg, 71% yield) was obtained as a pale yellow solid using the same method as in Manufacturing Example 35 using intermediate P-11 and C-7. MS (ESI) m / z = 375.98, 377.97 [M+H] + .
[0839] Manufacturing Example 42-3: 1-(5-Bromo-2-fluoro-3-pyridyl)-6-oxo-pyridazine-3-carboxylic acid (4-30)
[0840]
[0841] Intermediate 4-30 (45 mg, 78.85% yield, 93.6% purity, hydrochloride) was obtained as a yellow solid in the same manner as in Preparation Example 42-1 using commercially available (5-bromo-2-fluoropyridin-3-yl)boronic acid (P-10) and C-1. MS (ESI) m / z = 313.8 [M+H] + .
[0842] Manufacturing Example 42-4: 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-5-(trifluoromethyl)pyridazine-3-carboxylic acid (4-77)
[0843]
[0844] Step 1: Synthesis of methyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-5-(trifluoromethyl) pyridazine-3-carboxylate
[0845] To a solution of intermediate 3-8 (300 mg, 766.91 μmol) in DMF (5 mL) were added CuI (14.61 mg, 76.69 μmol) and methyl 2,2-difluoro-2-fluorosulfonyl-acetate (736.67 mg, 3.83 mmol, 487.86 μL). The mixture was stirred at 80 °C for 3 h. The reaction mixture was concentrated under reduced pressure to obtain the crude product. This was diluted with EtOAc (30 mL) and washed with brine (15 mL × 3). The organic layer was dehydrated over anhydrous Na2SO4 and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography (1% MeOH in DCM) to give methyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-5-(trifluoromethyl) pyridazine-3-carboxylate (40 mg, 9.59% yield, 69.9% purity) as a yellow oil. MS (ESI) m / z = 380.9 [M+H] + .
[0846] Step 2: Synthesis of 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-5-(trifluoromethyl)pyridazine-3-carboxylic acid
[0847] Intermediate 4-77 (30 mg, 27.26% yield, 35% purity) was obtained as a yellow solid using the same method as in step 2 of Preparation Example 35 using intermediate methyl 1-[5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-5-(trifluoromethyl) pyridazine-3-carboxylate. MS (ESI) m / z = 366.9 [M+H] + .
[0848] Manufacturing Example 42-5: 1-[5-[3-(1-tert-butoxycarbonyl-4-piperidyl)triazol-4-yl]-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-79)
[0849]
[0850] Intermediate 4-79 (450 mg, 81.58% yield, 88% purity) was obtained as a yellow solid by a similar method to Manufacturing Example 31 using intermediates T-21 and 2-1. MS (ESI) m / z = 468.1 [M+H] +.
[0851] Manufacturing Example 43: 1-(6-methyl-5-(1-methyl-1H-1,2,3-triazol-5-yl)pyridin-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (4-12)
[0852]
[0853]
[0854] Step 1: Synthesis of 2-methyl-3-(3-methyltriazol-4-yl)-5-nitro-pyridine
[0855] A solution of 3-bromo-2-methyl-5-nitro-pyridine (10 g, 46.08 mmol), tributyl-(3-methyltriazol-4-yl)stannane (17.15 g, 46.08 mmol) and Pd(PPh3)2Cl2 (1.62 g, 2.30 mmol) in toluene (100 mL) was purged with nitrogen three times and stirred at 100 °C for 16 h under nitrogen conditions. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (50% EtOAc in petroleum ether) to obtain 2-methyl-3-(3-methyltriazol-4-yl)-5-nitro-pyridine (7.7 g, 58.00% yield, 76.08% purity) as a yellow solid. MS (ESI) m / z = 220.1 [M+H] + .
[0856] Step 2: Synthesis of 6-methyl-5-(3-methyltriazol-4-yl)pyridin-3-amine
[0857] To a solution of 2-methyl-3-(3-methyltriazol-4-yl)-5-nitro-pyridine (7.7 g, 35.13 mmol) in EtOH (150 mL) and H2O (50 mL) were added Fe (9.81 g, 175.64 mmol) and NH4Cl (18.79 g, 351.28 mmol), and the mixture was stirred at 80 °C for 3 h under nitrogen conditions. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. Water (15 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (60 mL × 3). The combined organic layer was washed with brine (20 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product 6-methyl-5-(3-methyltriazol-4-yl)pyridin-3-amine (5.86 g, 84.62% yield, 95.98% purity) as a yellow solid. MS (ESI) m / z = 190.1 [M+H] + .
[0858] Step 3: Synthesis of dimethyl (2E)-2-[[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]hydrazono]-3-oxo-pentanedioate
[0859] To a solution of HCl (12 M, 8.39 mL) and 6-methyl-5-(3-methyltriazol-4-yl)pyridin-3-amine (3.78 g, 19.98 mmol) in H2O (20 mL) was added a solution of NaNO2 (1.38 g, 19.98 mmol) in H2O (15 mL) at 0 °C. Then, dimethyl 3-oxopentanedioate (3.48 g, 19.98 mmol, 2.88 mL) in EtOH (12 mL) and NaOAc (12.00 g, 146.27 mmol) in H2O (40 mL) were added to the reaction mixture. The reaction mixture was then stirred at 20 °C for 1 h. The reaction mixture was concentrated under reduced pressure and extracted with EtOAc (60 mL × 3). The combined organic layer was washed with brine (20 mL x 2), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (5% MeOH in DCM) to give dimethyl (2E)-2-[[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]hydrazono]-3-oxo-pentanedioate (6.1 g, 70.10% yield, 85.96% purity) as a yellow oil. MS (ESI) m / z = 375.1 [M+H] + .
[0860] Step 4: Synthesis of methyl 4-hydroxy-1-[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate
[0861] A mixture of dimethyl (2E)-2-[[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]hydrazono]-3-oxo-pentanedioate (6.1 g) in 1,2-dichlorobenzene (80 mL) was stirred at 180 °C for 8 h. The reaction mixture was filtered and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (4% MeOH in DCM) to give methyl 4-hydroxy-1-[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (1.18 g, 15.65% yield, 74% purity) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 12.22 (br s, 1H), 8.75 (d, J = 2.4 Hz, 1H), 8.04 (d, J = 2.4 Hz, 1H), 7.98 (s, 1H), 6.23 (s, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 2.42 (s, 3H); MS (ESI) m / z = 343.0 [M+H] + .
[0862] Step 5: Synthesis of methyl 1-[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-4-(trifluoromethylsulfonyloxy)pyridazine-3-carboxylate
[0863] To a solution of methyl 4-hydroxy-1-[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylate (0.98 g, 2.86 mmol) in DCM (15 mL) were slowly added TEA (869.09 mg, 8.59 mmol, 1.20 mL) and trifluoromethylsulfonyl trifluoromethanesulfonate (1.62 g, 5.73 mmol, 944.72 μL) in DCM (5 mL) at -70 °C, and the mixture was stirred at 20 °C for 2 h. Water (15 mL) was poured into the reaction mixture, and it was extracted with DCM (30 mL × 3). The combined organic layer was washed with brine (10 mL × 2), dried over Na2SO4, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (50% EtOH in petroleum ether) to obtain methyl 1-[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-4-(trifluoromethylsulfonyloxy)pyridazine-3-carboxylate (939 mg, 47.85% yield, 69.21% purity) as a yellow solid. MS (ESI) m / z = 475.1 [M+H] + .
[0864] Step 6: Synthesis of methyl 1-[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxopyridazine-3-carboxylate
[0865] A solution of methyl 1-[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-4-(trifluoromethylsulfonyloxy)pyridazine-3-carboxylate (939 mg, 1.98 mmol), Pd(OAc)2 (66.66 mg, 296.92 μmol), Dppp (244.92 mg, 593.84 μmol), and Et3SiH (299.22 mg, 2.57 mmol, 411.01 uL) in DMF (10 mL) was purged with nitrogen three times and stirred at 100 °C for 1 h under nitrogen. Water (15 mL) was added to the reaction mixture, and the mixture was extracted with EtOAc (40 mL × 3). The combined organic layer was washed with brine (20 mL × 2), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (3% MeOH in DCM) to obtain methyl 1-[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxopyridazine-3-carboxylate (850 mg, 1.56 mmol, 78.96% yield, 60% purity) as a yellow solid. MS (ESI) m / z = 327.1 [M+H] + .
[0866] Step 7: Synthesis of 1-[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid
[0867] To a solution of methyl 1-[6-methyl-5-(3-methyltriazol-4-yl)-3-pyridyl]-6-oxopyridazine-3-carboxylate (450 mg, 1.38 mmol) in THF (4 mL), H2O (2 mL) was added LiOH .H2O (173.61 mg, 4.14 mmol) was added. The mixture was then stirred at 25 °C for 1 h. Water (10 mL) was added to the reaction mixture, extracted with EtOAc (20 mL × 3), and the organic layer was discarded. The mixture was adjusted to pH = 2-3 using 1 N HCl aqueous solution and extracted with EtOAc (20 mL × 3). The combined organic layers were washed with brine (10 mL × 2), dried over Na2SO4, and concentrated under reduced pressure to obtain intermediate 4-12 (287 mg, 48.83% yield, 73.27% purity) as a yellow solid. MS (ESI) m / z = 313.0 [M+H] + .
[0868] Manufacturing Example 43-1: 1-[5-(3-ethyltriazol-4-yl)-6-methyl-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-13)
[0869]
[0870]
[0871] Intermediate 4-13 (55 mg, 55.45% yield, 67.66% purity) was obtained as a white solid using the same method as in Manufacturing Example 43 using Intermediate T-11. MS (ESI) m / z = 327.0 [M+H] + .
[0872] Manufacturing Example 44: 1-(6-chloropyridazin-4-yl)-6-oxo-pyridazine-3-carboxylic acid (4-14)
[0873]
[0874] Step 1: Synthesis of methyl 1-(6-chloropyridazin-4-yl)-6-oxo-pyridazine-3-carboxylate
[0875] A solution of 3,5-dichloropyridazine (5 g, 33.56 mmol), methyl 6-oxo-1H-pyridazine-3-carboxylate (5.17 g, 33.56 mmol), and DIEA (21.69 g, 167.81 mmol, 29.23 mL) in NMP (5 mL) was stirred in a microwave at 120 °C for 1 h. Water (100 mL) was poured into the reaction mixture, and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na2SO4, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (30% EtOAc in petroleum ether) to give methyl 1-(6-chloropyridazin-4-yl)-6-oxo-pyridazine-3-carboxylate (intermediate 3-16; 1.92 g, 19.95% yield, 93% purity) as a yellow solid. 1 H NMR (400 MHz, DMSO-d6) δ 9.67 (d, J = 2.0 Hz, 1H), 8.32 (d, J = 2.0 Hz, 1H), 7.97 (d, J = 10.0 Hz, 1H), 7.28 (d, J = 10.0 Hz, 1H), 3.92 (s, 3H); MS (ESI) m / z = 266.9 [M+H] + .
[0876] Step 2: Synthesis of 1-(6-chloropyridazin-4-yl)-6-oxo-pyridazine-3-carboxylic acid
[0877] To a solution of methyl 1-(6-chloropyridazin-4-yl)-6-oxo-pyridazine-3-carboxylate (580 mg, 2.18 mmol) in THF (6 mL) and H2O (2 mL) was added NaOH (174.00 mg, 4.35 mmol). The mixture was then stirred at 20 °C for 0.5 h. The reaction mixture was concentrated under reduced pressure to yield intermediate 4-14 (540 mg, 84.42% yield, 85.90% purity) as a yellow solid. MS (ESI) m / z = 253.1 [M+H] + .
[0878] Manufacturing Example 45: 1-[6-(2-methylpyrazol-3-yl)pyridazin-4-yl]-6-oxo-pyridazine-3-carboxylic acid (4-15)
[0879]
[0880] Step 1: Synthesis of methyl 1-[6-(2-methylpyrazol-3-yl)pyridazin-4-yl]-6-oxo-pyridazine-3-carboxylate
[0881] A solution of intermediate 3-16 (300 mg, 1.13 mmol), 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (351.14 mg, 1.69 mmol), BrettPhos Pd G3 (101.99 mg, 112.51 μmol) and K2CO3 (310.99 mg, 2.25 mmol) in dioxane (5 mL) and H2O (0.5 mL) was purged with nitrogen three times and stirred at 90 °C under nitrogen for 3 h. Water (30 mL) was poured into the reaction mixture, and extracted with EtOAc (30 mL x 3). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (30% EtOAc in petroleum ether) to obtain methyl 1-[6-(2-methylpyrazol-3-yl)pyridazin-4-yl]-6-oxo-pyridazine-3-carboxylate (67 mg, 17.77% yield, 93.2% purity) as a yellow solid. MS (ESI) m / z = 313.1 [M+H] + .
[0882] Step 2: Synthesis of 1-[6-(2-methylpyrazol-3-yl)pyridazin-4-yl]-6-oxo-pyridazine-3-carboxylic acid
[0883] To a solution of methyl 1-[6-(2-methylpyrazol-3-yl)pyridazin-4-yl]-6-oxo-pyridazine-3-carboxylate (67 mg, 214.55 μmol) in THF (2 mL) were added NaOH (17.16 mg, 429.10 μmol) and H2O (1 mL). The mixture was then stirred at 25 °C for 2 h. The reaction mixture was concentrated under reduced pressure to afford intermediate 4-15 (60 mg, 45.76% yield, 48.8% purity) as a white solid. MS (ESI) m / z = 299.0 [M+H] + .
[0884]
[0885] Manufacturing Example 46: 1-[6-(3-methyltriazol-4-yl)pyrazin-2-yl]-6-oxo-pyridine-3-carboxylic acid (4-27)
[0886]
[0887] Step 1: Synthesis of ethyl 1-(6-bromopyrazin-2-yl)-6-oxo-pyridine-3-carboxylate
[0888] A solution of ethyl 6-oxo-1H-pyridine-3-carboxylate (5.46 g, 32.65 mmol), 2,6-dibromopyrazine (9.32 g, 39.18 mmol), CuI (1.24 g, 6.53 mmol), Cs2CO3 (10.64 g, 32.65 mmol), and 2-(dimethylamino)acetic acid (3.37 g, 32.65 mmol) in dioxane (80 mL) was degassed and purged three times with N2. The mixture was stirred at 100 °C for 16 h under N2 atmosphere. The reaction mixture was diluted with water and extracted with EtOAc (50 mL X 3). The combined organic layers were washed with brine (50 mL), dehydrated over anhydrous Na2SO4, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica column chromatography (20% EtOAc in PE) to give ethyl 1-(6-bromopyrazin-2-yl)-6-oxo-pyridine-3-carboxylate (237 mg, 2.13% yield, 95.32% purity) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ 9.12 (s, 1H), 9.01 (s, 1H), 8.61 (d,J= 2.4 Hz, 1H), 7.94 (dd,J= 2.4, 9.6 Hz, 1H), 6.64 (d,J= 10.0 Hz, 1H), 4.29 (q,J= 7.2 Hz, 2H), 1.29 (t,J= 7.2 Hz, 3H); MS (ESI) m / z = 323.9 [M+H] + .
[0889] Step 2: Synthesis of ethyl 1-[6-(3-methyltriazol-4-yl)pyrazin-2-yl]-6-oxo-pyridine-3-carboxylate
[0890] A solution of ethyl 1-(6-bromopyrazin-2-yl)-6-oxo-pyridine-3-carboxylate (150 mg, 462.78 μmol), tributyl-3-methyltriazol-4-yl)stannane (223.88 mg, 601.61 μmol) and Pd(PPh3)2Cl2 (32.48 mg, 46.28 μmol) in dioxane (4 mL) was degassed, purged with nitrogen three times, and stirred at 100 °C for 16 h under a nitrogen atmosphere. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain ethyl 1-[6-(3-methyltriazol-4-yl)pyrazin-2-yl]-6-oxo-pyridine-3-carboxylate (104 mg, 68.87% yield, 100% purity) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ 9.29 (s, 1H), 9.15 (s, 1H), 8.79 (d,J= 2.6 Hz, 1H), 8.56 (s, 1H), 7.95 (dd,J= 2.6, 9.6 Hz, 1H), 6.67 (d,J= 9.6 Hz, 1H), 4.34 (s, 3H), 4.28 (q,J= 7.2 Hz, 2H), 1.31 - 1.28 (m, 3H); MS (ESI) m / z = 327.0 [M+H] + .
[0891] Step 3: Synthesis of 1-[6-(3-methyltriazol-4-yl)pyrazin-2-yl]-6-oxo-pyridine-3-carboxylic acid
[0892] Intermediate 4-27 (45 mg, 96.55% yield, 98.06% purity) was obtained as a yellow solid using the same method as in step 3 of Preparation Example 36 using ethyl 1-[6-(3-methyltriazol-4-yl)pyrazin-2-yl]-6-oxo-pyridine-3-carboxylate. MS (ESI) m / z = 299.1 [M+H] + .
[0893] Manufacturing Example 46-1: 1-[5-(3-Cyclopropyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridine-3-carboxylic acid (4-78)
[0894]
[0895] Intermediate 4-78 (120 mg, 93.23% yield, 96.8% purity) was obtained as a yellow solid using the same method as steps 2 and 3 of Manufacturing Example 36 using Intermediate 2-2 and T-14. MS (ESI) m / z = 323.9 [M+H] + .
[0896] Manufacturing Example 47: 1-[5-(3-Cyclopropyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-47)
[0897]
[0898] Intermediate 4-47 (35 mg, 88.82% yield, 97.3% purity) was obtained as a yellow solid using the same method as steps 2 and 3 of Manufacturing Example 36 using Intermediate 2-1 and T-14. 1 H NMR (400 MHz, DMSO-d6) δ 9.03 (d,J= 2.0 Hz, 1H), 8.95 (d,J= 2.4 Hz, 1H), 8.56 (t,J= 2.0 Hz, 1H), 8.17 (s, 1H), 7.96 (d,J= 9.6 Hz, 1H), 7.22 (d,J= 9.6 Hz, 1H), 4.01 (td,J= 3.6, 7.3 Hz, 2H), 1.20 - 1.15 (m, 2H), 1.12 (br d,J= 2.8 Hz, 2H); MS (ESI) m / z = 324.9 [M+H] + .
[0899] Manufacturing Example 47-1: 1-[5-(3-Isopropyltriazol-4-yl)-3-pyridyl]-6-oxo-pyridazine-3-carboxylic acid (4-32)
[0900]
[0901] Intermediate 4-32 (55 mg, 93.99% yield, 98.31% purity) was obtained as a yellow solid using the same method as steps 2 and 3 of Manufacturing Example 36 using Intermediate 2-1 and T-15. MS (ESI) m / z = 326.6 [M+H] + .
[0902] Preparation Example 48: 1-(5-Bromo-2-fluoro-3-pyridyl)-6-oxo-pyridine-3-carboxylic acid (4-73)
[0903]
[0904] Step 1: Synthesis of methyl 1-(5-bromo-2-fluoro-3-pyridyl)-6-oxo-pyridine-3-carboxylate
[0905] To a solution of methyl 6-oxopyrane-3-carboxylate (C-10; 8.07 g, 52.36 mmol) in pyridine (100 mL) was added 5-bromo-2-fluoro-pyridin-3-amine (5 g, 26.18 mmol). The mixture was stirred at 80 °C for 12 h under a nitrogen atmosphere. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product. The crude product was purified by silica column chromatography (12% EtOAc in PE) to obtain a residue. The residue was dissolved in MeOH (5 mL) and purified by prep-HPLC (Column: Welch Xtimate C18 250*50mm*10um; Mobile phase: [water(NH4HCO3)-MeCN]; 5%-55% B, 20 min). Most of the MeCN was removed under reduced pressure and the remaining solution was removed using a lyophilizer to obtain methyl 1-(5-bromo-2-fluoro-3-pyridyl)-6-oxo-pyridine-3-carboxylate (360 mg, 4.12% yield, 98.08% purity) as an off-white solid. MS (ESI) m / z = 326.8 [M+H] + .
[0906] Step 2: Synthesis of 1-(5-bromo-2-fluoro-3-pyridyl)-6-oxo-pyridine-3-carboxylic acid
[0907] Intermediate 4-73 (60 mg, 60.43% yield, 96.39% purity) was obtained as a white solid by the same method as step 2 of Preparation Example 36-9 using intermediate methyl 1-(5-bromo-2-fluoro-3-pyridyl)-6-oxo-pyridine-3-carboxylate. MS (ESI) m / z = 313.0 [M+H] + .
[0908] Manufacturing Example 49: 1-(6-chloropyridazin-4-yl)-N-[(1R)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]-6-oxo-pyridazine-3-carboxamide (D-1)
[0909]
[0910] To a solution of 1-(6-chloropyridazin-4-yl)-6-oxo-pyridazine-3-carboxylic acid (490 mg, 1.94 mmol) and intermediate A-3 (378.06 mg, 1.55 mmol, HCl salt) in DMF (6 mL) were added DIEA (752.07 mg, 5.82 mmol, 1.01 mL), HOBt (393.14 mg, 2.91 mmol), and EDCI (557.77 mg, 2.91 mmol). The mixture was degassed, purged with N2 three times, and stirred at 25 °C for 5 h under a N2 atmosphere. The reaction mixture was poured into water (8 mL) and extracted with EtOAc (20 mL × 3). The combined organic layer was washed with brine (10 mL × 2), dried over anhydrous Na2SO4, and concentrated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography (3% MeOH in DCM) to obtain intermediate D-1 (140 mg, 11.33% yield, 69.37% purity) as a brown oil. MS (ESI) m / z = 442.1 [M+H] + .
[0911] Manufacturing Example 49-1: 1-(6-chloropyridazin-4-yl)-N-[(1R)-1-[2-fluoro-3-(difluoromethyl)phenyl]ethyl]-6-oxo-pyridazine-3-carboxamide (D-2)
[0912]
[0913] Intermediate D-2 (37.0 mg, 30.83% yield) was obtained as a white solid using the same method as in Manufacturing Example 49 using Intermediate A-2. 1 H NMR (400 MHz, DMSO-d6) δ 9.97 (d, J = 2.0 Hz, 1H), 9.21 (d, J = 8.0 Hz, 1H), 8.75 (d, J = 2.0 Hz, 1H), 8.46 (s, 1H), 7.94 (d, J = 10.0 Hz, 1H), 7.72 (br t, J = 7.2 Hz, 1H), 7.57 -7.51 (m, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.28 (d, J = 10.0 Hz, 1H), 7.22 (t, J = 7.2 Hz, 1H), 5.44 (quint, J = 7.2 Hz, 1H), 4.43 (s, 3H), 1.55 (d, J = 7.2 Hz, 3H); MS (ESI) m / z = 471.2 [M+H] + .
[0914] Manufacturing Example 49-2: 1-(5-Bromo-2-fluoro-3-pyridyl)-N-[(1R)-1-[2-fluoro-3-(trifluoromethyl)phenyl]ethyl]-6-oxo-pyridazine-3-carboxamide (D-10)
[0915]
[0916] Intermediate D-10 (30 mg, 55.80% yield, 93.46% purity) was obtained as a yellow solid using the same method as in Manufacturing Example 49 using intermediates A-3 and 4-30. 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 8.10 (dd,J= 2.4, 7.6 Hz, 1H), 8.05 (m, 1H), 7.54 (t,J= 7.2 Hz, 2H), 7.35 (m, 1H), 7.26 - 7.20 (m, 1H), 7.12 (dd,J= 1.2, 9.6 Hz, 1H), 5.43 (m, 1H), 1.62 (d,J= 7.2 Hz, 3H); MS (ESI) m / z = 504.9 [M+H] + .
[0917] Manufacturing Example 49-3: 1-(5-Bromo-3-pyridyl)-N-[(1R)-1-[2-fluoro-3-[1-(hydroxymethyl)cyclopropyl]...
Claims
1. A compound represented by the following chemical formula I, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof: [Chemical Formula I] In the above chemical formula I, Z 1 and Z 3 are each independently N or CH; Z 2 is N or CR a And Z 4 is CH; or Z 2 is CR a And Z 4 is N; R a is H, halogen, OH, CN, substituted or unsubstituted C1-C6alkoxy, amino, substituted or unsubstituted C1-C6alkylamino, substituted or unsubstituted di(C1-C6alkyl)amino, substituted or unsubstituted C1-C6thioalkoxy, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C3-C7 partially unsaturated or saturated cycloalkyl, or a 4- to 7-membered heterocyclyl containing 1 or 2 heteroatoms selected from N, O and S; R 1 is H; D; halogen; OH; CN; C1-C6 alkyl optionally substituted with one or more deuterium, OH, oxo (=O) or halogen; -NR A R B ; -OR A ; partially unsaturated or saturated C3-C7 cycloalkyl; optionally substituted C6-C 10 Aryl; optionally substituted 5- to 10-membered heteroaryl; or and; R A and R B are each independently H or R a is a C1-C6 alkyl optionally substituted with; R 2 is H; C1-C6 alkyl optionally substituted with one or more deuterium, OH, C1-C6 alkoxy or halogen; one or more R 21a A 4- to 7-membered heterocyclyl comprising 1 or 2 heteroatoms selected from N, O and S, optionally substituted with; or one or more R 21b is a C3-C7 partially unsaturated or saturated cycloalkyl optionally substituted with; R 21a and R 21b are each independently C1-C6 alkyl optionally substituted with one or more halogen, CN, OH, C1-C6 alkoxy, carboxy or oxo; C1-C6 acyl; carboxy; C1-C6 alkoxycarbonyl; or C1-C6 alkylsulfonyl; R 3 is H, halogen, OH, C1-C6alkoxy, NH2, C1-C6alkylamino, di(C1-C6alkyl)amino, NO2 or CN; R 4 is H, halogen, OH, C1-C6alkoxy, NH2, C1-C6alkylamino, di(C1-C6alkyl)amino, NO2 or CN; A 1 Silver deuterium, halogen, OH, C1-C3 alkoxy, And C1-C6 alkyl substituted with one or more substituents independently selected from the group consisting of C1-C3 alkyl; or partially unsaturated or saturated C3-C7 cycloalkyl; wherein the one or more substituents may be bonded to the same or different carbons, and two C1-C3 alkyl bonded to the same carbon atom may optionally form a C3-C4 cyclic ring together with the carbon atoms to which they are bonded; A 2 is H, halogen, OH, CN or C1-C6 alkyl; A 3 is H, amino, C1-C6 alkylamino or di(C1-C6 alkyl)amino; Carbon atoms marked with * and ** are optionally replaced with one or more deuterium atoms; The compound of formula I is This is not it.
2. In paragraph 1, R 1 , R 2 and A 1 or at least one of which contains deuterium; and / or A compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof, wherein at least one of the carbon atoms indicated by * and ** is replaced with deuterium.
3. In paragraph 1, Z 4 A compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof, wherein the compound is CH.
4. In paragraph 3, Z 2 is CR a And, R a and R 4 All are H; R a is a 4- to 6-membered heterocyclyl containing 1 or 2 heteroatoms selected from halogen, OH, CN, C1-C6 alkoxy, amino, C1-C6 alkylamino, di(C1-C6 alkyl)amino, C1-C6 alkyl, C3-C7 partially unsaturated or saturated cycloalkyl, or N and O, and R 4 is H or a halogen; or R a is H, and R 4 is a halogen, a compound, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.
5. In paragraph 4, R a is H, F, -NHCH3, -N(CH3)2, -OCH3, -CH3 or And, R 4 A compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof, wherein the compound is H or F.
6. In paragraph 1, R 2 is one or more R 21a A 4- to 6-membered heterocyclyl comprising 1 or 2 heteroatoms selected from N and O, optionally substituted with; or one or more R 21b is a C3-C7 partially unsaturated or saturated cycloalkyl optionally substituted with; and / or R 3 is a halogen, R 21a is C1-C4 alkyl optionally substituted with one or more OH, C1-C4 alkoxy or oxo; C1-C4 acyl; C1-C4 alkoxycarbonyl; or C1-C4 alkylsulfonyl, and R 21b is a halogen, a compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof.
7. In paragraph 1, R 2 is -CH3, -CD 3, -CH2CH3, -CH(CH3)2, -CH2CH2OH, cyclopropyl, , cyclobutyl, , or And, R 3 A compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof, wherein the compound is H or Cl.
8. In paragraph 1, R 1 is H; D; halogen; CN; C1-C6 alkyl optionally substituted with one or more deuterium, OH, oxo (=O) or halogen; partially unsaturated or saturated C3-C7 cycloalkyl; C6-C 10 Aryl; or A compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof.
9. In paragraph 8, R 1 is H, D, F, Br, Cl, CN, methyl, ethyl, CD3, CF3, -CH2OH, -CH(OH)CH3, -C(OH)(CH3)2, -C(=O)CH3, cyclopropyl, cyclohexyl, cyclohexenyl, phenyl, or A compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof.
10. In paragraph 1, A 1 Silver deuterium, halogen, OH, C1-C3 alkoxy, And C1-C6 alkyl substituted with two or more substituents independently selected from the group consisting of C1-C3 alkyl; or partially unsaturated or saturated C3-C7 cycloalkyl; when two of said C1-C3 alkyl are bonded to the same carbon atom, they form a C3-C4 cyclic ring together with the carbon atoms to which they are bonded, A 2 is H, halogen or C1-C4 alkyl, A 3 Silver H or amino, compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof.
11. In paragraph 10, A 1 은 -CHF2, -CF3, -CF2CH3, -CF2CH2F, -CF2CH2OH, -CF2CD2OH, -CF2CH2OCH3, and selected from the group consisting of cyclobutenyl; A 2 A compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof, wherein the compound is H, F, Cl or -CH3.
12. In paragraph 1, In chemical formula I A compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof, selected from the following structures:
13. In paragraph 1, A compound represented by the following chemical formula I-1, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof: [Chemical Formula I-1] In the above chemical formula I-1, Z 1 and Z 3 are each independently N or CH; Z 2 is N or CR a and; R a is H, halogen, OH, CN, substituted or unsubstituted C1-C6alkoxy, substituted or unsubstituted C1-C6alkylamino, substituted or unsubstituted C1-C6thioalkoxy, or substituted or unsubstituted C1-C6alkyl; R 1 is H, halogen, OH, CN, C1-C6 alkyl optionally substituted with one or more deuterium or halogen, -NR A R B , -OR A , C3-C6 cycloalkyl, optionally substituted C6-C 10 Aryl, or an optionally substituted 5- to 10-membered heteroaryl; R A and R B are each independently R a is a C1-C6 alkyl optionally substituted with; R 2 is H, or C1-C6 alkyl optionally substituted with one or more deuterium or halogen; A 1 is C1-C6 alkyl substituted with one or more substituents independently selected from the group consisting of halogen, OH, C1-C3 alkoxy and C1-C3 alkyl, wherein said one or more substituents may be bonded to the same or different carbons, and two C1-C3 alkyl bonded to the same carbon atom may optionally form a C3-C4 cyclic ring together with the carbon atoms to which they are bonded; A 2 is H, halogen, OH, CN or C1-C6 alkyl; A 3 is H or amino, The compound of chemical formula I-1 is This is not it.
14. In paragraph 13, Z 1 is N, and Z 2 is CH, and Z 3 is N or CH; Z 1 and Z 2 are all CH, and Z 3 is N; or Z 1 and Z 2 are all N, and Z 3 A compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof, wherein N or CH.
15. In paragraph 13, R 1 This H, halogen, CN, C1-C3 alkyl or C3-C5 cycloalkyl; R 2 A compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof, wherein the compound is C1-C3 alkyl optionally substituted with one or more deuterium atoms.
16. In paragraph 13, A 1 C1-C3 alkyl substituted with two or more substituents independently selected from the group consisting of F, OH and methoxy; A 2 is H, halogen or C1-C3 alkyl, A 3 This H compound, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof.
17. In paragraph 13, A 1 C1-C3 alkyl substituted with two or more F, and A 2 A is H, halogen or C1-C3 alkyl, and A 3 A compound of which is amino, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof.
18. In paragraph 1, A compound selected from the group consisting of: or a solvate, stereoisomer or pharmaceutically acceptable salt thereof; 19. A pharmaceutical composition comprising a compound of any one of claims 1 to 18, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof, as an active ingredient.
20. In paragraph 19, A pharmaceutical composition for preventing or treating an SOS1-mediated disease.
21. In paragraph 20, A pharmaceutical composition wherein the above SOS1-mediated disease is cancer or RAS disease.
22. In paragraph 21, A pharmaceutical composition wherein the cancer is selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma, uterine cancer, cervical cancer, endometrial cancer, thyroid cancer, chronic lymphocytic leukemia, acute myeloid leukemia, bladder cancer, urothelial cancer, gastric cancer, head and neck squamous cell carcinoma, diffuse large B-cell lymphoma, esophageal cancer, hepatocellular cancer, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer, and sarcoma.
23. In paragraph 21, A pharmaceutical composition, wherein the RAS disease is selected from the group consisting of Neurofibromatosis type 1, Noonan Syndrome, Leopard Syndrome, Capillary Malformation-Arteriovenous Malformation Syndrome, Costello Syndrome, Cardio-Facio-Cutaneous Syndrome, Legius Syndrome, and Hereditary gingival fibromatosis.
24. A method for preventing or treating an SOS1-mediated disease, comprising administering to a subject a compound of any one of claims 1 to 18, or a solvate, stereoisomer or pharmaceutically acceptable salt thereof.
25. Use of a compound according to any one of claims 1 to 18, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, for the prevention or treatment of SOS1-mediated diseases.
26. Use of a compound according to any one of claims 1 to 18, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, for the manufacture of a medicament for preventing or treating a SOS1-mediated disease.
